MITOCHONDRIAL DELIVERY OF RECOMBINANT NUCLEIC ACIDS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0037] This application claims the benefit of priority of SG provisional application No. 10201603628Q, filed 06 May 2016, the contents of it being hereby incorporated by reference in its entirety for all purposes.

FIELD OF THE INVENTION

[0038] This disclosure relates to the field of molecular biology. In particular, the present invention relates to the use of mitochondria-targeting sequences for the transport of nucleic acid sequences.

BACKGROUND OF THE INVENTION

[0039] Mitochondria are the cellular organelles involved in the terminal part of respiration cycle in almost all living organisms. The genomic organization of the mitochondria is unique and codes for 37 genes, of which 22 are tRNA genes, two are mitochondrial ribosomal RNA (12s and 16s) genes and 13 genes for subunits of respiratory enzymes. Defects in these respiratory genes have been associated with a number of neurodegenerative disorders, such as ataxias, optic neuropathies, Parkinson's disease, and also associated with ageing. However, the uptake of nucleic acids by the mitochondria for mitochondrial protection and modulation is poorly investigated, and efficient mitochondrial delivery vectors have not been identified yet. Thus, there is a need for a delivery system capable of delivering payloads (for example, nucleic acid sequences that are carried by the delivery system) into the mitochondria of cells.

SUMMARY

[0040] In one embodiment, the present invention refers to a nucleic acid delivery construct comprising at least one sense or antisense RNA subdomain of the human cytomegalovirus β2.7 RNA, wherein each subdomain is capable of localization within the mitochondria, and a payload.

[0040a] Disclosed herein is a nucleic acid delivery construct and a payload, wherein the nucleic acid delivery construct comprises at least one sense or antisense RNA subdomain of the human cytomegalovirus β2.7 RNA, wherein each subdomain is capable of localization within the mitochondria.

[0041] In another embodiment, the present invention refers to a vector, a recombinant cell, or a recombinant organism comprising the nucleic acid sequence as disclosed herein.

[0041a] Disclosed herein is a vector, a recombinant cell, or a recombinant organism comprising the nucleic acid delivery construct as defined herein.

[0042] Disclosed herein is a nucleic acid sequence comprising at least one or more sense or antisense RNA sequences of the human cytomegalovirus β2.7 RNA selected from group consisting of domain 1 (Dl ; SEQ ID NO: 3 or 7), domain 2 (D2; SEQ ID NO: 4 or 8), domain 3 (D3; SEQ ID NO: 5 or 9) and domain 4 (D4; SEQ ID NO: 6 or 10).

[0043] In an embodiment, the present invention refers to the use of the nucleic acid delivery construct as disclosed herein in the manufacture of a medicament for treating a mitochondrial disorder.

[0044] In an embodiment, the present invention refers to the use of the nucleic acid delivery construct as disclosed herein in the manufacture of a medicament for treating a mitochondrial disorder.

[0044a] Disclosed herein is the use of the nucleic acid delivery construct and payload as defined herein in the manufacture of a medicament for treating a mitochondrial disorder.

BRIEF DESCRIPTION OF THE DRAWINGS

[0045] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings, in which:

[0046] **Fig. 1** shows the structural and functional analyses that identify a single structural subdomain that governs the complete mitochondrial localization activity of the full-length β2.7 RNA. **a)** HepG2 cells were transfected with in vitro transcribed β2.7 RNA. Cytoplasmic and mitochondrial fractions were purified and the relative distribution of the β2.7 RNA in each fraction was determined using real-time RT-PCR. Data represent means ± SD of 3 independent experiments (*p<0.05, Student's t-test). **b)** Thermodynamic profiling of the β2.7 RNA sequence of the CMV Towne strain using the algorithm foldsplit (HUSAR) and a window size of 200 nt and shift increment of 1 nt. The Gibbs free energy (ΔG) values of secondary structure formation for each window was plotted against the position of the sequence window. ΔG minima indicate four thermodynamically conserved and potentially functionally relevant structural subdomains Dl to D4. **c)** Well-defined secondary structure subdomains Dl to D4 could be assigned to each of the energetic minima within the minimum free energy structure (mfe) of T7 polymerase transcript of the Towne β2.7 RNA as predicted by mfold. **d)** shows a schematic representation of the β2.7 RNA domain structure along with the single domain deletion constructs (SDDC) and the single domain constructs (SDCs). **e)** shows the results of HepG2 cells that were transfected with in vitro transcribed, full-length β2.7 RNA or the SDDCs. Mitochondrial uptake was monitored using rtRT-PCR. Data represent mean values ± SD of 3 independent experiments (***p<0.001 , ****p<0.0001 one-way ANOVA, Dunnett's multiple comparison test). **f)** shows the results of HepG2 cells that were transfected with in vitro transcribed full-length β2.7 RNA or the SDCs

and mitochondrial uptake was measured using rtRT-PCR and domain-specific primers. Data represents ± SD of 3 independent experiments (*p<0.01, ***p<0.001, Student's t-test).

[0047] **Fig. 2** shows the structural and functional analyses that indicate a remarkable homology between the β2.7 RNA and its antisense RNA. **a)** Thermodynamic profiling of the Towne β2.7 antisense RNA using foldsplit (HUSAR) identified thermodynamically conserved structural subdomains D1AS to D4AS corresponding to domains D1 to D4 in the complementary strand. **b)** HepG2 cells were transfected with in vitro transcribed sense (T7) or antisense (SP6) full-length β2.7 RNA and mitochondrial uptake was quantified using rtRT-PCR and domain-specific primers (for D1 to D4) from left to right. Data represent mean values ± SD of three independent experiments (***p<0.001, Student's t-test). **c)** Mitochondrial localization of the full-length β2.7 antisense RNA and antisense SDDCs as detected using rtRT-PCR. Data represent mean values ± SD of three independent experiments (*p<0.05, **p<0.01, one-way ANOVA, Dunnett's multiple comparison Test). **d)** Mitochondrial localization of the full-length β2.7 RNA, the full-length β2.7 antisense RNA, and antisense SDCs measured using rtRT-PCR and domain-specific primers. Data represent mean values ± SD of 3 independent experiments (*p<0.05, **p<0.01, ***p<0.001, ***p<0.0001, one-way ANOVA, Tukey's multiple comparisons test).

[0048] **Fig. 3** shows the results of β2.7 RNA-mediated mitochondrial targeting of the GFP mRNA, which triggers mitochondrial GFP expression. **a)** Design of β2.7-GFP fusion constructs and controls. The β2.7 RNA sequence was fused to either the GFP sequence gene with genomic (gGFP) or mitochondrial (mtGFP) start and stop codons. To preserve the structures of sub-domains D1 to D4 of the β2.7 RNA upon fusion to the GFP sequence, a spacer sequence was designed and inserted. To target any cytoplasmic mtGFP to the nuclei, constructs were designed in which the mtGFP protein was fused to a nuclear localization sequence (NLS). Respective nuclear or mitochondrial translational stop codons (indicated by triangles) were placed downstream of the respective GFP or NLS sequences so that only the GFP protein or a GFP-NLS fusion was translated. **b)** Example demonstrating the functionality of the spacer sequence using RNA secondary structures predicted by mfold. Insertion of the spacer between the GFP mRNA and the β2.7 RNA restores β2.7 RNA subdomains D2 and D3. **c)** Mitochondrial targeting activity of β2.7 fusion RNAs relative to the β2.7-negative control or the parental β2.7 RNA. **d)** HepG2 cells were transfected with *in vitro* transcribed RNA and mitochondrial localization was monitored using rtRT-PCR. Data represent mean values of three independent experiments (****p<0.0001, one-way ANOVA, Dunnett's multiple comparison test). **e)** to **f)** Flow cytometry analyses comprising scatter plots and histogram shifts. HepG2 cells transfected with plasmid DNA vectors expressing the GFP_β2.7 fusion RNAs and GFP expression was monitored at day 3. **h)** Summary of flow cytometry data. The Geometric means, percentages of GFP-positive cells, and

Medians are indicated. Data represent 3 independent experiments (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA, Tukey's multiple comparisons Test and Student's t-test). i-k, HepG2 cells were transfected with NLS(+) or NLS(-) GFP-β2.7 RNA fusion constructs and co-localisation of GFP expression and mitochondrial stain (MitoTracker Red) in the confocal microscopy images was analysed and presented in three different ways using ImageJ algorithm JACOP: i, Pearson's coefficient; j, Mander's coefficient; and k, Overlap coefficient. Each five representative images were analysed (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, two-way ANOVA, Tukey's multiple comparison's Test).

[0049] **Fig. 4** shows that β2.7 RNA-mediated delivery of antisense RNA can trigger knockdown of mtATP6 and mtATP8. **a)** Minimum free energy (MFE) secondary structures of computationally-selected unstructured antisense RNA targeting the mitochondrial genes mtATP6 and mtATP8 as predicted by mfold. **b)** Design of the β2.7_antisense fusion RNAs and controls. Spacers S6 and S8 ensure the antisense RNA domains remain open upon fusion to the β2.7 RNA. **c)** MFE structures of the asATP6_β2.7 and β2.7_asATP8 fusion RNAs predicted by mfold. **d)** Knockdown of mtATP6 or mtATP8 mRNA levels measured using rtRT-PCR in HEK293T cells transfected with β2.7_antisense fusion RNAs (asATP6 or asATP8) or control RNA. Data represents means ± SD of 3 independent experiments (*p<0.05, ***p<0.001, one-way ANOVA, Dunnett's multiple comparisons test). **e)** Reduction of ATP levels in RNA-transfected HEK293T cells detected using the Cell Titre-Glo Assay. Data represent means +SD of 3 independent experiments (*p<0.05, **p<0.05, ***p<0.001, one-way ANOVA, Dunnett's multiple comparisons test). f, Cell viability of HEK293T cells 24 hours post-transfection of RNA determined by the Alamar Blue cell viability assay. Data represent means ± SD of 3 independent experiments (*p<0.05, **p<0.05, ***p<0.001, one-way ANOVA, Dunnett's multiple comparisons test).

[0050] **Fig. 5** shows results showing that distinct tandem repeats of β2.7 RNA sub-domains 2 and 3 show enhanced mitochondrial uptake and can protect mitochondrial Complex I. **a)** shows schematics of MFE structures of domain 2 (D2X4) and **b)** domain 3 (D3X4) tandem repeats as predicted by mfold. Spacers s1 to s4 were used to stabilize the structures of subdomains D2 and D3 in the tandem repeat constructs D2X4 and D3X4. **d)** shows a schematic, exemplary representation of constructs comprising tetrameric repeats of domain 2 (D2X4) or 3 (D3X4), combinations thereof (D3X4_D2X4 or D2X4_D3X4), or a domain 3/2 repeat ((D3_D2)X4). **c)** shows line graphs depicting median CT ratios. *In vitro* transcribed RNAs were serially diluted, reverse transcribed and subjected to rtPCR to determine the CT ratios for each dilution. Each standard curve effectively detected down to 104 molecules. **E)** shows column graphs depicting relative uptake levels of mitochondrial uptake of domain 2 or 3 monomers or tetramers relative to the parental β2.7 RNA in transfected HepG2 cells as determined by

rtRT-PCR. **F)** shows column graphs depicting relative uptake levels of mitochondrial uptake of different tandem repeat RNAs relative to the parental β2.7 RNA in transfected HepG2 cells as determined by rtRT-PCR. **g)** and **h)** show the results of a cell viability staining using Alamar blue cell viability assays, thereby monitoring protection of mitochondrial Complex I against 200μM rotenone treatment 24 hours (**g**)) or 48 hours (**h**)) post-transfection of HEK293T cells with *in vitro* transcribed RNA or plasmid expression vectors. Data was normalized relative to an untreated control. Data shown in E) to H) is represented as means plus standard deviation of 3 independent experiments (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA, Tukey's multiple comparisons Test).

[0051] **Fig. 6** shows schematic examples of using CMV β2.7 RNA-derived sequences/structures (mβ2.7) for mitochondrial delivery of recombinant nucleic acids. mβ2.7 can be either the full-length β2.7 RNA, a structural sub-domains thereof, a repeat of a β2.7 RNA. **a)** shows the fusing mβ2.7 to the 5' end of a recombinant no-coding or coding RNA. **b)** shows the fusing mβ2.7 to the 3' end of a recombinant no-coding or coding RNA. **c)** shows binding of mβ2.7 via complementary base pairing, i.e. a binding domain, towards double-stranded DNA (gene). **d)** shows linkage of mβ2.7 via complementary binding domains (DNA or RNA) to circular single-stranded DNA or a recombinant mitochondrial genome. **e)** shows the linkage of mβ2.7 via complementary binding domains, as shown in d), but the ssDNA enzymatically was converted to dsDNA and ligated. **f)** shows the linkage of mβ2.7 via complementary binding domains, as shown in d),but linking two or more mβ2.7 RNAs to a circular ssDNA.

[0052] **Fig. 7** shows a schematic map of the pVAX1 vector used in the present invention. The NdeI and BclI site were used to clone the construct into the pVAX1 vector.

[0053] **Fig. 8** shows a schematic of the overlap extension polymerase chain reaction (OE PCR) used to generate the single domain deletion constructs, which was carried out in two steps. In the first step, the region upstream of the deletion domain (ΔD) is PCR amplified using a common forward primer which carries the NheI site and OE reverse primer, which introduces the priming site for the region downstream of the ΔD. Subsequently, the domain downstream of the ΔD is PCR amplified using an OE forward primer, which introduces the priming site for the region upstream of the ΔD, and a common reverse primer which carries the BamHI site. Both PCR products were then gel purified and mixed together in equimolar amounts and then re-amplified with PCR, in which the OE introduced priming sites acted as primers for their respective counterparts thereby giving the full length construct with the desired deletion.

[0054] **Fig. 9** shows a schematic outlining the synthesis and cloning strategy of the single domain constructs. The forward and the reverse primers were designed to introduce the BspEI and HindIII sites

respectively. The PCR products were subsequently digested with BspEI and HindIII, purified and cloned into the pVAX1 vector using the BspEI and HindIII sites.

[0055] **Fig. 10** shows a schematic representation of the different constructs used to test mitochondrial GFP delivery. To facilitate mitochondria specific GFP expression, the genomic start and stop codons were PCR modified to mitochondria specific start (ATA) and stop codons (respectively).

[0056] **Fig. 11** shows a schematic representation of the PCR introduction of a nuclear localization sequence (NLS). The NLS sequence was PCR amplified from the pEBFP-NUC plasmid by PCR, using forward and reverse primers and inserted upstream of the stop codon (AGA).

[0057] **Fig. 12** shows a schematic representation of the cloning strategy used to synthesize the domain 2 and domain 3 tandem repeat sequences. The individual copies were first synthesized in 4 sets using PCR primers. Since all primers for a particular tandem repeat share the same binding region, the Tm is the same for all sets for a particular tandem repeat. Each set has its own set of spacers, as indicated by S1-S4 in the figure. The restriction sites were chosen so that the site at the 3'end of one set matched the one at the 5' end of the next set within the tandem repeat. The restriction sites used were NheI, EcoRI, KpnI, AgeI and HindIII. After PCR, the products were PCR purified and digested with their respective restriction sites. The digested PCR products were then mixed in equimolar amount of the digested vector backbone and ligated using T4 DNA ligase.

[0058] **Fig. 13** shows a schematic representation of the strategy for synthesis of D3X4_D2X4, as well as for D2X4_D3X4. The domain 2 tandem repeat (D2X4) was PCR amplified from the pVAX1 vector carrying D2X4. To prevent amplification of shorter fragments, primers were so designed that majority of the binding region of the primer lay on the vector backbone itself. Each of the primers introduced HindIII sites at either end. The PCR product was digested and re-ligated within the HindIII site of the pVAX1 vector carrying the D3X4 sequence. To prevent re-ligation of the vector, the digested vector was dephosphorylated with alkaline phosphatase. The second part of Fig. 13 shows a schematic representation of strategy used for D2X4_D3X4: Similarly The domain 3 tandem repeat (D3X4) was PCR amplified from the pVAX1 vector carrying D3X4.The primer design strategy employed was the same as used for the domain 2 tandem repeat (D2X4) outlined above. The PCR product was digested and re-ligated within the HindIII site of the de-phosphorylated pVAX1 vector carrying the D2X4 sequence.

[0059] **Fig. 14** shows a schematic representation of the strategy used for synthesizing (D3_D2)x4. In the first step the first D3 of D3x4 was cloned using the same restriction sites into the first repeat position of D2X4. In the second step, the third D3 of D3x4 was cloned using the same restriction sites into the third position of D2X4. The step 2 product thus obtained was then PCR amplified using

primers which introduce HindIII sites at either end. The PCR product was then ligated downstream of the step 2 product.

[0060] **Fig. 15** shows a schematic representation of the strategy used to isolate the sequences targeted by antisense RNA. Mitochondrial RNA was reverse transcribed with gene specific reverse primer sequences (ATP6Rv and ATP8Rv) to obtain first strand ATP6 and ATP8 cDNA pools. Subsequently, these pools were used as templates for PCR to obtain double stranded DNA sequences representing the target elements.

[0061] **Fig. 16** shows a schematic representation of the strategy used for synthesizing ATP6_β2.7.The ATP6 target sequence was re-amplified by PCR to introduce restriction sites in an opposite orientation to that in β2.7_pVAX1 sequence. The resulting product was digested with NheI and BspeI, and then ligated into the β2.7_pVAX1 vector backbone to obtain the ATP6_No spacer_β2.7. The products were screened by digestion with NdeI and NheI. Subsequently a spacer sequence was introduced downstream of this construct by a 2 step nested PCR. In the first step, a fragment of the β2.7 (β2.7F) was PCR amplified with a common forward primer and a reverse primer introducing a part of the spacer sequence (SF1). In the next step, the step 1 product was PCR amplified with the same forward primer as in step I and a reverse primer, which binds to SF1 and simultaneously introduces the remaining spacer sequence (SF2) and the HindIII site for cloning. This reconstituted the spacer sequence. The step 2 PCR product was cloned into the ATP6_No spacer_β2.7 to obtain the ATP6_β2.7.

[0062] **Fig. 17** shows a schematic representation of strategy used to generate β2.7_ATP8 construct. The purified ATP8 target sequence was PCR amplified with the reverse primer, thereby introducing a SpeI site. Simultaneously, a fragment was amplified from β2.7 by PCR so that the resulting product carried a BamHI and HindIII site at the 5' end and at the 3' end, respectively. The β2.7 PCR product and the ATP8 PCR product were single digested with HindIII and SpeI, respectively, mixed in equimolar amounts and ligated at 22°C for 4 hours. SpeI site can be ligated to HindIII site by a 2 base fill in which effectively destroys both sites. Post-ligation, the product of the correct size was purified from the gel, which has the β2.7 fragment fused to the antisense ATP8 sequence. Then, this ligation product was PCR amplified to introduce the HindIII site and cloned back into the β2.7_pVAX1 vector backbone to generate the intact sequence.

[0063] **Fig. 18** shows data and schematics of MT-ATP6 antisense tandem repeat fusion RNA ATP6_(D3)4_(D2)4 localising in the mitochondria and triggering highly efficient functional MT-ATP6 knockdown. **a)** shows a schematic representations of the ATP6_(D3)4_(D2)4 fusion RNA (upper panel) and ATP6_(D3)4_(D2)4 mfe structure (lower panel). **b)** shows the results of agarose gel electrophoresis of *in vitro* transcribed RNAs ATP6_pVAX, ATP6_β2.7, and ATP6_(D3)4_(D2)4. **c)** shows the western blot results of HEK293T cells, which were transfected with antisense fusion RNAs. The levels of ATP6

protein were monitored by western blot analyses 24 hours post-transfection. Mt-COXII (cytochrome c oxidase polypeptide II) was used as a mitochondrial loading control. **d)** shows a column graph depicting the reduction in ATP levels in HEK293T cells, which were transfected with antisense fusion RNAs along with the control RNAs. Reductions of ATP levels were determined 24 hours post-transfection using Cell Titre-Glo Assay. A cells-only control was used for normalization of the data sets (Dunnett's multiple comparisons test). **e)** shows images of ethidium bromide-free agarose gel electrophoresis of equimolar amounts of *in vitro* transcribed fluorescein-12 uracil-labelled RNAs. **f)** provides column graphs showing the fluorescence intensity to uracil ratios of fluorescein labelled RNAs. g) depicts Mander's overlap coefficient for either HEK293T or HepG2 (**h**)) cells, which were transfected with fluorescein-12 uracil-labelled RNA. Co-localization of the fluorescein-12 uracil-labelled RNA with the MitoTracker-Orange stained mitochondria was quantified from confocal microscopy images using ImageJ algorithm JACOP. Co-localization represented by Mander's overlap coefficient is shown. RNA labelling intensity-adjusted relative to Mander's overlap coefficient in HEK293T (**i)**) and HepG2 (**j)**) are shown. Five images were used for analysis (Tukey's multiple comparison test). Data represent each averages of five representative images ± SD. Significance of the data in g) and h) was tested using 1-way ANOVA with Dunnett's multiple comparisons test. Significance of the data in i) and j) was tested using Tukey's multiple comparison test.

[0064] **Fig. 19** shows HEK293T (**a**) or HepG2 (**b**) cells were transfected with fluorescein-12 uracil-labelled in vitro transcribed RNAs (green), nuclei were stained with Hoechst 33342 (blue), and mitochondria were stained with MitoTracker (red). Co-localisation of transfected RNA with mitochondria is indicated by a yellow signal in the overlay images.

[0065] **Fig. 20** shows minimum free energy (mfe) structures of tandem repeat RNAs, namely $(D2)_4$, $(D3)_4$, $(D3)_4_(D2)_4$, $(D2)_4_(D3)_4$, and $(D3_D2)_4$. These structures are as predicted by mfold.

DEFINITION OF TERMS

[0066] The term "naked nucleic acid" refers to a nucleic acid (either DNA or RNA) that is, as opposed to non-viral or viral vectors, not complexed with any other compound neither with histones, proteins, lipids, sugars, nanoparticular structures, viral capsids or envelopes nucleic acid that occurs, for example, during cell to cell transfer or transformation of cells with nucleic acid sequences.

[0067] The term "coding/non-coding nucleic acid sequences" refers to both coding and non-coding nucleic acid sequences. A non-coding nucleic acid (that is for example RNA or DNA) is a nucleic acid molecule that is not translated into a protein. Conversely, a coding nucleic acid molecule is a nucleic acid molecule that is translated into a protein. For example, when used in regards to RNA, these non-coding RNA are also termed non-protein-coding RNA (npcRNA), non-messenger RNA (nmRNA) and

functional RNA (fRNA). For example, a DNA sequence from which a functional, non-coding RNA is transcribed is often known as an RNA gene. Examples of non-coding RNA genes include, but are not limited to, highly abundant and functionally important RNAs such as, for example, transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), as well as RNAs such as small nucleolar RNAs (snoRNAs), microRNAs, small interfering RNAs (siRNAs), antisense RNAs (asRNA), small nuclear RNAs (snRNA or U-RNA), exosomal/extracellular RNAs (exRNAs), Piwi-interacting RNAs (piRNA), small Cajal body RNA genes (scaRNAs) and long non-coding RNAs (ncRNAs or lncRNAs), which include examples such as, but not limited to, X-inactive specific transcript (Xist) and HOX transcript antisense RNA (HOTAIR). The number of non-coding RNAs encoded within the human genome is unknown; however, transcriptomic and bioinformatic studies suggest the existence of thousands of non-coding RNAs. Since many of the newly identified non-coding RNAs have not been validated for their function, it is possible that many are non-functional. It is also likely that many non-coding RNAs are non-functional (often termed "junk RNA"), and are the result of spurious transcription.

[0068] The term "sense" and "antisense" refers to concepts used to compare the polarity of nucleic acid molecules, such as DNA or RNA, to other nucleic acid molecules. Depending on the context, these sense and antisense molecules may refer to different molecules compared to the common 5'-3' naming convention for nucleic acid sequences. For example, in double stranded DNA (dsDNA), a single strand of DNA may be called the sense strand (or positive (+) strand), if the RNA version of the same sequence is translated or translatable into proteins. The complementary strand to this positive DNA strand is called the antisense (or negative (-) strand). This is not to be confused with the concept of coding and non-coding nucleic acid sequences, as defined above. As an example, the two complementary strands of double-stranded DNA (dsDNA) are usually differentiated as the "sense" strand and the "antisense" strand. The DNA sense strand looks like the messenger RNA (mRNA) and can be used to read the expected protein code; for example, ATG in the sense DNA may correspond to an AUG codon in the mRNA, encoding the amino acid methionine. However, the DNA sense strand itself is not used to make protein by the cell. It is the DNA antisense strand which serves as the source for the protein code, because, with bases complementary to the DNA sense strand, it is used as a template for the mRNA. Since transcription results in an RNA product complementary to the DNA template strand, the mRNA is complementary to the DNA antisense strand. The mRNA is what is used for translation (protein synthesis). In an example for RNA, antisense RNA is an RNA sequence (or transcript) that is complementary to endogenous mRNA. In other words, it is a non-coding strand complementary to the coding sequence of RNA. Introducing a transgene coding for antisense RNA is, for example, a technique used to block expression of a gene of interest.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

[0069] Mitochondria, a double membrane-bound organelle found in all eukaryotic organisms, are typically associated with ATP production in all living eukaryotic cells. However, defects in enzymes that form part of the respiratory cycle result in, for example, mitochondria-associated diseases, which can be difficult to treat due to the inaccessibility of the mitochondrial genome. Therefore, in order to treat such diseases associated with, for example, defects in the mitochondrial genome, the present disclosure identifies subdomains and combinations of RNA sequences within, for example, the human cytomegalovirus (CMV) β2.7 RNA for targeted delivery of RNA into mitochondria, using the propensity the human cytomegalovirus β2.7 RNA for targeting and co-localising into mitochondria. Thus, disclosed herein is the mitochondrial delivery of a recombinant coding RNA into the mitochondria, which leads to, for example recombinant mitochondrial gene expression. Also disclosed herein is the mitochondrial delivery of, for example, a non-coding antisense RNA into the mitochondria, which triggers functional knockdown of mitochondrial gene expression. The identified sequences are for use in gene therapy to, for example, suppress mitochondrial malfunction, or to restore mitochondrial gene functions in neurodegenerative, or other mitochondria-associated diseases, or for anti-ageing purposes.

[0070] It was shown that the 5' terminal part of the human cytomegalovirus β2.7 RNA, the so-called p137 RNA, co-localizes with mitochondrial complex I protecting complex I activity, however, functional coding or non-coding RNA has not yet being delivered using the β2.7 RNA sequences. The generation of a vector system that allows delivering recombinant nucleic acids into the mitochondria allow for, for example the genetic therapy of mitochondria-associated, yet incurable, human diseases. The distinct non-coding RNA originating from the human cytomegalovirus, the so called β2.7 RNA, was found to localize to the mitochondria of mammalian cells and bind to mitochondrial complex I. Thus, in one example, the nucleic acid delivery system as disclosed herein comprises RNA, or DNA, or combinations thereof. In another example, the nucleic acid delivery system comprises RNA. In another example, the nucleic acid delivery system comprises DNA.

[0071] Thus, in one example, the present invention refers to a nucleic acid delivery construct comprising at least one sense or antisense RNA subdomain of the human cytomegalovirus β2.7 RNA, wherein each subdomain is capable of localisation within the mitochondria. In another example, the nucleic acid delivery construct comprises at least one sense RNA subdomain of the human cytomegalovirus β2.7 RNA. In another example, the nucleic acid delivery construct comprises at least one antisense RNA subdomain of the human cytomegalovirus β2.7 RNA. In yet another example, the nucleic acid delivery construct comprises one or more sense or antisense RNA subdomains of the human cytomegalovirus β2.7 RNA.

[0072] The nucleic acid delivery construct, as disclosed herein, can comprise a number of sense or antisense RNA subdomains. In one example, the number of subdomains in the nucleic acid delivery construct is, but is not limited to, between 1 to 10 subdomains, between 5 to 15 subdomains, between 12 to 22 subdomains, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 subdomains. In other words, a nucleic acid delivery construct according to the present disclosure comprises between 1 to 10 RNA sequences, between 5 to 15 RNA sequences, between 12 to 22 RNA sequences, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 RNA sequences.

[0073] The present disclosure relates to the identification of RNA sequences within CMV β2.7 RNA for targeted delivery into mitochondria. That is to say that the human cytomegalovirus β2.7 RNA, when introduced to a cell, seeks out and enters the mitochondria, and, as a result, is not found in the cytoplasm of said cell. The same can be said for each of the RNA subdomains of the human cytomegalovirus β2.7 RNA. The identified RNA sequences consist of four thermodynamically conserved structural sub-domains (D1 to D4). From these sub-domains, tandem repeats and combinations of RNA sequences are constructed. Tandem repeats constructed from functionally relevant domains, for example domain 2 (D2X4) and domain 3 (D3X4), among which, for example, domain 3 (D3X4), exhibits enhanced mitochondrial localization potential. Combination of tandem repeats are constructed as, for example, (D3X4_D2X4 or D2X4_D3X4), in which (D3X4_D2X4) exhibits highest mitochondrial targeting potential. Domain 1 and 4 exhibit similar structures on the antisense transcript and the antisense domains AS1 and AS4 exhibit substantial mitochondrial localization potential. Delivery of CMV β2.7 RNA-derived sequences with coding RNA into mitochondria leads to recombinant mitochondrial gene expression. For example, the dual tetrameric of domains D3 and D2 (D3x4_D2x4) protects mitochondrial complex I with higher efficiency than the wild type β2.7 RNA.

[0074] Thus, in one example, the nucleic acid sequence is as disclosed herein, wherein each subdomain is capable of localisation within the mitochondria but does not localise into the cytoplasm.

[0075] Disclosed herein are isolated RNA sequences of the human cytomegalovirus p137 RNA, which is the 5' terminal end of the human cytomegalovirus β2.7 RNA. This 5' terminal end of the human cytomegalovirus β2.7 RNA sequences comprises of four, thermodynamically conserved, structural subdomains, named D1 to D4, respectively, each of which is capable of targeting the mitochondria of a cell. Thus, in one example, the nucleic acid delivery construct, as disclosed herein, comprises RNA sequences from human cytomegalovirus β2.7 RNA, which are, but are not limited to, β2.7 RNA (SEQ ID NO: 1 or SEQ ID NO: 2), domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7) of β2.7 RNA, domain 2 (D2; SEQ ID NO: 4 or SEQ ID NO: 8) of β2.7 RNA, domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) of β2.7 RNA, domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of β2.7 RNA and

combinations thereof. In one example, the nucleic acid delivery construct comprises one type of RNA sequence as disclosed herein. Examples of types of RNA sequences are, but are not limited to, sense RNA, antisense RNA, messenger RNA (mRNA), transfer RNA (tRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snRNA), Piwi-interacting RNA (piRNA), tRNA-derived RNA (tsRNA), small rDNA-derived RNA (srRNA), ribosomal RNA (rRNA), long non-coding RNA (lncRNA), short hairpin RNA (shRNA) and transfer-messenger RNA (tmRNA). In one example, the nucleic acid delivery construct comprises sense RNA. In another example, the nucleic acid delivery construct comprises antisense RNA. In a further example, the nucleic acid delivery construct comprises a combination of sense and antisense RNA. In another example, the nucleic acid delivery construct comprises a combination of the RNA sequences as disclosed herein. In yet another example, the nucleic acid delivery construct comprises a combination of the RNA sequences as disclosed herein, wherein the nucleic acid delivery construct can comprise multiple repeats of a single RNA sequence. In another example, the nucleic acid delivery construct comprises the full length sequence of β2.7 RNA (SEQ ID NO: 1 (sense)). In another example, the nucleic acid delivery construct comprises the full length sequence of β2.7 RNA (SEQ ID NO: 2 (antisense)). In yet another example, the nucleic acid delivery construct comprises domain 1 of β2.7 RNA (SEQ ID NO: 3 (sense). In yet another example, the nucleic acid delivery construct comprises domain 1 of β2.7 RNA (SEQ ID NO: 7 (antisense)). In a further example, the nucleic acid delivery construct comprises domain 2 of β2.7 RNA (SEQ ID NO: 4 (sense)). In one example, the nucleic acid delivery construct comprises domain 2 of β2.7 RNA (SEQ ID NO: 8 (antisense)). In another example, the nucleic acid delivery construct comprises domain 3 of β2.7 RNA (SEQ ID NO: 5 (sense)). In yet another example, the nucleic acid delivery construct comprises domain 3 of β2.7 RNA (SEQ ID NO: 9 (antisense)). In a further example, the nucleic acid delivery construct comprises domain 4 of β2.7 RNA (SEQ ID NO: 6 (sense)). In one example, the nucleic acid delivery construct comprises domain 4 of β2.7 RNA (SEQ ID NO: 10 (antisense)). In another example, the nucleic acid delivery construct comprises domain 2, domain 3 and domain 4 of β2.7 RNA (SEQ ID NO: 11 (sense) or SEQ ID NO: 40 (antisense)). In a further example, the nucleic acid delivery construct comprises domain 1, domain 3 and domain 4 of β2.7 RNA (SEQ ID NO: 12 (sense) or SEQ ID NO: 41 (antisense)). In a further example, the nucleic acid delivery construct comprises domain 1, domain 2 and domain 4 of β2.7 RNA (SEQ ID NO: 13 (sense) or SEQ ID NO: 42 (antisense)). In another example, the nucleic acid delivery construct comprises domain 1, domain 2 and domain 3 of β2.7 RNA (SEQ ID NO: 14 (sense) or SEQ ID NO: 43 (antisense)).

[0076] As used herein, the term “sequence identity” refers to the situation where two polynucleotide or amino acid sequences are identical, or have a number of identical residues (i.e., on a nucleotide-by-nucleotide or residue-by-residue basis) over the comparison window. The term “percentage of sequence

identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) or residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms "sequence identity", as used herein, denotes a characteristic of a polynucleotide or amino acid sequence, wherein the polynucleotide or amino acid may comprise a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 18 nucleotide (6 amino acid) positions, frequently over a window of at least 24 to 48 nucleotide (8 to 16 amino acid) positions, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the sequence, which may include deletions or additions, which total 20 percent or less of the reference sequence over the comparison window. The reference sequence may be a subset of a larger sequence. Thus, in another example, the nucleic acid delivery system, as disclosed herein, comprises RNA sequences from human cytomegalovirus β2.7 RNA, wherein the RNA sequences have a sequence identity of between 70% to 99%, of between 75% to 85%, of between 78% to 88%, of between 80% to 89%, of about 90%, of about 91%, of about 92%, of about 93%, of about 94%, of about 95%, of about 96%, of about 97%, of about 98%, or of about 99% of one or more of the RNA sequences disclosed herein. In one example, the nucleic acid delivery construct is as disclosed herein, wherein the RNA sequences from human cytomegalovirus β2.7 RNA has a sequence identity of about 90%, of about 91%, of about 92%, of about 93%, of about 94%, of about 95%, of about 96%, of about 97%, of about 98%, or of about 99% of one or more of the RNA sequences, which are, but are not limited to, β2.7 RNA (SEQ ID NO: 1 or SEQ ID NO: 2), domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7) of β2.7 RNA, domain 2 (D2; SEQ ID NO: 4 or SEQ ID NO: 8) of β2.7 RNA, domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) β2.7 RNA, domain (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of β2.7 RNA and combinations thereof.

[0077] The nucleic acid delivery constructs, as disclosed herein, can also further include one or more changes in the nucleic acid sequence. In one example, such a change is a mutation in the RNA sequence. In another example, the nucleic acid delivery construct comprises one or more non-structural mutations. In yet another example, the nucleic acid delivery construct comprises one or more structure neutral mutations. As used herein, the term "non-structural mutation" or "structure neutral mutation" refers to a mutation in a nucleic acid sequence which changes the sequence of the nucleic acid sequence, but preserves the functional structure of the mutated sequence compared to the unmutated sequence.

[0078] From these subdomains, tandem repeats and combinations of RNA sequences are constructed. As used herein, the term “tandem repeats” refers to sections within a nucleic acid sequence where a pattern of one or more nucleotides is repeated and the repetitions are directly adjacent to each other. For example, a sequence of ATGGC repeated 3 times in a row, thus resulting in a sequence comprising ATGGC ATGGC ATGGC, is understood to be a tandem repeat. Based on the invention as disclosed herein, sequences are constructed from functional RNA domains, that is from any of the subdomains D1, D2, D3 or D4. Examples of such constructed domains are, but are not limited to, domain 2 (a four-time repeat of domain 2, in other words D2X4) and domain 3 (a four-time repeat of domain 3, in other words D3X4). Thus, in one example, the nucleic acid delivery system as disclosed herein comprises combinations and/or multiples of the RNA sequences disclosed herein, including, but not limited to, duplicates (2), triplicates (3), quadruplicates (4), quintuplicates (5), sextuplicates (6), septuplicates (7) octuplicates (8) or longer repeats of single domains. In other words, the combinations and/or multiples of the RNA sequences disclosed herein include, but are not limited to, dimers, trimers, tetramers, or polymers of single domains.

[0079] As used herein, the term “spacer” refers to a sequence of nucleic acids that are inserted at either the 5’ or 3’ end of a nucleic acid sequence, or at both ends of a nucleic acid sequence, within a construct. The spacer is inserted at defined positions within the nucleic acid sequence in order to ensure that the structural integrity of a nucleic acid sequence, for example in an RNA sequence, remains. This ensures the retention of function or characteristic of the RNA sequence, for example, the mitochondrial targeting capability of the nucleic acid construct. The spacer also functions to prevent any steric effects from occurring and to enable the nucleic acid sequence to attain its natural tertiary structure, thereby also facilitating the retention of its function. Thus, in one example, the nucleic acid delivery construct as disclosed herein comprises between 1 to 10, between 5 to 15, between 8 to 24, at least one, at least two, at least three, at least four, at least 5, about 6, about 7, about 8 or about 9 spacer sequences. In one example, the nucleic acid delivery construct comprises about 6 spacer sequences. In another example, the nucleic acid delivery construct comprises about 7 spacer sequences. In yet another example, the nucleic acid delivery construct comprises about 8 spacer sequences. In a further example, the nucleic acid delivery construct comprises about 9 spacer sequences.

[0080] As stated above, the spacers sequences can be placed anywhere within the nucleic acid sequence. For example, spacers can found at the beginning (that is the 5’ end) of an RNA sequence. Spacers can also be found at the end (that is the 3’ end) of an RNA sequence. When more than one spacer is used, these spacers can also be found at both the 5’ and 3’ ends of an RNA sequence. Thus, in one example, when the nucleic acid delivery construct comprises at least two or more spacers, at least

one spacer sequence is at the 5' end and at least one other spacer sequence is at the 3' end of the RNA sequence of human cytomegalovirus β2.7 RNA.

[0081] The length of a spacer is defined, for example, by the specific function that the spacer is intended to fulfil. For example, if the function of a spacer is to prevent steric hindrance between two or more RNA sequences, this spacer could then be between tens to hundreds of nucleotides long, depending on the size of the resulting RNA structure. In other words, the spacer sequence disclosed in the present invention is sufficiently long to prevent any steric hindrance from arising between neighbouring RNA subdomains and/or wherein the length of the spacer sequence is sufficiently long to allow neighbouring RNA subdomains to fold into their thermodynamically preferred structure. Having said that, a person skilled in the art would appreciate that the spacer length is dependent on the length, structure, and combination(s) of the at least one sense or antisense RNA subdomains as disclosed in the nucleic acid delivery system disclosed herein. In one example, the spacer sequence is between 5 to 40 nucleotides, between 5 to 30 nucleotides, between 6 to 10 nucleotides, between 8 to 14 nucleotides, between 15 to 20 nucleotides, between 22 to 28 nucleotides, between 25 to 37, between 28 to 39 nucleotides, about 7 nucleotides, about 9 nucleotides, about 11 nucleotides, about 12 nucleotides, about 13 nucleotides, about 15 nucleotides, about 17 nucleotides, about 21 nucleotides, about 27 nucleotides, about 29 nucleotides, about 30 nucleotides, about 34 nucleotides, about 36 nucleotides in length. In one example, the spacer sequence is 5 nucleotides long. In another example, the spacer sequence is 6 nucleotides long. In yet another example, the spacer sequence is 13 nucleotides long. In a further example, the spacer sequence is 17 nucleotides long. In one example, the spacer sequence is 24 nucleotides long. In yet another example, the spacer sequence is 32 nucleotides long.


[0082] In one example, the spacer sequence is, but is not limited to S1a (SEQ ID NO:27), S1b (SEQ ID NO:28), S2a (SEQ ID NO:29), S2b (SEQ ID NO:30), S3a (SEQ ID NO:31), S3b (SEQ ID NO:32), S4a (SEQ ID NO:33), S4b (SEQ ID NO:34), S6a (SEQ ID NO:35), S6b (SEQ ID NO:36), S8a (SEQ ID NO:37), S8b (SEQ ID NO:38) and Spacer F3A (SEQ ID NO: 39), and combinations thereof.

[0083] Spacer sequences may also contain functional nucleic acid sequences, or other structural or functional motifs. For example, a spacer sequence can further optionally comprise a stop codon.

[0084] As used herein, the term "nuclear localization signal" or "NLS" refers to nucleic acid sequences coding for one or more additional secretory signals or signalling peptides. These nuclear localization sequences can be added to the 5' or 3' end of the nucleic acid sequence, thereby resulting in the expression of such a nuclear localization sequence at the C-terminus or N-terminus or both the C- and N-termini of a peptide. One example known in the art is the addition of a nuclear localisation sequence (NLS) which directs the nascent protein for import from the cytoplasm into to the nucleus of the cell. There are many different versions of nuclear localisation sequences and their length and

composition is dependent on the cell type from which they have been isolated. For example, the nuclear localisation sequence of nucleoplasmin is "AVKRPAATKKAGQAKKKKLD", whereas the nuclear localisation sequence of c-myc is "PAAKRVKLD". Thus, in one example, the nucleic acid delivery construct further optionally comprises a nuclear localization signal (NLS).


[0085] In one example, the nucleic acid delivery system disclosed herein is a RNA sequence according to the formula I:



(I)

wherein each X is independently, but not limited to, D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof, including duplicates, triplicates, quadruplicates, quintuplicates, sextuplicates, septuplicates, octuplicates, or longer repeats of single domains; and wherein each X is optionally preceded or followed or flanked by at least one or more spacer sequences as defined herein. In other words, in one example, the nucleic acid delivery system is a dimer, wherein each X is independently, but not limited to, D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof; and wherein each X is optionally preceded or followed or flanked by at least one or more spacer sequences as defined herein.

[0086] In one example, the nucleic acid delivery system disclosed herein is a RNA sequence according to the formula II:




(II)

wherein each X is independently, but not limited to, D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10), or combinations thereof, including duplicates, triplicates, quadruplicates, quintuplicates, sextuplicates, septuplicates, octuplicates, or longer repeats of single domains; and wherein the spacer sequences S1a, S1b, S2a, S2b, S3a, S3b S4a and S4b are as disclosed herein. In one example, X is D2 (SEQ ID NO: 4 or SEQ ID NO: 8). In another example, X is D3 (SEQ ID NO: 5 or SEQ ID NO: 9). In yet another example, the nucleic acid delivery construct according to formula II comprises a nucleic acid sequence according to SEQ ID NO: 15 or SEQ ID NO: 51. In a further example, the nucleic acid delivery construct according to formula II comprises a nucleic acid sequence according to SEQ ID NO:

16 or SEQ ID NO: 52. In other words, in one example, the nucleic acid delivery system is a tetramer, wherein each X is independently, but not limited to, D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof; and wherein each X is optionally preceded or followed or flanked by at least one or more spacer sequences as defined herein.


[0087] In one example, the nucleic acid delivery system disclosed herein is a RNA sequence according to the formula III:



(III)

wherein X and Y are different from each other, wherein each X and each Y are independently, but not limited to, D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof, including duplicates, triplicates, quadruplicates, quintuplicates, sextuplicates, septuplicates, octuplicates, or longer repeats of single domains; and wherein the spacer sequences S1a, S1b, S2a, S2b, S3a, S3b S4a and S4b are as defined herein. In one example, X is D3 (SEQ ID NO: 5 or SEQ ID NO: 9) and Y is D2 (SEQ ID NO: 4 or SEQ ID NO: 8). In another example, X is D2 (SEQ ID NO: 4 or SEQ ID NO: 8) and Y is D3 (SEQ ID NO: 5 or SEQ ID NO: 9). In a further example, the nucleic acid delivery construct according to formula III comprises a nucleic acid sequence according to SEQ ID NO: 17 or SEQ ID NO: 54. In another example, the nucleic acid delivery construct according to formula III comprises a nucleic acid sequence according to SEQ ID NO: 18. In other words, in one example, the nucleic acid delivery system is a tetramer, wherein each X and Y are independently, but not limited to, D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof; and wherein each X and Y are optionally preceded or followed or flanked by at least one or more spacer sequences as defined herein.

[0088] In one example, the nucleic acid delivery system disclosed herein is an octamer of RNA sequences according to the formula IV:



(IV)

wherein X and Y are different from each other, wherein each X and each Y are independently, but not limited to, D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof, including duplicates, triplicates, quadruplicates, quintuplicates, sextuplicates, septuplicates, octuplicates, or longer repeats of single domains; and wherein the spacer sequences S1a, S1b, S2a, S2b, S3a, S3b S4a and S4b are as defined herein. In one example, X is D3 (SEQ ID NO: 5 or SEQ ID NO: 9) and Y is D2 (SEQ ID NO: 4 or SEQ ID NO: 8). In another example, the nucleic acid delivery construct according to formula III comprises a nucleic acid sequence according to SEQ ID NO: 19.

[0089] In order for the claimed nucleic acid delivery system to function as a delivery system, the nucleic acid sequence needs to further comprise a payload. As used herein, the term “payload” refers to one or more nucleic acid sequences that can be inserted into the sequence of the nucleic acid delivery system, which, as a result of its insertion, then acts on or within the mitochondria of the cell. A payload can be, but is not limited to, a recombinant nucleic acid sequence, RNA, DNA, modified nucleic acids, nucleic acid analogues and nucleic acid mimics including pyranosyl nucleic acids (p-RNA), threose nucleic acids (TNA), glycol nucleic acids (GNA), peptide nucleic acids (PNA), alanyl nucleic acids (ANA), locked nucleic acids (LNA), morpholinophosphoramidates (MF), non-nucleic acid-based molecules including peptides, proteins, lipids, carbohydrates, synthetic polymers, small molecular weight compounds, and the like. In one example, the recombinant nucleic acid sequence is, but is not limited to, non-coding nucleic acid sequence, coding nucleic acid sequence, single-stranded nucleic acid sequence, linear double-stranded nucleic acid sequence, antisense nucleic acid sequences, sense nucleic acid sequence circular single-stranded nucleic acid sequence and circular double-stranded nucleic acid sequence. In another example, the recombinant nucleic acid sequence is a complete, natural or recombinant mitochondrial genome. In yet another example, the nucleic acid delivery construct comprises a sequence according to any one of SEQ ID NO: 20 to SEQ ID NO: 84.

[0090] Furthermore, said payload needs to be attached to the nucleic acid delivery system in order to be able to be transported. In one example, the payload is covalently linked to the nucleic acid delivery system. In another example, the payload is non-covalently linked to the nucleic acid delivery system. Non-covalent linkage can be achieved via electrostatic interactions including ionic interactions,

hydrogen bonding, or halogen bonding, via Van der Waals forces including dipole-dipole interactions, induced dipole interactions, or London dispersion forces, via π-effects including π – π interactions, cation- or anion- π interactions, or polar- π interactions, or via hydrophobic effects. A covalent linkage, on the other hand, is a linkage that involves the sharing of electron pairs between atoms. Examples of covalent bonds or linkages include many kinds of interactions including, but not limited to, σ-bonding, π-bonding, metal-to-metal bonding, agostic interactions, bent bonds, and three-centre two-electron bonds.

[0091] Akin to the physical concepts governing, for example, the aeronautical concept of payload transportation, a person skilled in the art would appreciate that the size of a payload dictates the size of the carrier (that is the nucleic acid delivery system) required to carry such a payload to its intended destination. Thus, in one example, the total size of nucleic acid delivery construct is proportional to the size of a payload. This means that a nucleic acid delivery system for a payload of, for example, 200 nucleic acids in length, would be four times larger than a nucleic acid delivery system of a payload which is only 50 nucleic acids long. Conversely, a payload, which is only 10 nucleic acids long, can make use of a nucleic acid delivery system that is half the size of a nucleic acid delivery system for a payload which is 20 nucleic acids long. Thus, in one example, the nucleic acid delivery system is scalable. In another example, the nucleic acid delivery system is scalable according to, or proportionally to, the size of the payload.

[0092] The potential of the most active RNA, (D3)4_(D2)4, to co-deliver the MT-ATP6-directed antisense RNA into the mitochondria was investigated. To this end, the MT-ATP6 antisense RNA was fused to the 5' end of (D3)4_(D2)4 via a spacer, thereby generating the construct ATP6_(D3)4_(D2)4. The spacer was selected to preserve both the open structure of the antisense RNA, as well as the domain structures within (D3)4_(D2)4 according to predictions with mfold (Fig. 18a). HEK293T cells were transfected with the *in vitro* transcribed RNAs and target gene knockdown was monitored on the protein level using western blot 24 hours post transfection (Fig. 18b,c). Compared with ATP6_β2.7 RNA, the ATP6_(D3)4_(D2)4 RNA triggered a substantially stronger knockdown of the MT-ATP6 protein leading to a 2.1-fold higher reduction of cellular ATP levels (Fig. 18d). This data indicates mitochondrial targeting is scalable and not restricted by an impaired by increasing length of the targeting vector. In order to have direct proof of mitochondrial RNA targeting, RNAs were labelled with fluorescein-12-uracil during *in vitro* transcription, and the integrity and labelling efficiency of the RNA was assessed using agarose gel electrophoresis (Fig. 18e). Band intensities were quantified using the software ImageJ v1.48 (Fig. 19) and intensity to uracil count or length ratios were calculated (Fig. 18f). These ratios were comparable for all RNAs, indicating similar labelling efficiencies. Subsequently, HEK293T or HepG2 cells were transfected with the labelled RNA, and mitochondria stained with

MitoTracker Orange (Fig. 19). The Manders overlap coefficient (MOC) was determined as a metric of co-localisation of the labelled RNA and mitochondria (Fig. 18g,h). All β2.7-RNA/-domain chimeras showed significant levels of co-localisation compared with the β2.7-negative RNAs. RNAs harbouring the (D3)4_(D2)4 tandem repeat structures exhibited a significantly stronger co-localisation effect compared with β2.7-RNA containing RNAs when comparing the RNA-labelling, intensity-adjusted Manders overlap coefficients in HEK293T (Fig. 18i) or HepG2 cells (Fig. 18j).

[0093] Also encompassed in the present disclosure are vectors, recombinant cells, recombinant organisms and nucleic acid sequences, which comprise or express the nucleic acid delivery system as disclosed herein. In one example, a vector comprises the nucleic acid delivery system as disclosed herein. In another example, the vector comprises a naked nucleic acid, or a non-viral vector, or a viral vector, or combinations thereof.

[0094] In one example, a recombinant cell comprises the nucleic acid sequence as disclosed herein. In another example, the recombinant cell expresses the nucleic acid sequence in a consecutive manner (that is, consecutively). In yet another example, the recombinant cell expresses the nucleic acid sequence in a non-consecutive manner (that is, non-consecutively). In one example, a recombinant organism comprises the nucleic acid sequence as disclosed herein. In another example, the recombinant organism expresses the nucleic acid sequence in a consecutive manner (that is, consecutively). In yet another example, the recombinant organism expresses the nucleic acid sequence in a non-consecutive manner (that is, non-consecutively).

[0095] In one example, a nucleic acid sequence comprises at least one or more sense or antisense RNA sequences of the human cytomegalovirus β2.7 RNA. In another example, the RNA sequences of the human cytomegalovirus β2.7 RNA are, but are not limited to, domain 1(D1; SEQ ID NO: 3 or 7), domain 2 (D2; SEQ ID NO: 4 or 8), domain 3 (D3; SEQ ID NO: 5 or 9) and domain 4 (D4; SEQ ID NO: 6 or 10).

[0096] Also disclosed within the scope of the present invention are methods of treating diseases. Mitochondrial disorders are usually caused by heterogeneity resulting from unequal segregation of defective mitochondrial DNA (mDNA). Thus, one therapeutic method is to reduce the abundance of defective messenger RNA (mRNA), thereby allowing the wild type messenger RNA to re-populated the mitochondria. The identified sequences can thus be used in gene therapy to suppress mitochondrial malfunction, or to restore mitochondrial gene functions in neurodegenerative, or other mitochondria-associated diseases, or for anti-aging purposes.

[0097] The parental human cytomegalovirus β2.7 RNA can protect the mitochondrial complex I from certain inhibitors and, thus protect the mitochondria from oxidative stress and DNA damage, thereby increasing cell viability. The parental human cytomegalovirus β2.7 RNA was also found to

prevent death of dopaminergic neurons in the brain. The death of dopaminergic neurons in the brain is considered to be a hallmark of Parkinson's disease. It has been shown that, for example, a short 100 nucleotide long subdomain (domain 2 of the β2.7 RNA) successfully protected the mitochondrial complex I to a similar extent as the parental β2.7 RNA sequences. Therefore, domain 2, among the other domains disclosed herein, can be implemented in the treatment of Parkinson's disease. The term parental sequence refers to the original β2.7 RNA sequence derived from human cytomegalovirus strain towne (GenBank: FJ616285.1).

[0098] Cell penetrating peptides can be used to successfully deliver β2.7 derived sequences into, for example, lung tissue of human and animal models. This delivery serves to treat impaired oxidative phosphorylation (OXPHOS), for example, and in another example, increase reactive oxygen species (ROS) levels associated with chronic obstructive pulmonary disorder (COPD). Additionally, antisense RNA can be used to target hereditary mitochondrial defects in the lungs

[0099] β2.7 RNA, or subdomains thereof, can also be used to deliver intact mitochondrial genomes for treatment of disorders with mitochondrial DNA (mDNA) deletions, such as Kearns-Sayre Syndrome (KSS), Pearson Syndrome and progressive opthalmoplegia (PEO), all of which share overlapping phenotypes and which are associated with a common 4977 base pair deletion within the mitochondrial DNA.

[00100] Thus, in one example, there is disclosed a method of treating a mitochondrial disorder. In another example, the method of treating a mitochondrial disorder comprises administering to a subject the nucleic acid delivery construct as disclosed herein. In yet another example, the method comprises using the nucleic acid delivery construct to deliver antisense RNA. The mitochondrial disorder can be, but is not limited to, maternally inherited diabetes mellitus, Leber's hereditary optic neuropathy (LHON), neuropathy, ataxia, retinitis pigmentosa, myoclonic epilepsy with ragged red fibers (MERRF), mitochondrial myopathy encephalopathy lactic acidosis and stroke like symptoms (MELAS), Parkinson's disease, chronic obstructive pulmonary disorder (COPD), Kearns-Sayre Syndrome (KSS), Pearson Syndrome and progressive opthalmoplegia (PEO).

[00101] Said mitochondrial disorders can be treated in various ways, for example, by targeting one or more mitochondrial genes, which are, but not limited to, MT-TL1 (tRNA leucine), MT-ND1, MT-ND4, MT-ND6, MT-ATP6, MT-TK (tRNA lysine), MT-ND1, MT-ND5, MT-TH (histidine), MT-TL1 (leucine), MT-TV (valine), and combinations thereof.

[00102] One example of the treatment of mitochondrial disorders is the antisense-mediated suppression of defective mitochondrial genes/gene functions. This involves, for example, the use of the nucleic acid delivery system as disclosed herein to deliver antisense RNA into the mitochondria. For example, the ability of the human cytomegalovirus β2.7-mediated delivery of antisense RNA to

successfully knock down mt-ATP6 mRNA within mitochondria has been demonstrated in the present application. Defects in the mt-ATP6 have been associated with, for example but not limited to, neuropathy, ataxia, and retinitis pigmentosa (NARP). In the example of NARP, the β2.7-mediated antisense RNA delivery system has been used to successfully knock down defective mRNA associated with NARP, thereby allowing the wild type ATP6 mRNA to re-populate the mitochondria. Hence, the nucleic acid system as disclosed herein can be used for treatment of NARP.

[00103] Another example of how the claimed invention can be used in the treatment of mitochondrial disorders is the delivery of a mitochondrial gene. Alternatively to suppressing defective mRNAs using antisense RNA, the nucleic acid delivery system as disclosed herein can be used to deliver an intact (mitochondrial) gene into the mitochondrial to increase the ratio of intact mRNA to defective RNA. Provided below is a non-exhaustive list of target genes and their associated diseases.

[00104] **Table 1: A list of target genes and associated diseases.**

Disease	**Affected gene**
Maternally inherited diabetes mellitus	MT-TL1 (tRNA leucine)
Leber's hereditary optic neuropathy (LHON)	MT-ND1, MT-ND4, MT-ND6
Neuropathy, Ataxia and Retinitis pigmentosa (NARP)	MT-ATP6
Myoclonic epilepsy with ragged red fibres (MERRF)	MT-TK (tRNA lysine)
Mitochondrial myopathy encephalopathy lactic acidosis and stroke like symptoms (MELAS)	MT-ND1, MT-ND5, MT-TH (histidine), MT-TL1 (leucine), MT-TV (valine).

MT-TL1: Mitochondrial encoded tRNA leucine; MT- TV: Mitochondrial encoded tRNA valine; MT-TK: Mitochondrial encoded tRNA lysine; MT-TH: Mitochondrial encoded tRNA histidine; MT-ND1: Mitochondrial encoded NADH dehydrogenase 1; MT-ND4: Mitochondrial encoded NADH dehydrogenase 1; MT-ND5: Mitochondrial encoded NADH dehydrogenase 5; MT-ND6: Mitochondrial encoded NADH dehydrogenase 6; MT-ATP6: Mitochondrial encoded ATP synthase 6.

[00105] Yet another example of the treatment of mitochondrial disorders is a combination of both suppressing defective mitochondrial gene function and the delivery of intact genes into the mitochondria to increase the ratio between intact and defective genes.

[00106] As disclosed herein, a therapeutic application of the invention can be either the delivery of antisense sequences to suppress defective gene expression, or, alternatively, to deliver intact genes to complement the correct gene function, or a combination of both.

[00107] Thus in one example, there is disclosed a method of enhancing mitochondrial gene function, or suppressing defective mitochondrial gene function, or both (provided that in this case, the mitochondrial genes are different from each other). In the case of both enhancing mitochondrial gene function and suppressing defective mitochondrial gene function, the enhancing and suppressing of gene function can take place simultaneously or sequentially. In one example, the enhancing and suppressing of gene function takes place simultaneously. In another example, the mitochondrial gene functions are different from each other. In yet another example, the method comprises administering to a subject the nucleic acid delivery sequence as disclosed herein.

[00108] For example, domain 3 (D3X4) is shown to exhibit enhanced mitochondrial localisation potential. Combination of tandem repeats are constructed as, for example, D3X4_D2X4 or D2X4_D3X4, whereby D3X4_D2X4 is shown to exhibit the highest mitochondrial targeting potential. It is further shown that domains 1 and 4 exhibit similar structures on the antisense transcript, and that the antisense domains AS1 and AS4 exhibit substantial mitochondrial localization potential.

[00109] Delivery of CMV β2.7 RNA-derived sequences with coding RNA into mitochondria leads to recombinant mitochondrial gene expression. For example, the dual tetramer of domains D3 and D2 (denoted as D3x4_D2x4) protects mitochondrial complex I with higher efficiency than, for example the wild type β2.7 RNA.

[00110] Using computational methods, four thermodynamically conserved structural sub-domains within the β 2.7 RNA were identified. All four domains showed substantial mitochondrial localization, and it was shown that the complete mitochondrial localization activity of the full-length β2.7 RNA could also be achieved by, for example, use of a single sub-domain termed domain 3. Furthermore, two of the four domains (for example, domains 1 and 4) exhibited highly similar structures on the antisense transcript and the antisense domains AS1 and AS4 exhibited substantial mitochondrial localization potential. A tetramer of, for example, sense domain 3 was found to have a twice higher mitochondrial localization activity and, in another example, a tetramer of domains 3 followed by a tetramer of domain 2 exhibited a three-fold higher activity compared with, for example the β 2.7 RNA or domain 3. β2.7 RNA-derived sequences were used to deliver recombinant nucleic acids into mitochondria in order to trigger mitochondria-specific phenotypes: Firstly, in one example, a coding RNA was furnished with mitochondria-specific start and stop codons, leading to mitochondria-specific recombinant gene expression; secondly, antisense RNAs targeting mitochondria-specific genes were used to trigger functional knockdown of mitochondria-specific gene expression. This technology therefore finds use

in mitochondrial gene therapy or, for example, for mitochondrial delivery of non-nucleic acid compounds.

[00111] As an example of the use of the claimed invention, an exemplary method involves delivery of CMV β2.7 RNA-derived sequences with coding RNA into mitochondria, which in turn leads to recombinant mitochondrial gene expression. Delivery of CMV β 2.7 RNA-derived sequences, for example, with antisense RNA into mitochondria triggers functional knockdown of mitochondrial gene expression. One example of such a delivery construct is a tetrameric repeat of the β 2.7 RNA subdomain 3, which has been shown to exhibit enhanced mitochondrial localization potential. Exemplary arrangement of, for example two tetrameric repeats of β2.7 RNA subdomains 3 and 2 (D3x4_D2x4), which exhibit high mitochondrial targeting potential. Exemplary dual tetrameric of domains D3 and D2 (D3x4_D2x4) are shown to protect mitochondrial complex I with higher efficiency than the wildtype β2.7 RNA. Exemplary application of the outlined method is in genetic therapy, for example, to suppress mitochondrial malfunction or, in another example, to restore mitochondrial gene functions. Examples of application also include use in neurodegenerative or other mitochondria-associated diseases or for anti-aging.

[00112] Another example of the use of the claimed invention includes the use of the claimed nucleic acid delivery system together with CRISPR/Cas technology, that is using the claimed nucleic acid delivery system for delivery of the mRNA coding for the Cas9 endonuclease together with a single guide (sg)RNA, or for delivery of the respective genes coding for these components. The Cas9 enzyme together with the sgRNA can then form a ribonucleoprotein complex that can specifically cleave and functionally inactive defect mitochondrial genes or genomes.

[00113] A further application is to provide plasmid-based mitochondrial targeting vectors. A sequence of interest for the transcription of a coding or a non-coding RNA can be inserted either upstream or downstream to the mitochondrial targeting sequences. The chimeric RNAs can then be transcribed from the DNA templates either *in vitro* and then delivered into the target cells, or endogenously after transfection of target cells with the DNA vector. Variations of these vectors for the production of viral delivery particles, for example, but not limited to, lentiviral, adenoviral, adeno-associated virus, are envisioned as well.

[00114] The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms "comprising", "including", "containing", etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various

modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.

[00115] The invention has been described broadly and generically herein. Each of the narrower species and sub-generic groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

[00116] Other embodiments are within the following claims and non- limiting examples. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[00117] Throughout this disclosure, certain embodiments may be disclosed in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

EXPERIMENTAL SECTION

Identification of thermodynamically conserved structural subdomains with the CMV β2.7 RNA

[00118] Using the software foldsplit, four thermodynamically conserved structural subdomains (named D1 to D4, respectively) within the non-coding β2.7 RNA of CMV were identified (Fig. 1b). Thermodynamic conservation frequently correlates with RNA function. Each of these four domains can be assigned to a well-defined structural subdomain within the RNA secondary structure predicted for the complete β2.7 RNA (Fig. 1c).

The CMV β2.7 RNA and distinct functional subdomains thereof localize to the mitochondria of human cells

[00119] Mitochondrial localization, for example, (i) of the full-length β2.7 RNA, (ii) of each of the four single domains D1 to D4, and (iii) of single domain deletion constructs (Fig. 1d-f) were investigated. While all of the deletion mutants and three of four single domains showed reduced mitochondrial targeting, domain 3 exhibited the complete mitochondrial targeting potential of the full-length β2.7 RNA.

Distinct CMV β2.7 RNA antisense domains localize to the mitochondria of human cells

[00120] The antisense sequences of the constructs disclosed herein were considered for use as negative controls and therefore were also investigated in terms of their structures and thermodynamic conservation. Unexpectedly, the structure of the antisense β2.7 RNA was highly symmetric compared with the structure of the sense β2.7 RNA. A highly similar thermodynamic conservation was observed and it was possible to identify four conserved structural subdomains (D1_AS to D4_AS) in the corresponding position within the β2.7 RNA antisense sequence (Fig. 2a). A detailed structural analysis revealed in particular antisense domains D1_AS and D4_AS were structurally almost identical compared with the corresponding sense domains D1 and D4. The mitochondrial localization (i) of the full-length antisense β2.7 RNA, (ii) of each of the four single antisense domains D1_AS to D4_AS, and (iii) of antisense single domain deletion constructs (Fig. 2b-d) were investigated. The full-length antisense β2.7 RNA showed significantly weaker mitochondrial uptake compared with the sense RNA (Fig. 2b) and the deletion of each of the four antisense domains D1_AS to D4_AS further reduced mitochondrial targeting (Fig. 2c). When testing the individual antisense domains, it was shown that antisense domains D1_AS and D4_AS exhibited an about 5-fold higher activity compared with the full-length antisense RNA reaching about 70% of the mitochondrial targeting activity of the sense full-length β2.7 RNA (Fig. 2d).

The CMV β2.7 RNA co-delivers recombinant coding RNA into the mitochondria leading to mitochondrial expression of a recombinant protein

[00121] A β2.7 RNA full-length RNA was fused to the 3' end of EGFP mRNA via a spacer sequence, which ensured that the active structure of the β2.7 RNA was not changing upon fusing it to the EGFP sequence (Fig. 3a,b). Two different version of the EGFP mRNA were considered: 1. The conventional mRNA equipped with regular start and stop codon for cytoplasmic expression; and 2. A modified version equipped with mitochondrial start and stop codon which can only be translated in the mitochondria but not in the cytoplasm of cells. In addition, a version of the mitochondrial EGFP sequence was generated in which the EGFP protein was fused to a nuclear localization peptide so that any EGFP protein that reached the cytoplasm would be targeted to the nucleus in order to suppress any

overlapping EGFP signals originating from the cytoplasm and the mitochondria. All sequences and controls were then tested for mitochondrial targeting using real-time RT-PCR (Fig. 3c) or EGFP expression using flow cytometry (FACS) and confocal microscopy (Fig. 3d-j). Mitochondrial targeting of the β2.7 RNA was not hampered by fusing it to the EGFP mRNA (Fig. 3c). FACS analyses indicated that the mitochondrial egfp sequence (mtGFP_s) alone did not trigger any EGFP expression. Significant EGFP expression, which must originate from the mitochondria, was able to be detected after fusing it to the β2.7 RNA (mtGFP_s_ β2.7) (Fig. 3g). Confocal imaging was not sensitive enough to visualize co-localization of EGFP and a mitochondria-specific stain (MitoTracker Red). However, three different co-localization coefficients indicated significant co-localization of the EGFP and MitoTracker Red in case of the mtGFP_s_ β2.7 but not for the mtGFP_s control (Fig. 3h-j).

The CMV β2.7 RNA co-delivers antisense RNA into the mitochondria leading to suppression of mitochondrial expression of a recombinant protein

[00122] Next, the β2.7 RNA was fused to computationally selected, unstructured antisense RNAs targeting the mitochondrial gene, for example, MT-ATP6 and MT-ATP8 which are both involved in mitochondrial ATP synthesis (Fig. 4). The antisense RNAs were fused to the β2.7 RNA via spacers to ensure the active structures of both sequences (antisense and β2.7 RNA) were maintained during the fusion process. The mitochondrial RNA targeting was then measured using rtRT-PCR (Fig. 4e), knockdown of mitochondrial ATP synthesis (Fig. 4f), and reduction of cell viability as a consequence of reduced ATP levels (Fig. 4g). Fusion of the β2.7 RNA targeted the antisense RNAs to the mitochondria, triggered knockdown of mitochondrial MT-ATP6 or MT-ATP8 mRNA levels, and significantly reduced cell viability.

A tetrameric repeat of the β2.7 RNA subdomain 3 exhibits enhanced mitochondrial localization potential

[00123] It was aimed to improve the mitochondrial targeting potential of the β2.7 RNA, for example by using multiple repeats of the most active β2.7 RNA subdomains, in one example D3 and D2. Tetrameric repeats of domains D3 or D2 were constructed and investigated for mitochondrial targeting using rtRT-PCR (Fig. 5a-f). While the D2 tetramer mitochondrial targeting was comparable to that of the full-length β2.7 RNA, the D3 tetramer showed a two-times higher mitochondrial targeting activity.

The arrangement of two tetrameric repeats of β2.7 RNA subdomains 3 and 2 (D3x4_D2x4) exhibits highest mitochondrial targeting potential

[00124] Next constructs comprising (i) four repeats of D3 followed by four repeats of D2 (D3x4_D2x4), or (ii) four repeats of D2 followed by four repeats of D3 (D2x4_D3x4), or (iii) alternating domains D3 and D2 [(D3_D2)x4] were tested. While D2x4_D3x4 and (D3_D2)x4 exhibited reduced mitochondrial targeting activities comparable with the full-length β2.7 RNA, construct D3x4_D2x4 was found to be about 3-fold more active (Fig. 5g).

The dual tetrameric of domains D3 and D2 (D3x4_D2x4) protects mitochondrial complex I with higher efficiency than the wildtype β2.7 RNA

[00125] The 5' terminal part of the β 2.7 RNA was reported earlier to protect the mitochondrial complex I from inhibitors such as rotenone. It was investigated as to whether domains D3 or D2 alone, or their multimeric arrangements, were able to protect complex I against rotenone when delivering either, for example, the in vitro synthesized RNAs or alternatively plasmids expressing the RNAs endogenously (Fig. 5h,i). While the D2, D3, D3x4, and D3x4_D2x4 RNAs were as protective as the full-length β 2.7 RNA when delivering RNA directly, D3x4_D2x4 was found to be more active when delivering RNA expressing plasmid DNA.

Strategies of delivering recombinant nucleic acids into mitochondria using mitochondrial targeting sequences

[00126] Recombinant RNA or DNA can be either covalently linked to mitochondrial targeting sequences or alternatively be non-covalently linked via complementary base pairing. The recombinant nucleic acid can be either single-stranded, linear double-stranded, circular single-stranded, or circular double-stranded. One or multiple mitochondrial targeting sequences can be used to form one mitochondrial targeting complex. (Fig. 6)

Materials and Methods

Design of the parental construct

[00127] The purpose of designing the construct was to clone it into the pVAX1 (Invitrogen) and pEGFP-C1 (Addgene) vectors to study domain characteristics and transgene delivery respectively. The restriction sites were selected using the online algorithm NEBcutter v2.0. The construct was synthesized by Geneart (Life Technologies). The construct was subsequently cloned into the pVAX1 vector. The CMV promoter sequence was obtained from the pVAX1 plasmid vector. The CMV promoter was to facilitate expression of the RNA in animal cells. The T7 promoter was to facilitate in vitro transcription of the parental constructer whereas the SP6 promoter was inverted to facilitate in vitro transcription of the antisense RNA sequence. HindIII was used to linearize plasmid for T7 transcription and BspE1 was

used to linearize the plasmid for SP6 transcription. NheI, XbaI, and BclI sites were used for cloning, The SV40 poly A signal was added to facilitate Polyadenylation and nuclear export of mRNA. The spacer represents the vector sequence between the kanamycin promoter and the polyA signal and KanaP is the part of the promoter which is initially removed from the vector during cloning using BclI. DraIII was included to facilitate cloning into the pEGFP-C1 vector (see Fig. 7).

Synthesis of the Single Domain Deletion constructs (SDDC)

[00128] To study the effect of individual domains on β2.7 RNA function, constructs were generated having individual domains deleted. The strategy used to delete the domains was overlap extension PCR as indicated in Fig. 8.

Overlap extension (OE) PCR strategy for synthesis of SDDC

[00129] Overlap extension polymerase chain reaction (OE PCR) was carried out in two steps. In the first step, the region upstream of the deletion domain (DD) was PCR amplified using a common forward primer which carries the NheI site and the OE reverse primer, which introduces the priming site for the region downstream of the DD. Subsequently, the domain downstream of the DD was PCR amplified using an OE forward primer, which introduces the priming site for the region upstream of the DD. and a common reverse primer, which carries the BamH1 site. Both PCR products were then gel-purified and mixed together in equimolar amounts and then re-amplified using PCR, in which the OE introduced priming sites acted as primers for their respective counterparts, thereby giving the full length construct with the desired deletion.

Synthesis of the Single Domain constructs (SDC)

[00130] The Single domains were PCR amplified from the parental β2.7_pVAX1. The PCR conditions for each of the single domains were as follows: Single Domains 1(SD1_pVAX1): Using β2.7_pVAX1 as template PCR was carried out using D1F and D1R following which the PCR product was cloned using the BspE1 and HindIII sites. The PCR conditions reaction mixture included 10ng of template, 5µl of 10X Taq buffer, 4mM of MgCl2,0.2mM of each dNTP, 300nM of each primer and 0.25µl of Taq Polymerase (ThermoScientific).The final volume was made up to 50µl with Ultrapure Nuclease free water (Invitrogen). The reaction conditions used were 94°C for 5 minutes, 25 cycles of 94°C for 30 seconds, 56°C for 30 seconds, 72°C for 30 seconds, 72°C for 5 minutes. Single Domain 2 (SD2_pVAX1). Single Domain 3(SD3_pVAX1), and Single Domain 4 (SD4_pVAX1) constructs were generated the same way but using the specific PCR primer D2F and D2R, D3F and D3R or D4F and D4R instead (see Fig. 9).

Strategy for Single domain amplification

[00131] The forward and the reverse primers were designed to introduce the BspEI and HindIII sites respectively. The PCR products were subsequently digested with BspEI and HindIII purified and cloned into the pVAX1 vector using the BspE1 and HindIII sites.

Synthesis of the GFP fusion constructs

[00132] Design of the GFP Fusion constructs: All the GFP fusion constructs were designed using the pEGFP-C1 (Addgene) plasmid vector. The β2.7 RNA sequence was cloned downstream of the eGFP sequence in the plasmid using restriction sites BspE1 and DraIII. Next the eGFP sequence was PCR amplified from the plasmid to introduce the restriction site at either end along with the spacer sequence. To enable mitochondria-specific gene expression, the start and stop codons of the eGFP message were modified with mitochondria specific start and stop codons. Since the analysis of GFP expression would be carried out using plasmid vectors primarily the structure of the CMV transcript was analysed for structural preservation using mfold. The PCR conditions are described below. 50µl PCR reaction was set up having 10ng of pEGFP-C1 template, 5mM of 10Xtaq buffer, 4mM Mgcl2, 300nm of each primer, 0.2mM of each dNTP and 0.25µl of Taq Polymerase (ThermoScientific). The cycler was set at 94°C for 5 minutes, 25 cycles of 94°C for 30s, 55°C for 30s, 72°C for 1 minute, 72°C for 10 minutes. The parental β2.7 sequence with the SV40 poly A was cut out from the β2.7_pVAX1 vector, gel purified and ligated downstream of the eGFP sequence using the BspE1 and DraIII sites as indicated in Fig. 10.

[00133] The cloning process described above creates the Genomic GFP + β2.7. The 2nd control namely genomic GFP + Spacer + β2.7 was created by amplifying the eGFP sequence from the original pEGFP-C1 vector by PCR using PCR primers with the reverse primer introducing the spacer sequence and the NheI site following which it was cloned back into the Genomic GFP+ β2.7 vector. To enable mitochondria specific expression, the start and stop codons of the eGFP sequence were modified using PCR primers with the forward primer introducing the mt start codon and the reverse primer introducing the spacer sequence and the mitochondria specific stop codon following which it was cloned back into the pEGFP-C1 vector carrying the β2.7 using NheI site to generate mtGFP + Spacer + β2.7. In both these cases the GFP sequences were cloned into the vector using a single NheI restriction site and hence to prevent vector backbone re-ligation, it was dephosphorylated simultaneously with Alkaline phosphatase during digestion with NheI. As a negative control the mtGFP + spacer sequence with a portion of the CMV promoter was PCR amplified from the mtGFP + Spacer+ β2.7 plasmid using primers which carried NdeI and BamHI sites respectively. Simultaneously the pEGFP-C1 plasmid vector was digested between the NdeI site and BamHI site to remove the original GFP sequence and a

part of the CMV promoter. The PCR product was then digested with NdeI and BamHI, purified and ligated back into the gel purified vector backbone which re-constitutes the CMV promoter and replaces the eGFP sequence with the mtGFP + spacer sequence.

Adding a SV40 nuclear localization signal to the GFP fusion constructs

[00134] To facilitate imaging by confocal microscopy, a SV40 nuclear localization signal (NLS) was PCR amplified from the pEBFP_NUC (Addgene) and cloned downstream of the GFP sequence in all GFP expressing constructs, including the mitochondrial constructs. The NLS carries a mitochondria specific stop codon in frame and, as a result, only cytoplasmic GFP is targeted to the nucleus, whereas intra-mitochondrial GFP remains localized in the mitochondria. This is because translation in the mitochondria generates an incomplete NLS. The pEBFP-NUC plasmid carries 3 tandem repeats of the NLS sequence and hence the PCR primers were designed to flank the tandem repeats. PCR amplification and design strategy is explained in figure. Post-cloning, the constructs were screened using a single XhoI digestion. The PCR conditions were as follows. Using the pEBFP_NUC as a template PCR was carried out using the NLS_cloning Fw and NLS_cloning Rv following which the samples were PCR purified and cloned downstream of the GFP sequence between the Bsp1407I and the BspEI sites. The PCR conditions used were as follows: 10ng of pEBFP-NUC template, 5mM of Taq buffer, 4mM Mgcl2, 0.2mM of each dNTP, 300nM of NLS_cloning Fw and NLS_cloning Rv respectively, 0.25µl of Taq Polymerase (ThermoScientific) and the volume was made up to 50µl with ultrapure Nuclease Free Water (Invitrogen). The cycling conditions used were 94°C for 5 minutes, 25 cycles of 94°C for 30 seconds, 52°C for 30 seconds, 72°C for 5 minutes.

[00135] The NLS sequence was PCR amplified from the pEBFP-NUC plasmid by PCR using forward and reverse primers which introduced BsrGI and BspEI sites, respectively (see Fig. 11). Additionally the forward primer also destroyed an extra BspE1 site upstream of the NLS by a single T-G substitution. The PCR product was then subsequently digested with BsRGI and BspE1 respectively and ligated downstream of the GFP sequence in all the constructs. The PCR product carries an XhoI site, which was used to screen the clones by digestion.

Synthesis of the tandem repeat constructs

[00136] To study the interaction of the domains tandem repeats of two functional domains, in this example namely domains 2 and 3, were created. Four different arrangements were created as follows below.

Constructs having four copies of domain 3(D3X4) and domain 2(D2X4), respectively

[00137] The strategy for generating the constructs were created as shown in Fig. 12. The restriction sites were chosen using NEB cutterV2.0. The structures of the T7 and CMV transcripts of these tandem repeats were stabilized using spacer sequences and were validated using RNAfold and mfold. Each repeat and its associated spacer were synthesized using PCR primers (4 sets) which inserted the spacer and the respective restriction site and then cloned into the pVAX1 vector. Since the primers for each set within the same tandem repeat had the same binding region, the annealing temperature remained the same for all PCR sets for a particular tandem repeat. The cycling conditions used in PCR are provided below

Domain 2 Tandem Repeats

Construction of tandem repeat using a multiple ligation process.

[00138] The individual copies were first synthesized is 4 sets using PCR primers (see Fig. 12). Since all primers for a particular tandem repeat share the same binding region hence the Tm is the same for all sets for a particular tandem repeat. Each set has its own set of spacers as indicated by S1-S4 in the figure. The restriction sites were chosen such that the site at the 3'end of one set matches the one at the 5' end of the next set within the tandem repeat. After PCR the products were PCR purified and digested with their respective restriction sites. At the same time the pVAX1 vector was digested with NheI and HindIII and the vector backbone was gel purified. The digested PCR products were then mixed with equimolar amount of the digested vector backbone and Ligated using T4 DNA ligase.

Construction strategy for D3X4_D2X4

[00139] Similarly, the domain 2 tandem repeat (D2X4) was PCR amplified from the pVAX1 vector carrying D2X4 (see Fig. 13). To prevent amplification of shorter fragments, primers were so designed that majority of the binding region of the primer lay on the vector backbone itself. Each of the primers introduced HindIII sites at either end. The PCR product was digested and re-ligated within the HindIII site of the pVAX1 vector carrying the D3X4 sequence. To prevent re-ligation of the vector, the vector was dephosphorylated with Alkaline phosphatase.

Construction strategy for D2X4_D3X4

[00140] Similarly, the domain 3 tandem repeat (D3X4) was PCR amplified from the pVAX1 vector carrying D3X4.The primer design strategy employed was the same as used for D3X4_D2X4. The PCR product was digested and re-ligated within the HindIII site of the de-phosphorylated pVAX1 vector carrying the D2X4 sequence.

Constructs having alternate repeats of domain 3 and domain 2 each (D3_D2)4

[00141] The alternative repeat construct was generated in four steps. Both D3X4 and D2x4 share the same set of restriction sites. Prior to the cloning the CMV and the T7 transcripts were validated using mfold and RNAfold. A detailed cloning scheme is described in Fig. 14.

[00142] In the first step a single copy of domain 3 was cloned using the NheI and EcorI site. In the 2nd step another copy of domain 3 was cloned between the KpnI and the AgeI sites. The product thus obtained is now used as PCR template using Domain 3 tandem Fw and Domain 2 tandem Rv both of which carry HindIII sites. The PCR product of the correct size is gel-purified and ligated back into the de-phosphorylated pVAX1 plasmid carrying the step 2 product. The clones were then screened by digestion and verified by sequencing (AITBiotech).

Design of Antisense RNA for mitochondrial targeting

Choice of target and selection of candidates

[00143] The candidates for mitochondrial targeting used were Mt-ATP6 and Mt-ATP8, which are essentially subunits of the Complex V (ATPase). The antisense RNA targeting the two genes were designed using HUSAR foldanalyze at window sizes of 100, 200 and 300 and a shift of 1 nucleotide following which candidates with maximum number of unpaired bases at either the 5' or 3'end were selected. These sequences were subsequently fused to the β2.7 RNA, either at the 5' end or the 3' end based on location of the open ends, and structural preservation was analysed using mfold.

Purification of the target sequences

[00144] Target sequences were obtained from isolated mitochondrial RNA using a procedure described in the figure below. The reaction conditions for reverse transcription were as follows: 500ng of mtRNA was mixed with 1µl of 10mM dNTP mix, 1 µl of 2uM gene specific reverse primer made up to a final volume of 14µl with RNase free water. The mixture was heated at 65c for 5 mins followed by snap chill on ice for 2 mins. This reaction mixture was then mixed with 4µl of 5x first strand buffer, 1µl of 100mM DTT, 20U of RNaseOUT (Invitrogen), 0.5µl of SuperScriptIV, the final volume of the reaction being 20µl and incubated at 55°C for 1 hour, followed by heat inactivation at 70°C for 15 minutes.

Isolation of target sequences for antisense generation

[00145] Mitochondrial RNA was reverse transcribed with gene specific reverse primer sequences (ATP6Rv and ATP8Rv) to obtain first strand ATP6 and ATP8 cDNA pools. Subsequently these pools

were used as templates for PCR to obtain double stranded DNA sequences representing the target elements (see Fig. 15).

Cloning of target sequences to generate the antisense

Cloning of the ATP6 antisense sequence

[00146] Since the ATP6 antisense sequence had the maximum number of unpaired bases at the 5' end, it had to be fused to the 5' end of β2.7 sequence. To obtain the antisense sequence, the target sequence obtained from mitochondrial RNA pool was reversed and cloned into the β2.7_pVAX1 vector, downstream of the T7 promoter and upstream of the β2.7 sequence. The purified ATP6 target was PCR amplified using ATP6_Cloning_Fw and ATP6_Cloning_Rv.The cloning strategy is described in Fig. 16.

Synthesis and cloning of the ATP6 antisense sequence

[00147] The ATP6 target sequence was re-amplified by PCR to introduce restriction sites in an opposite orientation to that in β2.7_pVAX1 sequence. The resulting product was digested with NheI and BspeI and then ligated into the β2.7_pVAX1 vector backbone. The products were screened by digestion with NdeI and NheI. Subsequently a spacer sequence was introduced downstream of the this construct by nested PCR and then verified by sequencing (AITBiotech).

Cloning of the ATP8 antisense sequence

[00148] The ATP8 target sequence was cloned downstream of the β2.7 sequence, since the unpaired bases were primarily at the 3' end. The ATP8 target was amplified by nested PCR to introduce the desired restriction sites and the stabilizing spacer sequence, and cloned downstream of the β2.7 sequence (see Fig. 17).

Cloning Strategy for generating β2.7_ATP8 fusion construct

[00149] The Purified ATP8 target sequence was PCR amplified with the reverse primer introducing a SpeI site. Simultaneously, a fragment was amplified from β2.7 by PCR so that the resulting product carried a BamHI and HindIII site at the 5' end and at the 3' end, respectively. The β2.7 PCR product and the ATP8 PCR product were single digested with HindII and SpeI respectively, mixed in equimolar amounts and ligated at 22°C for 3 hours using T4 DNA ligase (ThermoScientific). SpeI site can be ligated to HindIII site by a 2 base fill-in, which effectively destroys both restriction sites. Post-ligation, the product of the correct size was purified from the gel, the product this having the β2.7 fragment fused to the antisense ATP8 sequence. This ligation product was the PCR-amplified to introduce the BamHI

and HindIII sites, respectively, and cloned back into the β2.7_pVAX1 vector backbone to generate the intact sequence. The clones were verified by BamHI and HindIII double digest, and then verified by sequencing (AITBiotech).

Synthesis of RNA by in vitro transcription

[00150] *In vitro* transcription was carried out using T7 (ThermoScientific) and SP6 RNA polymerase (ThermoScientific). SP6 Polymerase was used for synthesizing antisense RNAs and the β2.7_GFP RNAs. The rest of the RNAs were synthesized using T7 RNA polymerase. The last 6 bases of the T7 and the SP6 promoter were selected, respectively, as previously described, and ultimately become a part of the T7 and the SP6 transcripts, respectively.

Preparation of templates for *in vitro* transcription

[00151] All plasmid vectors to be used for *in vitro* transcription were extracted overnight with Phenol:Chloroform:Isoamyl alcohol (25:24:1) and precipitated the next day using ethanol. The templates for *in vitro* transcription were prepared by PCR or by plasmid linearization. All restriction enzymes used for plasmid linearization generated 5' overhangs to prevent formation of runaway transcripts. In case of PCR synthesized templates, the forward primer introduced the sequence of the T7/SP6 promoter for *in vitro* transcription. Both PCR templates and linearized plasmids were purified by PCR purification kit (Qiagen).

***In vitro* transcription (IVT)**

[00152] IVT was carried out using T7/SP6 RNA polymerase (ThermoScientific). 1ug of linearized plasmid/ purified PCR template was incubated with 1x Transcription buffer, 10mM NTP mix, 20U of RNaseOUT (Invitrogen) and 30U of SP6/T7 RNA polymerase in a final volume of 50µl at 37c for 2 hours. Post 2 hour incubation, 3U of DNase I was added to the reaction mixture and incubated for at least 30 minutes at 37°C. RNA was then purified by Phenol chloroform extraction.

Transfection

[00153] All transfections were carried out using Lipofectamine 2000 (Invitrogen) in Opti-MEM (GIBCO).

Transfection of HepG2 cells for Analysis of RNA uptake

[00154] HepG2 cells were grown in T75 flasks in DMEM with antibiotics and transfected at 90% confluency. Transfection was carried out in Opti-MEM (GIBCO). 1ug equivalent of β2.7 RNA and its

derivatives was transfected as per manufacturer's protocol. Media was changed 6 hours after transfection. 24 hours after transfection Mitochondrial RNA was isolated for analysis by Real Time PCR.

Transfection of Hek293T cells for analysis of mitochondrial RNA knockdown

[00155] 10^5 cells of 293T Hek293T were grown in 24-well plates in DMEM with antibiotics and transfected the next day. Transfection was carried out in Opti-MEM (GIBCO). 800ng equivalent of antisense_β2.7 fusion RNA was transfected as per manufacturer's protocol. Media was changed 6 hours after transfection. 24 hours after transfection, the total RNA was isolated and analysed by real time PCR.

Transfection of HepG2 cells for FACS analysis and confocal microscopy

[00156] For FACS analysis 30,000 HepG2 cells were grown in 24-well plates and transfected at 30% confluency. Transfection was carried out in Opti-MEM (GIBCO). 800 ng of the control pEGFP-c1 and β2.7_GFP fusion plasmids (+NLS) was transfected as per manufacturer's protocol. Media was changed 6 hours after transfection. 24 hours after transfection, the cells were trypsinised and analysed for GFP expression using flow cytometry. For confocal microscopy analysis 20,000 HepG2 cells were seeded in 1.5uM Chamber Slides (iBIO). Area of a chamber in the slides has the same as that of wells in 48-well plates and thus, transfection was carried out accordingly. 400ng of the control pEGFP_C1 and β2.7_GFP fusion plasmids (+NLS) were transfected as per manufacturer's protocol. 24 hours after transfection, the cells were stained with respective dyes and analysed using confocal microscopy.

Transfection of HEK293T for cell viability analysis

[00157] 50000 HEK293T cells were seeded in 24-well plates. 800ng equivalent of the β2.7 RNA was added to each well and total RNA/ well was adjusted to 800ng using RNA previously isolated from untreated HEK293T cells. Media was changed after 6 hours. 10^5 Hek293T cells were seeded in 24-well plates and transfected with 1.5µg of β2.7 RNA_antisense fusion RNA. Since previously isolated RNA may contain target sequences hence the total RNA/well was adjusted to 1.5µg using feeder RNA (yeast tRNA) instead of isolated RNA. Media was subsequently changed 6 hours after transfection.

Transfection of Hek293T for CellTiter-Glo assay

[00158] 25000 Hek293T cells were seeded in 96-well plates and transfected with 300ng equivalent of the β2.7 RNA_antisense RNA. Amount of RNA per well was adjusted using feeder RNA. Media was changed 6 hours after transfection.

Isolation of RNA and real time PCR

Isolation of Mitochondrial RNA

[00159] Mitochondria were isolated from HepG2 cells using the Mitochondria Isolation Kit (Biochain) as per manufacturer's guidelines. The isolated mitochondria were re-suspended in 1x Mitochondria Isolation Buffer. To remove contaminating cytoplasmic RNA, the mitochondrial suspension was treated with RNaseA (ThermoScientific) as previously described. Post-incubation, RNase A was inactivated by addition of 2x volumes of Trizol Reagent, following which the RNA was extracted using Trizol Reagent (Invitrogen), as per manufacturer's guidelines.

Isolation of Total RNA

[00160] Hek293T cells seeded in 24-well plates were washed with 1X PBS. Subsequently, 200µl of Trizol Reagent was added. The mixture in the 24-well was resuspended until the solution loses viscosity. The components were then transferred to an Eppendorf tube and RNA was isolated as per manufacturer's guidelines.

DNase treatment and cDNA synthesis

[00161] 500 ng of isolated RNA (mitochondrial/ total) was incubated with 1u DNase I (ThermoScientific) and 20U of RnaseOUT at 37°C for 30 minutes. Post-incubation, ethylenediaaminetetraacetric acid (EDTA) was added to a final concentration of 3.75mM and incubated at 75c for 12 minutes to inactivate DNase I. This reaction mixture was then reverse transcribed with 1x RT buffer, 5.5mM MgCl2, 20U of RNaseOUT, 500uM of each dNTP, 200ng of Random Primers(Invitrogen), and 25U of multiscribe reverse transcriptase (ABI) at a final volume of 20µl at 37°C for 2 hours, followed by heat inactivation at 85°C for 15 minutes.

Real time PCR

[00162] 1µl of cDNA was mixed with 5µl of 2x SYBR CFX master mix and 400nm of each (forward and reverse) primer. Real Time PCR was carried out in ABI 7900HT Real Time PCR machine using the following Thermal cycling conditions: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. Each sample was run in duplicates.

Relative quantification

[00163] 12s rRNA was used as an internal control for normalization. Relative RNA levels were determined using the ΔΔCT method. Levels of cytoplasmic contaminant β-Actin were determined by comparison with an untreated mitochondrial sample.

Absolute quantification

[00164] *In vitro* transcribed RNA (to be transfected RNA) was serially diluted from 10^{10} to 10^{01} molecules, reverse transcribed and subjected to real-time PCR as described above. RNA standard curves were prepared by plotting Median CT values against the number of molecules per reaction. The copy number of each RNA (No. of molecules per micrograms (µg) of isolated RNA) was determined by comparison with the respective standard curve using the SDS2.4 software.

Analysis of GFP expression by flow cytometry

Sample preparation

[00165] HepG2 cells seeded in 24-wells were trypsinized, following which the trypsin was inactivated by the addition of complete DMEM. Cells in DMEM were resuspended 8 to 10 times to free cell clumps, and subsequently pelleted in a centrifuge at 6000g for 5 minutes. Cells were then washed with 1x PBS and re-suspended in complete DMEM for flow cytometry analysis.

Flow cytometry analysis

[00166] Flow cytometry analysis was carried out using a Beckmann Coulter CyAnADP flow cytometer. Cells were illuminated with a 488nm laser, and gated using forward (FSC-A) and side scatter (SSC-A), along with doublet exclusion using FSC pulse width analysis. GFP expression was measured using a 510nm to 540nm bandpass filter. Up to 20,000 cells were measured on days 1, 3 and 5 post-transfection. Data was analysed using FlowJO 7.6.1.

Confocal Microscopy

[00167] Cells were transfected in chamber slides and analysed on 3rd day after transfection. Cells were stained with Hoechst 33342 (molecular probes) and/or Mitotracker Orange CMH2TMRos (Molecular Probes), as per manufacturer's guidelines. Cells were then counterstained with HCS CellMask Deep Red stain (Molecular Probes). Images were captured with Olympus FluoView FV1000 (Olympus, Japan) laser scanning confocal microscope, using a 60x/1.00 water objective, with 405nm solid state laser diode (Hoechst), 488nm argon ion laser (GFP), 543nm HeNe Green laser (Mitoctracker) and 633nm HeNe Red (cell mask). Images were subsequently analysed using ImageJ V1.48.

Rotenone induced cell death

[00168] 200mM rotenone stock solutions were prepared in anhydrous DMSO (Sigma). Rotenone stock solution was diluted to a final concentration of 200uM in compete DMEM and filtered using a 0.22uM filter. 24 hours after transfection, rotenone_DMEM was administered to Hek293T cells and cell death was determined 24, 48 and 72 hours after transfection using an alamar blue assay. After cell death assessment, cells were washed with PBS and fresh drug was administered for analysis on the subsequent time point.

Alamar blue cell viability assay

[00169] Hek293T cells seeded in 24-well plates were subjected to alamar blue (Invitrogen) cell viability assay, as per manufacturer's guidelines. Fluorescence was measured at emission/excitation (530/590) using Biotek Synergy H1 Reader, with the sensitivity set to 60. The percentage (%) reduction in cell viability was determined by comparison with a cell-only control.

Measurement of ATP levels

[00170] Hek293T cells were transfected in 96-well plates and ATP levels were determined 24 hours after transfection using a CellTiter-Glo® Luminescent Cell Viability Assay (Promega). Luminescence was measured using a TECAN infinite M200PRO plate reader. Absolute ATP levels were determined from ATP standard curve, prepared as per manufacturer's guidelines. Relative changes in ATP levels were determined by comparison with a cell-only control.

Statistical analysis

[00171] Statistical analysis was carried out using GraphPad Prism Software 6.0. All numerical values presented as mean+SD (means plus standard deviation) of three independent experiments. Statistical significance was determined using Student's t-test and ANOVA.

Generation of construct ATP6_(D3)4_(D2)4

[00172] A stabilizing spacer sequence was inserted in (D2)4 downstream of the final D2 repeat to yield the (D2)4_S construct. The (D2)4_S was PCR amplified with primers introducing HindIII sites at either end. Subsequently the PCR product was HindIII digested and cloned within the HindIII site to yield the ATP6_(D3)4_(D2)4 construct.

***In vitro* transcription (IVT) of fluorescein-12 uracil-labelled RNA**

[00173] Fluorescent RNA was synthesized by T7 RNA polymerase (Thermo Scientific™) via in vitro transcription using fluorescein-12-UTP (Enzo). 1 μg of linearized plasmid/purified PCR template was incubated with 5 μl of 5x transcription buffer, 5 μL of 10 mM NTP mix (10 mM GTP, 10 mM CTP, 10 mM ATP, 7.5 mM UTP, 2.5 mM fluorescein-12 UTP) 10 U of RNaseOUT™ (Invitrogen) and 20 U of T7 RNA polymerase in a final volume of 25 μL at 37°C for 3 h. 3 U of DNase I was the added to the reaction mixture and incubated for at least 30 min at 37°C to remove DNA template. RNA was then purified using the PCR purification kit (Qiagen). Quality of RNA was analyzed on ethidium bromide-free 1.5% agarose gel. Gels were illuminated on UV trans-illuminator and captured using a Samsung galaxy S7 smartphone. Intensity of the bands was determined using ImageJ v1.48.

Confocal Microscopy

[00174] Cells were transfected in chamber slides and analyzed 24h after transfection. Cells were stained with Hoechst 33342 (Molecular Probes), MitoTracker Orange CMH2TMRos (Molecular Probes) as per manufacturer's guidelines. Images were captured with Olympus FluoView FV1000 (Olympus, Japan) laser scanning confocal microscope using a 60x/1.00 water objective , with 405nm solid state laser diode (Hoechst) ,488 nm argon ion laser(GFP), 543 nm HeNe Green laser (Mitotracker) Images were subsequently analyzed using ImageJ V1.48. The extent of co-localization of GFP (green) within the mitochondrial (Red) fraction was determined using the plugin JACOP and the mander's overlap coefficient (MOC) was reported.

TABLES

[00175] **Table 2: Overview of sequences presented in the attached sequence listing.** "AS" stands for antisense; "endo" stands for endogenously transcribed RNA. These sequences were tested as plasmids. "_core" stands for core sequences, which are the minimum polynucleotide sequences (without spacers) that are operable.

SEQ ID NO:	Name	Core	Promoter	Restriction sites	Spacer	Poly A
Tested as in vitro transcribed RNA (no polyA)						
1	Full length β2.7 RNA (sense)	Yes	Yes	Yes	No	No
2	Full length β2.7 RNA_AS (antisense)	Yes	Yes	Yes	No	No
3	Sense Domain 1: D1	Yes	Yes	Yes	No	No
4	D2	Yes	Yes	Yes	No	No
5	D3	Yes	Yes	Yes	No	No
6	D4	Yes	Yes	Yes	No	No
7	Antisense Domain 1: D1AS	Yes	Yes	Yes	No	No
8	D2AS	Yes	Yes	Yes	No	No
9	D3AS	Yes	Yes	Yes	No	No
10	D4AS	Yes	Yes	Yes	No	No
11	Sense Domain 1 Deletion Mutant: ΔD1	Yes	Yes	Yes	No	No
12	ΔD2	Yes	Yes	Yes	No	No
13	ΔD3	Yes	Yes	Yes	No	No
14	ΔD4	Yes	Yes	Yes	No	No
15	Multimer Sequence D2x4	Yes	Yes	Yes	Yes	No
16	Multimer Sequence D3x4	Yes	Yes	Yes	Yes	No
17	Multimer Sequence D3x4_D2x4	Yes	Yes	Yes	Yes	No
18	Multimer Sequence D2x4_D3x4	Yes	Yes	Yes	Yes	No
19	Multimer Sequence (D3_D2)x4	Yes	Yes	Yes	Yes	No
20	gGFP_β2.7	Yes	Yes	Yes	Yes	No
21	gGFP_s_β2.7	Yes	Yes	Yes	Yes	No
22	mtGFP_s_β2.7	Yes	Yes	Yes	Yes	No
23	mtGFP_s	Yes	Yes	Yes	Yes	No
24	asATP6_s6_ β2.7	Yes	Yes	Yes	Yes	No
25	β2.7_s8_asATP8	Yes	Yes	Yes	Yes	No
26	asATP6_$D3_4$_$D2_4$	Yes	Yes	Yes	Yes	No
Spacers (only)						
27	S1a	No	No	No	Yes	No
28	S1b	No	No	No	Yes	No

29	S2a	No	No	No	Yes	No
30	S2b	No	No	No	Yes	No
31	S3a	No	No	No	Yes	No
32	S3b	No	No	No	Yes	No
33	S4a	No	No	No	Yes	No
34	S4b	No	No	No	Yes	No
35	S6a	No	No	No	Yes	No
36	S6b	No	No	No	Yes	No
37	S8a	No	No	No	Yes	No
38	S8b	No	No	No	Yes	No
39	Spacer Figure 3a	No	No	No	Yes	No
Tested as *in vitro* transcribed RNA (no polyA)						
40	Antisense Domain 1 Deletion Mutant: ΔD1AS	Yes	Yes	Yes	No	No
41	ΔD2AS	Yes	Yes	Yes	No	No
42	ΔD3AS	Yes	Yes	Yes	No	No
43	ΔD4AS	Yes	Yes	Yes	No	No
Tested as plasmid DNA (endogenous transcript, all features)						
44	gGFP_β2.7_endo	Yes	Yes	Yes	Yes	Yes
45	gGFP_s_β2.7_endo	Yes	Yes	Yes	Yes	Yes
46	mtGFP_s_β2.7_endo	Yes	Yes	Yes	Yes	Yes
47	gGFP_NLS_s_β2.7_endo	Yes	Yes	Yes	Yes	Yes
48	mtGFP_s_endo	Yes	Yes	Yes	Yes	Yes
49	Full length β2.7 RNA_endo (sense)	Yes	Yes	Yes	Yes	Yes
50	β2.7 RNA domain 2_endo (sense)	Yes	Yes	Yes	Yes	Yes
51	β2.7 RNA domain 3_endo (sense)	Yes	Yes	Yes	Yes	Yes
52	Multimer sequence D2x4_endo	Yes	Yes	Yes	Yes	Yes
53	Multimer sequence D3x4_endo	Yes	Yes	Yes	Yes	Yes
54	Multimer sequence D3x4_D2x4_endo	Yes	Yes	Yes	Yes	Yes
55	β2.7_core	Yes	No	No	No	No
56	D1_core	Yes	No	No	No	No
57	D2_core	Yes	No	No	No	No
58	D3_core	Yes	No	No	No	No
59	D4_core	Yes	No	No	No	No
60	ΔD1_core	Yes	No	No	No	No
61	ΔD2_core	Yes	No	No	No	No
62	ΔD3_core	Yes	No	No	No	No
63	ΔD4_core	Yes	No	No	No	No
64	β2.7 RNA_AS_core	Yes	No	No	No	No
65	Domain 1 antisense: D1AS_core	Yes	No	No	No	No
66	D2AS_core	Yes	No	No	No	No
67	D3AS_core	Yes	No	No	No	No

68	D4AS_core	Yes	No	No	No	No
69	ΔD1AS_core	Yes	No	No	No	No
70	ΔD2AS_core	Yes	No	No	No	No
71	ΔD3AS_core	Yes	No	No	No	No
72	ΔD4AS_core	Yes	No	No	No	No
73	Multimer sequence D2x4_core	Yes	No	No	No	No
74	Multimer sequence D3x4_core	Yes	No	No	No	No
75	Multimer sequence D3x4_D2x4_core	Yes	No	No	No	No
76	Multimer sequence D2x4_D3X4_core	Yes	No	No	No	No
77	Multimer sequence (D3_D2)x4_core	Yes	No	No	No	No
Fusions of the sense β2.7 RNA to different payloads but excluding promoter, spacer, restriction site, and polyA sequences						
78	gGFP_β2.7 (core)	Yes	No	No	No	No
79	gGFP_s_β2.7 (core)	Yes	No	No	No	No
80	mtGFP_s_β2.7 (core)	Yes	No	No	No	No
81	mtGFP_s (core)	Yes	No	No	No	No
82	asATP6_s6_ β2.7 (core)	Yes	No	No	No	No
83	β2.7_s8_asATP8 (core)	Yes	No	No	No	No
84	ATP6_$(D3)_4$_$(D2)_4$ (core)	Yes	No	No	No	No

[00176] **Table 3: Sequences.** The following sequences 1 to 26 and 44 to 47 were tested as *in vitro* transcribed RNA using as DNA template either linearized DNA (RNA ending with cleavage site) or PCT products (RNA ending with the end of the PCR template). As promoters, either the T7 RNA (RNA starts with GGCGCU) or the SP6 (RNA starts with GGAGUC) promoter was used. After the 6 transcribed promoter nucleotides, there is either a restriction site or not.

SEQ ID NO:	**Name (type)**	**Sequence**
1	Full length β2.7 RNA (sense)	GGCGCUUCCGGAAGAGCUAGCUCCCCAGAUCGCUGCUGCCCCGGC GUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGUCG GCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCGUG GCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUGGA AGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUCUC GUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGAGU UUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAUGC ACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCAUC AGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCGUCG CCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGGGU CGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUUUUA UCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACC

		UACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAA GCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGAAU UCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAAACAAG GUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCC CCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUC CGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCG CAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCA UAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUA UAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAAG ACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCAA GCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAAC GAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAAUAGA AACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUC CUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGA CGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGA GAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGU CGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCC GGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAA GAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACC CGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUU UCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGA CACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAA CAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAG UAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCG CACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGA UGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUAC UACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAGGU UUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCA AUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGU AGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAUC AAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUU AGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAACA GAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACACA CUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUGAC UUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAA GACCAAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACA AUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGG AUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAU CUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUU UCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCG GUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUU UUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACAG AGUAGUAGACACAAUAAAUGAGAAGUUUGCAUGCAAGCU
2	Full length β2.7 RNA (antisense)	GGAGUCAAGCUUGCAUGCAAACUUCUCAUUUAUUGUGUCUACUAC UCUGUGUUGCUACAGGGAGUGAAGGGGGUGAAGGCAAACAAAAA AAAAAGGAACAAAAUAAUAGAUUAGCAGAAGGAAUAAUCCGUGC GACCGAGCUUGUGCUUCUUUUCUUAUAAGGAGGCAAAUAUACUAG GGAAAACUUAAGAAUAGGAAGAAACCGAGGUUUGGGAGAAAAGC UGAGAUAAAAUAGCGCAUUUUCCAUACAGAGGUUGUUGUUUUUG

		UGGAUCCUAAGAGGUUUCAAGUGCGAAUCUCAAAGUUCUCACGAG AAUAUUGUCUUCAAGAAUCGACAACUGUGGUCCAAGAUUUUUUUU UGGUCUUUUUAGGUUCUGCGAGGGACAUCACGAUGGAUCGUUGCG AUGAAGUCACGCGUACGCCUCUGGUGUGGCGCGGUGUCGUGACAG GAGAGUGUGUUUUCAGUGCAGAGCUGUCUUGAUUCCUAUAUCCGA GUAUCUGUUUUCUCGUAAGGACGGUAAUCUUCUUUGGUGUAAGU ACAUCUAAAAGCUGCAAACUAUAUUUUAAGGGCUGUCUCUAGGUG UACUUUGAUGCUGGAGUUUUUCGCUGUGUUGAUGUGAAUAAAUC UACUACUACUAUUAUAUGCAGAAAGAGUGAUUAUGCCGAGACAAG AUUGCAUUGGCUGAACUGUUUCAAAAACGCCUACACUCUACUUAU CCGUAAACCUAAGGUAAUACUAUGUGUAAGUUGUUUUUUUUUCU UUUUGUAGUAAAAUGGUGAUACGUGCAAUUAAAACUGUAUUCCA UGUUUCCAUCCUUUCAUUUCAACUUUAAAGGCGGCUUUGAGAGCG AAGAAGUGCGAGGAUAAAAAUGGAUGACUCCUUCGUGUCCAGGGA GUCGACUACUGCAACGCUGAUUGAUUAAAAGAUGGUCUCCGAUGA UGAUGUUGUUAUUGAUCGAAUCAUGGUGCAGAACGGCGACGGAG AGGAGCGUGUCCGCCGCCGGGAAGGUGGUCUCUUUCUCUUUUCUU UUUUCAAGAAAUCUUCCAUGUGUUUAUCGUAGUGAUCGAAAUCGA CUGAUCUCGGGUUCUUUUUGUUGGUUUCUUUUCGGUUAAUCAUGU AUUGUUUUCUUUUUUUACAGAAAGAUACUUUUUUCAUGAGCAAU UCCUCGCCCGGCGCCGGCAUGCCGAGGUGGGGCCACUGCGAUCAG CGGCAUGCCGACGCCGACCCGGGGAUCUUGGAUUCACCGUUUUCU CUCUUCUCUCUCUACAUACAGACCGGGUGGCAGGAGCGGUAAGGA AUCAUCGUCGUCUUUCAUUCUUCGAUGAUUAUGGUAAUACUAAAU CUUAUCUAGGAGCAUAUACAUCUAAGAUUGGAGUACUAGUAGUCG UUUGUGGUUUCUAUUUUUUUUUAUAUUUAUCUAUGACAGUUUUU CUGUUUUUCGUUUUGAUAAUAAUAUAAUAAAAACUCAUGGACGU GAAAUCUGGCUUGGUUGUGGUGAUUUCAUUCUCAUUAUUGUUGU UUUCUUUCCGUCUUGCGGAUGAAGAUGUUGCGAUGCGGUUGUUGU UGGUGUUGCUAUACACCGAGAGAGAUGAUCUUUUUGUUCUUCUGG UUCAUUUCCUAUGAUUGUUUGGCUGCUGACCGACGCGUCAGGAUG UGCAGGGCAUGCGGGGAAUCAGGACCGGACACGGGAUAAUUUCAU CUACCUAUACGGAGAUCGCGGUCCUCGCCAUGAGGAUCGCGACAG GCGCGUCGAGGGGGCAGGAACACCCUUGCGGAUUGACAUUCUUGG UGGUGUUUCGUUGUUGUCGGUAGUUGUUGUUGACGAUGAGGAUA AAUAAAAAUGACCUUGUUUUUGUUCUGUUUUCUCUUGUUGGGAA UCGUCGACUUUGAAUUCUUCGAGUUAUCGGAAAGCUGAGGUACCC AAAUGUCUGUAGCUUUUUUCUUUUUACCCUCUUGUUUAUCAUCUG CGAUUCGUGGUAGGUAGGAGAGGGAAAUGAUAAUCCGAGAUUAA GGAAAGGAGAAGAUAAAAAAUAAAAAAAAAUAAUAAAACAGAAG CCGACCGGCCGCCGACCCGUUCCCCAGGACCAGCCUACGAGGAACG GAUAACGCGGUGGCGACGGCAGCGGUGGUGGCGCUGGGGGUGGCG GUAGUGGUGCUGCUGAUGGUAGUCGGGACGGAGGAGAGACGAUG CAUACAUACACGCGUGCAUGCUGCAUGGGUGGAUGGUACGGCCGG GAGACGCGGAAGAGAAACUCACAUAAAAAGGUGAUAAAAAGAGC GGUUGAAAAAAGAAAACGAGAUUCGACCAGACAGAAGAGAAGGA CCGGGGCUUGGCGACCCUUCCACGACUGCCGUUGUCAUCUCGGCU CCUCCAUCUUCUCCCGGCCACGGGCGGCUAAGUCACCGCCGUUCUC CCCAUCCGUCCGAGCGCCGACCGACCAGCCGGCCGAUUCGCCCGCC

		GGGGCUUCUGGAGAACGCCGGGGCAGCAGCGAUCUGGGGAUGUGC UAGCUCCGG
3	Sense domain 1: D1	GGCGCUUCCGGACAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGU CGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCG CCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGU CGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCG AAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAU GUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGC AGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGAC UACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCU GCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGG AACGGGUCGGCGGCCGGUCGGCUUCUGAAGCU
4	Sense domain 2: D2	GGCGCUUCCGGAUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUC GGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUA AACAAGAGGGUAAAAAGAAAAAAAGCU
5	Sense domain 3: D3	GGCGCUUCCGGAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACA ACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAG GGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGA GGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGG UCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGC AGCCAAACAAUCAUAGGAAAUGAACAAGCU
6	Sense domain 4: D4	GGCGCUUCCGGACGGCGUCGGCAUGCCGCUGAUCGCAGUGGCCCC ACCUCGGCAUGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAG UAUCUUUCUGUAAAAAAAGAAAACAAUACAUGAUUAACCGAAAA GAAACCAACAAAAAGAACCCGAGAUCAGUCGAUUUCGAUCACUAC GAUAAACACAUGGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAG ACCACCUUCCCGGCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGC ACCAUGAUUCGAUCAAUAACAACAUCAUCAUCGGAGACCAUCUUU UAAUCAAUCAGCGUUGCAGUAGUCGACUCCCUGGACACGAAGGAG UCAUCCAUUUUUAUCCUCGCAAGCU
7	Antisense domain 1: D1AS	GGAGUCAAGCUUCAGAAGCCGACCGGCCGCCGACCCGUUCCCCAG GACCAGCCUACGAGGAACGGAUAACGCGGUGGCGACGGCAGCGGU GGUGGCGCUGGGGGUGGCGGUAGUGGUGCUGCUGAUGGUAGUCG GGACGGAGGAGAGACGAUGCAUACAUACACGCGUGCAUGCUGCAU GGGUGGAUGGUACGGCCGGGAGACGCGGAAGAGAAACUCACAUAA AAAGGUGAUAAAAAGAGCGGUUGAAAAAAGAAAACGAGAUUCGA CCAGACAGAAGAGAAGGACCGGGGCUUGGCGACCCUUCCACGACU GCCGUUGUCAUCUCGGCUCCUCCAUCUUCUCCCGGCCACGGGCGGC UAAGUCACCGCCGUUCUCCCCAUCCGUCCGAGCGCCGACCGACCAG CCGGCCGAUUCGCCCGCCGGGGCUUCUGUCCGG
8	Antisense domain 2: D2AS	GGAGUCAAGCUUUUUUUCUUUUUACCCUCUUGUUUAUCAUCUGCG AUUCGUGGUAGGUAGGAGAGGGAAAUGAUAAUCCGAGAUUAAGG AAAGGAGAAGAUAAAAAAUAAAAUCCGG
9	Antisense domain 3: D3AS	GGAGUCAAGCUUGUUCAUUUCCUAUGAUUGUUUGGCUGCUGACCG ACGCGUCAGGAUGUGCAGGGCAUGCGGGGAAUCAGGACCGGACAC GGGAUAAUUUCAUCUACCUAUACGGAGAUCGCGGUCCUCGCCAUG AGGAUCGCGACAGGCGCGUCGAGGGGGCAGGAACACCCUUGCGGA UUGACAUUCUUGGUGGUGUUUCGUUGUUGUCGGUAGUUGUUGUU GACGAUGAGGAUAAAUAAAAAUGACCUCCGG

10	Antisense domain 4: D4AS	GGAGUCAAGCUUGCGAGGAUAAAAAUGGAUGACUCCUUCGUGUCC AGGGAGUCGACUACUGCAACGCUGAUUGAUUAAAAGAUGGUCUCC GAUGAUGAUGUUGUUAUUGAUCGAAUCAUGGUGCAGAACGGCGA CGGAGAGGAGCGUGUCCGCCGCCGGGAAGGUGGUCUCUUUCUCUU UUCUUUUUUCAAGAAAUCUUCCAUGUGUUUAUCGUAGUGAUCGAA AUCGACUGAUCUCGGGUUCUUUUUGUUGGUUUCUUUUCGGUUAAU CAUGUAUUGUUUUCUUUUUUUACAGAAAGAUACUUUUUUCAUGA GCAAUUCCUCGCCCGGCGCCGGCAUGCCGAGGUGGGGCCACUGCG AUCAGCGGCAUGCCGACGCCGUCCGG
11	Sense domain 1 deletion mutant: ΔD1	GGCGCUUCCGGAAGAGCUAGCUCCCCAGAUCGCUGCUGCCCCGGC GUUCUCUUUUAUUAUUUUUUUUUAUUUUUUUAUCUUCUCCUUUCCU UAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCA GAUGAUAAACAAGAGGGUAAAAAGAAAAAAGCUACAGACAUUUG GGUACCUCAGCUUUCCGAUAACUCGAAGAAUUCAAAGUCGACGAU UCCCAACAAGAGAAAACAGAACAAAAACAAGGUCAUUUUUAUUUA UCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCA AGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUG UCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUG AAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAU CCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCA GAAGAACAAAAAGAUCAUCUCUCUCGGUGUAUAGCAACACCAACA ACAACCGCAUCGCAACAUCUUCAUCCGCAAGACGGAAAGAAAACA ACAAUAAUGAGAAUGAAAUCACCACAACCAAGCCAGAUUUCACGU CCAUGAGUUUUUAUUAUAUUAUUAUCAAAACGAAAAACAGAAAA ACUGUCAUAGAUAAAUAUAAAAAAAAAAUAGAAACCACAAACGACU ACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUAGAUAAGAUUUA GUAUUACCAUAAUCAUCGAAGAAUGAAAGACGACGAUGAUUCCUU ACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAGAAGAGAGAAA ACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCAUGCCGCUGAU CGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCGAGGAAUUGC UCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAACAAUACAUG AUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAUCAGUCGAU UUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGAAAAAAGAA AAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUCCUCUCCG UCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCAUCAUCG GAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGACUCCCUG GACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUCGCUCU CAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAUGGAA UACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAGAAAA AAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUAAGUA GAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUUGUCU CGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAUUUAU UCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACCUAGA GACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUACAC CAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGAUAUA GGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUCACGA CACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGAU CCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAAU CUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAGA ACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACAA

		CAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUCC CAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUUU GCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUAU UCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGCC UUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAA UAAAUGAGAAGUUUGCAUGCAAGCU
12	Sense domain 2 deletion mutant: ΔD2	GGCGCUUCCGGAAGAGCUAGCUCCCCAGAUCGCUGCUGCCCCGGC GUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGUCG GCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCGUG GCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUGGA AGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUCUC GUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGAGU UUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAUGC ACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCAUC AGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCGUCG CCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGGGU CGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUAGCUACAGACAU UUGGGUACCUCAGCUUUCCGAUAACUCGAAGAAUUCAAAGUCGAC GAUUCCCAACAAGAGAAAACAGAACAAAAACAAGGUCAUUUUUAU UUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCA CCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGC CUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAG AUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCA CAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAA CCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUAUAGCAACACCA ACAACAACCGCAUCGCAACAUCUUCAUCCGCAAGACGGAAAGAAA ACAACAAUAAUGAGAAUGAAAUCACCACAACCAAGCCAGAUUUCA CGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAACGAAAAACAGA AAAACUGUCAUAGAUAAAUAUAAAAAAAAAAUAGAAACCACAAAC GACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUAGAUAAGA UUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGACGACGAUGAU UCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAGAAGAG AGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCAUGCCG CUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCGAGGA AUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAACAAU ACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAUCAG UCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGAAAA AAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUCCU CUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCAU CAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGACU CCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUC GCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAU GGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAG AAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUA AGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUU GUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAU UUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACC UAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUU ACACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGA UAUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUC

		ACGACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAA CGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAA AAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGU GAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAA ACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUU CUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAU AUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGA UUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUU UGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGAC ACAAUAAAUGAGAAGUUUGCAUGCAAGCU
13	Sense domain 3 deletion mutant: ΔD3	GGCGCUUCCGGAAGAGCUAGCUCCCCAGAUCGCUGCUGCCCCGGC GUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGUCG GCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCGUG GCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUGGA AGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUCUC GUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGAGU UUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAUGC ACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCAUC AGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCGUCG CCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGGGU CGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUUUUA UCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACC UACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAA GCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGAAU UCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAAACAAA GAAGAACAAAAAGAUCAUCUCUCUCGGUGUAUAGCAACACCAACA ACAACCGCAUCGCAACAUCUUCAUCCGCAAGACGGAAAGAAAACA ACAAUAAUGAGAAUGAAAUCACCACAACCAAGCCAGAUUUCACGU CCAUGAGUUUUUAUUAUAUUAUUAUCAAAACGAAAAACAGAAAA ACUGUCAUAGAUAAAUAUAAAAAAAAAAUAGAAACCACAAACGACU ACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUAGAUAAGAUUUA GUAUUACCAUAAUCAUCGAAGAAUGAAAGACGACGAUGAUUCCUU ACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAGAAGAGAGAAA ACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCAUGCCGCUGAU CGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCGAGGAAUUGC UCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAACAAUACAUG AUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAUCAGUCGAU UUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGAAAAAAGAA AAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUCCUCUCCG UCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCAUCAUCG GAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGACUCCCUG GACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUCGCUCU CAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAUGGAA UACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAGAAAA AAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUAAGUA GAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUUGUCU CGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAUUUAU UCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACCUAGA GACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUACAC CAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGAUAUA

		GGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUCACGA CACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGAU CCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAAU CUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAGA ACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACAA CAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUCC CAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUUU GCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUAU UCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGCC UUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAA UAAAUGAGAAGUUUGCAUGCAAGCU
14	Sense domain 4 deletion mutant: ΔD4	GGCGCUUCCGGAAGAGCUAGCUCCCCAGAUCGCUGCUGCCCCGGC GUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGUCG GCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCGUG GCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUGGA AGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUCUC GUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGAGU UUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAUGC ACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCAUC AGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCGUCG CCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGGGU CGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUUUUA UCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACC UACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAA GCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGAAU UCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAAACAAG GUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCC CCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUC CGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCG CAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCA UAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUA UAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAAG ACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCAA GCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAAC GAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUAGA AACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUC CUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGA CGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGA GAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUACUUCU UCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAAC AUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAA AGAAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGA UAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUC UUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAG AUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACA CCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUAC UUACACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCG GAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUG UCACGACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGC

		AACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAA AAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUC GUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAA AAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUU UUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGU AUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACG GAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUG UUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAG ACACAAUAAAUGAGAAGUUUGCAUGCAAGCU
15	Multimer sequence D2x4	GGCGCUUCCGGAAGAGCUAGCUUUUAUUUUUUAUCUUCUCCUUUC CUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCG CAGAUGAUAAACAAGAGGGUAAAAAGAAAAAAGCGCGAAUUCCG AUCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCA UUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGG GUAAAAAGAAAAAGAUCGUAUCCGGUACCUGUGGUUUUAUUUUU UAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUA CCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAA CCACACCUCCACCGGUGGGCCGUUUUAUUUUUUAUCUUCUCCUUU CCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUC GCAGAUGAUAAACAAGAGGGUAAAAAGAAAAACGGCCCAAGCU
16	Multimer sequence D3x4	GGCGCUUCCGGAAGAGCUAGCCCGGCGGUCAUUUUUAUUUAUCCU CAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAA UGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGC GAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAU UAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUG ACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGCCGG GAAGCGCCGAAUUCAUAUCGAUCGGUCAUUUUUAUUUAUCCUCAU CGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGU CAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAU CCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAU CCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGC GUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGAUCGAAUA AAGGUACCUGUGGGGUCAUUUUUAUUUAUCCUCAUCGUCAACAAC AACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAA GGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCG AGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCG GUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAG CAGCCAAACAAUCAUAGGAAAUGAACCCCACAUUUUACCGGUAAU ACCGGGGGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUAC CGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGU UCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCG CGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGA UUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAA ACAAUCAUAGGAAAUGAACCCCCCGGAAGCU
17	Multimer sequence D3x4_D2x4	GGCGCUUCCGGAAGAGCUAGCCCGGCGGUCAUUUUUAUUUAUCCU CAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAA UGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGC GAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAU UAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUG ACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGCCGG

		GAAGCGCCGAAUUCAUAUCGAUCGGUCAUUUUUAUUUAUCCUCAU CGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGU CAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAU CCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAU CCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGC GUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGAUCGAAUA AAGGUACCUGUGGGGUCAUUUUUAUUUAUCCUCAUCGUCAACAAC AACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAA GGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCG AGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCG GUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAG CAGCCAAACAAUCAUAGGAAAUGAACCCCACAUUUUACCGGUAAU ACCGGGGGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUAC CGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGU UCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCG CGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGA UUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAA ACAAUCAUAGGAAAUGAACCCCCCGGAAGCUUUCCGGAAGAGCUA GCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAU UUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGG UAAAAAGAAAAAAGCGCGAAUUCCGAUCUUUUAUUUUUUAUCUUC UCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCA CGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAGAUCGU AUCCGGUACCUGUGGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAU CUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUG AUAAACAAGAGGGUAAAAAGAAAAACCACACCUCCACCGGUGGGC CGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAU UUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGG UAAAAAGAAAAACGGCCCAAGCUUGACUCCUAUAGUGUCACCUAA AUGUCUAG
18	Multimer sequence D2x4_D3x 4	GGCGCUUCCGGAAGAGCUAGCUUUUAUUUUUUAUCUUCUCCUUUC CUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCG CAGAUGAUAAACAAGAGGGUAAAAAGAAAAAAGCGCGAAUUCCG AUCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCA UUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGG GUAAAAAGAAAAAGAUCGUAUCCGGUACCUGUGGUUUUAUUUUU UAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUA CCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAA CCACACCUCCACCGGUGGGCCGUUUUAUUUUUUAUCUUCUCCUUU CCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUC GCAGAUGAUAAACAAGAGGGUAAAAAGAAAAACGGCCCAAGCUUC CGGCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGA CAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCC UGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCG AUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUU CCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACA AUCAUAGGAAAUGAACCGCCCGGGAAGCGCCGAAUUCAUAUCGAUC GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAAC AACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCC CCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCU

		CCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCC GCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUC AUAGGAAAUGAACCGAUCGAAUAAAGGUACCUGUGGGGUCAUUU UUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAAC ACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGAC GCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAG GUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCC UGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAA UGAACCCCACAUUUUACCGGUAAUACCGGGGGGUCAUUUUUAUUU AUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACC AAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCU GUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAU GAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACA UCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACC CCCCGGAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAG
19	Multimer sequence (D3_D2)x4	GGCGCUUCCGGAAGAGCUAGCCCGGCGGUCAUUUUUAUUUAUCCU CAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAA UGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGC GAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAU UAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUG ACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGCCGG GAAGCGCCGAAUUCCGAUCUUUUAUUUUUUAUCUUCUCCUUUCCU UAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCA GAUGAUAAACAAGAGGGUAAAAAGAAAAAGAUCGUAUCCGGUAC CUGUGGGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACC GACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUU CCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGC GAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAU UCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAAC AAUCAUAGGAAAUGAACCCCACAUUUUACCGGUGGGCCGUUUUAU UUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCU CCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGA AAAACGGCCCAAGCUUUCCGGAAGAGCUAGCCCGGCGGUCAUUUU UAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACA CCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACG CGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGG UAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCU GCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAU GAACCGCCGGGAAGCGCCGAAUUCCGAUCUUUUAUUUUUUAUCUU CUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACC ACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAGAUCG UAUCCGGUACCUGUGGGGUCAUUUUUAUUUAUCCUCAUCGUCAAC AACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCG CAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUG GCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGU CCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUC AGCAGCCAAACAAUCAUAGGAAAUGAACCCCACAUUUUACCGGUG GGCCGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAU CAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA

		GGGUAAAAAGAAAAACGGCCCAAGCUUGACUCCUAUAGUGUCACC UAAAUGUCUAG
20	gGFP_β2.7	GGAGUCUCAGAUCCGCUAGCGCUACCGGUCGCCACCAUGGUGAGC AAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAG CUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAG GGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUC UGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCA CCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAU GAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGU CCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUACAAGAC CCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAACCGCAU CGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCCUGGG GCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUAUCAU GGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGAUCCG CCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUACCA GCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGACAAC CACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACGAG AAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGGG AUCACUCUCGGCAUGGACGAGCUGUACAAGUCCGGAUGAGCUAGC UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCU UCUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCU UUUUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCC GUACCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGU CUCUCCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCC CCAGCGCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCG UAGGCUGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUU UUAUUAUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCG GAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAA ACAAGAGGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCA GCUUUCCGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAA GAGAAAACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUCG UCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCA AUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCC UCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCC CGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCG UCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAA AAAGAUCAUCUCUCUCGGUGUAUAGCAACACCAACAACAACCGCA UCGCAACAUCUUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUG AGAAUGAAAUCACCACAACCAAGCCAGAUUUCACGUCCAUGAGUU UUUAUUAUAUUAUUAUCAAAACGAAAAACAGAAAAACUGUCAUA GAUAAAUAUAAAAAAAAAUAGAAACCACAAACGACUACUAGUACU CCAAUCUUAGAUGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCA UAAUCAUCGAAGAAUGAAAGACGACGAUGAUUCCUUACCGCUCCU GCCACCCGGUCUGUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAU CCAAGAUCCCCGGGUCGGCGUCGGCAUGCCGCUGAUCGCAGUGGC CCCACCUCGGCAUGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAA AAGUAUCUUUCUGUAAAAAAAGAAAACAAUACAUGAUUAACCGA

		AAAGAAACCAACAAAAAGAACCCGAGAUCAGUCGAUUUCGAUCAC UACGAUAAACACAUGGAAGAUUUCUUGAAAAAAGAAAAGAGAAA GAGACCACCUUCCCGGCGGCGGACACGCUCCUCUCCGUCGCCGUUC UGCACCAUGAUUCGAUCAAUAACAACAUCAUCAUCGGAGACCAUC UUUUAAUCAAUCAGCGUUGCAGUAGUCGACUCCCUGGACACGAAG GAGUCAUCCAUUUUUAUCCUCGCACUUCUUCGCUCUCAAAGCCGC CUUUAAAGUUGAAAUGAAAGGAUGGAAACAUGGAAUACAGUUUU AAUUGCACGUAUCACCAUUUUACUACAAAAAGAAAAAAAAACAAC UUACACAUAGUAUUACCUUAGGUUUACGGAUAAGUAGAGUGUAG GCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUUGUCUCGGCAUAA UCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAUUUAUUCACAUCA ACACAGCGAAAAACUCCAGCAUCAAAGUACACCUAGAGACAGCCC UUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUACACCAAAGAA GAUUACCGUCCUUACGAGAAAACAGAUACUCGGAUAUAGGAAUCA AGACAGCUCUGCACUGAAAACACACUCUCCUGUCACGACACCGCG CCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGAUCCAUCGU GAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAAUCUUGGAC CACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAGAACUUUGA GAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACAACAACCUC UGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUCCCAAACCU CGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUUUGCCUCCU UAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUAUUCCUUCU GCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGCCUUCACCC CCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAAUAAAUGA GAAGUAAGCU
21	gGFP_s_β2 .7	GGAGUCUCAGAUCCGCUAGCGCUACCGGUCGCCACCAUGGUGAGC AAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAG CUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAG GGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUC UGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCA CCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAU GAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGU CCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUACAAGAC CCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAACCGCAU CGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCCUGGG GCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUAUCAU GGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGAUCCG CCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUACCA GCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGACAAC CACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACGAG AAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGGG AUCACUCUCGGCAUGGACGAGCUGUACAAGUCCGGAUGACACCAC CCCGGAGAACAGCUCCUCGCUAGCUCCCCAGAUCGCUGCUGCCCCG GCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGU CGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCG UGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUG GAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUC UCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGA GUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAU GCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCA

		UCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCGU CGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGG GUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUUU UAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUA CCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAA AGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGAA UUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAAACAA GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAAC AACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCC CCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCU CCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCC GCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUC AUAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGU AUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAA GACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCA AGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAA CGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAAUAG AAACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCU CCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAG ACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAG AGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCG UCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCG CCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAA AGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAAC CCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAU UUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGG ACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUA ACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCA GUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUC GCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGG AUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUA CUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAGG UUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCC AAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAG UAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAU CAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUU UAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAAC AGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACAC ACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUGA CUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAA AGACCAAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGAC AAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAG GAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUA UCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUU UUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUC GGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUU UUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACA GAGUAGUAGACACAAUAAAUGAGAAGUAAGCU
22	mtGFP_s_β 2.7	GGAGUCUCAGAUCCGCUAGCGCUACCGGUCGCCACCAUAGUGAGC AAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAG

		CUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAG GGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUC UGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCA CCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAU GAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGU CCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUACAAGAC CCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAACCGCAU CGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCCUGGG GCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUAUCAU GGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGAUCCG CCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUACCA GCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGACAAC CACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACGAG AAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGGG AUCACUCUCGGCAUGGACGAGCUGUACAAGUCCGGAAAGACACCA CCCCGGAGAACAGCUCCUCGCUAGCUCCCCAGAUCGCUGCUGCCCC GGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGG UCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCC GUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGU GGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAU CUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUG AGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCA UGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACC AUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCG UCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACG GGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUU UUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCU ACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAA AAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGA AUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAAACA AGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAA CAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGC CCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUC UCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCC CGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAU CAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUG UAUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCA AGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACC AAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAA ACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUA GAAACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGC UCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAA GACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUA GAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGC GUCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGC GCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAA AAGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAA CCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGA UUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCG GACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAU

		AACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGC AGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCU CGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAG GAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUU ACUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAG GUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGC CAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUA GUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCA UCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUU UUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAA CAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACA CACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUG ACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAA AAGACCAAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGA CAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUA GGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUU AUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGU UUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCU CGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCU UUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACAC AGAGUAGUAGACACAAUAAAUGAGAAGUAAGCU
23	mtGFP_s	GGAGUCUCAGAUCCGCUAGCGCUACCGGUCGCCACCAUAGUGAGC AAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAG CUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAG GGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUC UGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCA CCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAU GAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGU CCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUACAAGAC CCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAACCGCAU CGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCCUGGG GCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUAUCAU GGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGAUCCG CCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUACCA GCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGACAAC CACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACGAG AAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGGG AUCACUCUCGGCAUGGACGAGCUGUACAAGUCCGGAAGACACCAC CCCGGAGAACAGCUCCUC
24	asATP6_s6 _ β2.7	GGAGUCUCCGGAAUAAGCGCCAGUAGAAUUAGAAUUGUGAAGAU GAUAAGUGUAGAGGGAAGGUUAAUGGUUGAUAUUGCUAGGGUGG CGCUUCCAAUUAGGUGCGUGAGUAGGUGGCCUGCAGUAAUGUUAA AGCAAGGGUUAUUCCGAAUUGGGCUAGCUCCCCAGAUCGCUGC UGCCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCU GGUCGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAG CCGCCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGC AGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGG UCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUU UAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCA UGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCC

		GACUACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACC GCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUG GGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUU UUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCC CUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAA AAGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAAC UCGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAAC AAAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUA CCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUG UUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACC GCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUG AUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCA AACAAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUC UCGGUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCA UCCGCAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACC ACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUU AUCAAAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAA AAAAUAGAAACCACAAACGACUACUAGUACUCCAAUCUUAGAUGU AUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAA UGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGU AUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGG UCGGCGUCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUG CCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGU AAAAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAA AAGAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUG GAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGG CGGCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGA UCAAUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGC GUUGCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUU AUCCUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAU GAAAGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACC AUUUUACUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUAC CUUAGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGU UCAGCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUA UAAUAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUC CAGCAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGC AGCUUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGA GAAAACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGA AAACACACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUAC GCGUGACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAAC CUAAAAAGACCAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUU GAAGACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACC UCUUAGGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCU AUUUUAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCU UAAGUUUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCAC AAGCUCGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUG UUCCUUUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGC AACACAGAGUAGUAGACACAAUAAAUGAGAAGU**CCAAUUCGGA** **AUAACCC**AAGCU

25	β2.7_s8_as ATP8	GGCGCUUCCGGAAUAGGUUGGAUUGGGGGCUAGCUCCCCAGAUCG CUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCC GGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGAC UUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAA CGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGU CUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACC UUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCA CCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCG UCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCAC CACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGU CCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUU UUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAU UUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGG UAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGA UAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACA GAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACA ACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAG GGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGA GGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGG UCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGC AGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAU CUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCGCAACAU CUUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAA UCACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUA UUAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAU AAAAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAAUCUUA GAUGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCG AAGAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCACCCGG UCUGUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUC CCCGGGUCGGCGUCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUC GGCAUGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCU UUCUGUAAAAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAACC AACAAAAAGAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAA CACAUGGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCU UCCCGGCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGA UUCGAUCAAUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAA UCAGCGUUGCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCA UUUUUAUCCUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUU GAAAUGAAAGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGU AUCACCAUUUUACUACAAAAAGAAAAAAAAACAACUUACACAUAG UAUUACCUUAGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGA AACAGUUCAGCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUC UGCAUAUAAUAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAA AAACUCCAGCAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUA GUUUGCAGCUUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCC UUACGAGAAAACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUG CACUGAAAACACACUCUCCUGUCACGACACCGCGCCACACCAGAG GCGUACGCGUGACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCG CAGAACCUAAAAAGACCAAAAAAAAAUCUUGGACCACAGUUGUCG AUUCUUGAAGACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUU

		GAAACCUCUUAGGAUCCACAAAAACAACAACCUCUGUAUGGAAAA UGCGCUAUUUUAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCC UAUUCUUAAGUUUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAG AAGCACAAGCUCGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUU AUUUUGUUCCUUUUUUUUUUGUUUGCCUUCACCCCUUCACUCCC UGUAGCAACACAGAGUAGUAGACACAAUAAAUGAGAAGUAAGCU UCCCCAAACCAACCUCUACCGGAAGCGCCUUUUUUUCGUUCAUUU UGGUUCUCAGGGUUUGUUAUAAUUUUUUAUUUUUAUGGGCUUUG GUGAGGGAGGUAGGUGGUAGUUUGUGUUUAAUAUUUUUAGUUGG GUGAUGA
26	ATP6_D3$_4$ _D2$_4$	GGAGUCUCCGGAAUAAGCGCCAGUAGAAUUAGAAUUGUGAAGAU GAUAAGUGUAGAGGGAAGGUUAAUGGUUGAUAUUGCUAGGGUGG CGCUUCCAAUUAGGUGCGUGAGUAGGUGGCCUGCAGUAAUGUUAA AGCAAGGGUUAUUCCGAAUUGGGCUAGCCCGGCGGUCAUUUUU AUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACAC CACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGC GCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGU AGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUG CACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUG AACCGCCGGGAAGCGCCGAAUUCAUAUCGAUCGGUCAUUUUUAUU UAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCAC CAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCC UGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGA UGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCAC AUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAAC CGAUCGAAUAAAGGUACCUGUGGGGUCAUUUUUAUUUAUCCUCA UCGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUG UCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGA UCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUA UCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACG CGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCCACAUUU UACCGGUAAUACCGGGGGGUCAUUUUUAUUUAUCCUCAUCGUCA ACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUC CGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCA UGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGU GUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCG GUCAGCAGCCAAACAAUCAUAGGAAAUGAACCCCCCGGAAGCUUU CCGGAAGAGCUAGCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAU CUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUG AUAAACAAGAGGGUAAAAAGAAAAAAGCGCGAAUUCCGAUCUUU UAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCC UCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAA AGAAAAAGAUCGUAUCCGGUACCUGUGGUUUUAUUUUUUAUCUU CUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACC ACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAACCACAC CUCCACCGGUGGGCCGUUUUAUUUUUUAUCUUCUCCUUUCCUUAA UCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAU GAUAAACAAGAGGGUAAAAAGAAAAACGGCCCCCAUGAAUAAGGC CCAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAGAUACUAAG GGAGUCUUGC

27	S1a	CCGGC
28	S1b	GCCGG
29	S2a	CGAUC
30	S2b	GAUCG
31	S3a	UGUGG
32	S3b	CCACA
33	S4a	CCGGGG
34	S4b	CCCCGG
35	S6a	AAGCAAGGGUUAUUCCGAAUUGG
36	S6b	CCAAUUCGGAAUAACCC
37	S8a	GGUUGGAUUGGGG
38	S8b	CCCCAAACCAACCUCUACCGGAAGCGCCUUUU
39	Spacer Figure 3a	CACCACCCCGGAGAACAGCTCCTC The same spacer was found to stabilize all the GFP fusion constructs
40	Antisense domain 1 deletion mutant: ΔD1AS	GGAGUCAAGCUUGCAUGCAAACUUCUCAUUUAUUGUGUCUACUA CUCUGUGUUGCUACAGGGAGUGAAGGGGGUGAAGGCAAACAAAA AAAAAAGGAACAAAAUAAUAGAUUAGCAGAAGGAAUAAUCCGUG CGACCGAGCUUGUGCUUCUUUUCUUAUAAGGAGGCAAAUAUACUA GGGAAAACUUAAGAAUAGGAAGAAACCGAGGUUUGGGAGAAAAG CUGAGAUAAAAAUAGCGCAUUUUCCAUACAGAGGUUGUUGUUUUU GUGGAUCCUAAGAGGUUUCAAGUGCGAAUCUCAAAGUUCUCACGA GAAUAUUGUCUUCAAGAAUCGACAACUGUGGUCCAAGAUUUUUUU UUGGUCUUUUUAGGUUCUGCGAGGGACAUCACGAUGGAUCGUUGC GAUGAAGUCACGCGUACGCCUCUGGUGUGGCGCGGUGUCGUGACA GGAGAGUGUGUUUUCAGUGCAGAGCUGUCUUGAUUCCUAUAUCCG AGUAUCUGUUUUCUCGUAAGGACGGUAAUCUUCUUUGGUGUAAG UACAUCUAAAAGCUGCAAACUAUAUUUUAAGGGCUGUCUCUAGGU GUACUUUGAUGCUGGAGUUUUUCGCUGUGUUGAUGUGAAUAAAU CUACUACUACUAUUAUAUGCAGAAAGAGUGAUUAUGCCGAGACAA GAUUGCAUUGGCUGAACUGUUUCAAAAACGCCUACACUCUACUUA UCCGUAAACCUAAGGUAAUACUAUGUGUAAGUUGUUUUUUUUUC UUUUUGUAGUAAAAUGGUGAUACGUGCAAUUAAAACUGUAUUCC AUGUUUCCAUCCUUUCAUUUCAACUUUAAAGGCGGCUUUGAGAGC GAAGAAGUGCGAGGAUAAAAAUGGAUGACUCCUUCGUGUCCAGGG AGUCGACUACUGCAACGCUGAUUGAUUAAAAGAUGGUCUCCGAUG AUGAUGUUGUUAUUGAUCGAAUCAUGGUGCAGAACGGCGACGGA GAGGAGCGUGUCCGCCGCCGGGAAGGUGGUCUCUUUCUCUUUUCU UUUUUCAAGAAAUCUUCCAUGUGUUUAUCGUAGUGAUCGAAAUCG ACUGAUCUCGGGUUCUUUUUGUUGGUUUCUUUUCGGUUAAUCAUG UAUUGUUUUCUUUUUUUACAGAAAGAUACUUUUUUCAUGAGCAA UUCCUCGCCCGGCGCCGGCAUGCCGAGGUGGGGCCACUGCGAUCA GCGGCAUGCCGACGCCGACCCGGGGAUCUUGGAUUCACCGUUUUC UCUCUUCUCUCUCUACAUACAGACCGGGUGGCAGGAGCGGUAAGG AAUCAUCGUCGUCUUUCAUUCUUCGAUGAUUAUGGUAAUACUAAA UCUUAUCUAGGAGCAUAUACAUCUAAGAUUGGAGUACUAGUAGUC GUUUGUGGUUUCUAUUUUUUUUUAUAUUUAUCUAUGACAGUUUU UCUGUUUUUCGUUUUGAUAAUAAUAUAAUAAAAACUCAUGGACG UGAAAUCUGGCUUGGUUGUGGUGAUUUCAUUCUCAUUAUUGUUG UUUUCUUUCCGUCUUGCGGAUGAAGAUGUUGCGAUGCGGUUGUUG UUGGUGUUGCUAUACACCGAGAGAGAUGAUCUUUUUGUUCUUCUG

		GUUCAUUUCCUAUGAUUGUUUGGCUGCUGACCGACGCGUCAGGAU GUGCAGGGCAUGCGGGGAAUCAGGACCGGACACGGGAUAAUUUCA UCUACCUAUACGGAGAUCGCGGUCCUCGCCAUGAGGAUCGCGACA GGCGCGUCGAGGGGGCAGGAACACCCUUGCGGAUUGACAUUCUUG GUGGUGUUUCGUUGUUGUCGGUAGUUGUUGUUGACGAUGAGGAU AAAUAAAAAUGACCUUGUUUUUGUUCUGUUUUCUCUUGUUGGGA AUCGUCGACUUUGAAUUCUUCGAGUUAUCGGAAAGCUGAGGUACC CAAAUGUCUGUAGCUUUUUUCUUUUUACCCUCUUGUUUAUCAUCU GCGAUUCGUGGUAGGUAGGAGAGGGAAAUGAUAAUCCGAGAUUA AGGAAAGGAGAAGAUAAAAAAUAAAAAAAAAAUAAUAAAAGAGAA CGCCGGGGCAGCAGCGAUCUGGGGAUGUGCUAGCUCCGG
41	Antisense domain 2 deletion mutant: ΔD2AS	GGAGUCAAGCUUGCAUGCAAACUUCUCAUUUAUUGUGUCUACUA CUCUGUGUUGCUACAGGGAGUGAAGGGGGUGAAGGCAAACAAAA AAAAAAGGAACAAAAUAAUAGAUUAGCAGAAGGAAUAAUCCGUG CGACCGAGCUUGUGCUUCUUUUCUUAUAAGGAGGCAAAUAUACUA GGGAAAACUUAAGAAUAGGAAGAAACCGAGGUUUGGGAGAAAAG CUGAGAUAAAAUAGCGCAUUUUCCAUACAGAGGUUGUUGUUUUU GUGGAUCCUAAGAGGUUUCAAGUGCGAAUCUCAAAGUUCUCACGA GAAUAUUGUCUUCAAGAAUCGACAACUGUGGUCCAAGAUUUUUUU UUGGUCUUUUUAGGUUCUGCGAGGGACAUCACGAUGGAUCGUUGC GAUGAAGUCACGCGUACGCCUCUGGUGUGGCGCGGUGUCGUGACA GGAGAGUGUGUUUUCAGUGCAGAGCUGUCUUGAUUCCUAUAUCCG AGUAUCUGUUUUCUCGUAAGGACGGUAAUCUUCUUUGGUGUAAG UACAUCUAAAAGCUGCAAACUAUAUUUUAAGGGCUGUCUCUAGGU GUACUUUGAUGCUGGAGUUUUUCGCUGUGUUGAUGUGAAUAAAU CUACUACUACUAUUAUAUGCAGAAAGAGUGAUUAUGCCGAGACAA GAUUGCAUUGGCUGAACUGUUUCAAAAACGCCUACACUCUACUUA UCCGUAAACCUAAGGUAAUACUAUGUGUAAGUUGUUUUUUUUUC UUUUUGUAGUAAAAUGGUGAUACGUGCAAUUAAAACUGUAUUCC AUGUUUCCAUCCUUUCAUUUCAACUUUAAAGGCGGCUUUGAGAGC GAAGAAGUGCGAGGAUAAAAAUGGAUGACUCCUUCGUGUCCAGGG AGUCGACUACUGCAACGCUGAUUGAUUAAAAGAUGGUCUCCGAUG AUGAUGUUGUUAUUGAUCGAAUCAUGGUGCAGAACGGCGACGGA GAGGAGCGUGUCCGCCGCCGGGAAGGUGGUCUCUUUCUCUUUUCU UUUUUCAAGAAAUCUUCCAUGUGUUUAUCGUAGUGAUCGAAAUCG ACUGAUCUCGGGUUCUUUUUGUUGGUUUCUUUUCGGUUAAUCAUG UAUUGUUUUCUUUUUUUACAGAAAGAUACUUUUUUCAUGAGCAA UUCCUCGCCCGGCGCCGGCAUGCCGAGGUGGGGCCACUGCGAUCA GCGGCAUGCCGACGCCGACCCGGGGAUCUUGGAUUCACCGUUUUC UCUCUUCUCUCUCUACAUACAGACCGGGUGGCAGGAGCGGUAAGG AAUCAUCGUCGUCUUUCAUUCUUCGAUGAUUAUGGUAAUACUAAA UCUUAUCUAGGAGCAUAUACAUCUAAGAUUGGAGUACUAGUAGUC GUUUGUGGUUUCUAUUUUUUUUUAUAUUUAUCUAUGACAGUUUU UCUGUUUUUCGUUUUGAUAAUAAUAUAAUAAAAACUCAUGGACG UGAAAUCUGGCUUGGUUGUGGUGAUUUCAUUCUCAUUAUUGUUG UUUUCUUUCCGUCUUGCGGAUGAAGAUGUUGCGAUGCGGUUGUUG UUGGUGUUGCUAUACACCGAGAGAGAUGAUCUUUUUGUUCUUCUG GUUCAUUUCCUAUGAUUGUUUGGCUGCUGACCGACGCGUCAGGAU GUGCAGGGCAUGCGGGGAAUCAGGACCGGACACGGGAUAAUUUCA UCUACCUAUACGGAGAUCGCGGUCCUCGCCAUGAGGAUCGCGACA

		GGCGCGUCGAGGGGGCAGGAACACCCUUGCGGAUUGACAUUCUUG GUGGUGUUUCGUUGUUGUCGGUAGUUGUUGUUGACGAUGAGGAU AAAUAAAAAUGACCUUGUUUUUGUUCUGUUUUCUCUUGUUGGGA AUCGUCGACUUUGAAUUCUUCGAGUUAUCGGAAAGCUGAGGUACC CAAAUGUCUGUAGCUAAAAAUAAUAAAACAGAAGCCGACCGGCCG CCGACCCGUUCCCCAGGACCAGCCUACGAGGAACGGAUAACGCGG UGGCGACGGCAGCGGUGGUGGCGCUGGGGGUGGCGGUAGUGGUGC UGCUGAUGGUAGUCGGGACGGAGGAGAGACGAUGCAUACAUACAC GCGUGCAUGCUGCAUGGGUGGAUGGUACGGCCGGGAGACGCGGAA GAGAAACUCACAUAAAAAGGUGAUAAAAAGAGCGGUUGAAAAAA GAAAACGAGAUUCGACCAGACAGAAGAGAAGGACCGGGGCUUGGC GACCCUUCCACGACUGCCGUUGUCAUCUCGGCUCCUCCAUCUUCUC CCGGCCACGGGCGGCUAAGUCACCGCCGUUCUCCCCAUCCGUCCGA GCGCCGACCGACCAGCCGGCCGAUUCGCCCGCCGGGGCUUCUGGA GAACGCCGGGGCAGCAGCGAUCUGGGGAUGUGCUAGCUCCGG
42	Antisense domain 3 deletion mutant: ΔD3AS	GGAGUCAAGCUUGCAUGCAAACUUCUCAUUUAUUGUGUCUACUA CUCUGUGUUGCUACAGGGAGUGAAGGGGGUGAAGGCAAACAAAA AAAAAAGGAACAAAAUAAUAGAUUAGCAGAAGGAAUAAUCCGUG CGACCGAGCUUGUGCUUCUUUUCUUAUAAGGAGGCAAAUAUACUA GGGAAAACUUAAGAAUAGGAAGAAACCGAGGUUUGGGAGAAAAG CUGAGAUAAAAUAGCGCAUUUUCCAUACAGAGGUUGUUGUUUUU GUGGAUCCUAAGAGGUUUCAAGUGCGAAUCUCAAAGUUCUCACGA GAAUAUUGUCUUCAAGAAUCGACAACUGUGGUCCAAGAUUUUUUU UUGGUCUUUUUAGGUUCUGCGAGGGACAUCACGAUGGAUCGUUGC GAUGAAGUCACGCGUACGCCUCUGGUGUGGCGCGGUGUCGUGACA GGAGAGUGUGUUUUCAGUGCAGAGCUGUCUUGAUUCCUAUAUCCG AGUAUCUGUUUUCUCGUAAGGACGGUAAUCUUCUUUGGUGUAAG UACAUCUAAAAGCUGCAAACUAUAUUUUAAGGGCUGUCUCUAGGU GUACUUUGAUGCUGGAGUUUUUCGCUGUGUUGAUGUGAAUAAAU CUACUACUACUAUUAUAUGCAGAAAGAGUGAUUAUGCCGAGACAA GAUUGCAUUGGCUGAACUGUUUCAAAAACGCCUACACUCUACUUA UCCGUAAACCUAAGGUAAUACUAUGUGUAAGUUGUUUUUUUUUC UUUUUGUAGUAAAAUGGUGAUACGUGCAAUUAAAACUGUAUUCC AUGUUUCCAUCCUUUCAUUUCAACUUUAAAGGCGGCUUUGAGAGC GAAGAAGUGCGAGGAUAAAAAUGGAUGACUCCUUCGUGUCCAGGG AGUCGACUACUGCAACGCUGAUUGAUUAAAAGAUGGUCUCCGAUG AUGAUGUUGUUAUUGAUCGAAUCAUGGUGCAGAACGGCGACGGA GAGGAGCGUGUCCGCCGCCGGGAAGGUGGUCUCUUUCUCUUUUCU UUUUUCAAGAAAUCUUCCAUGUGUUUAUCGUAGUGAUCGAAAUCG ACUGAUCUCGGGUUCUUUUUGUUGGUUUCUUUUCGGUUAAUCAUG UAUUGUUUUCUUUUUUUACAGAAAGAUACUUUUUUCAUGAGCAA UUCCUCGCCCGGCGCCGGCAUGCCGAGGUGGGGCCACUGCGAUCA GCGGCAUGCCGACGCCGACCCGGGGAUCUUGGAUUCACCGUUUUC UCUCUUCUCUCUCUACAUACAGACCGGGUGGCAGGAGCGGUAAGG AAUCAUCGUCGUCUUUCAUUCUUCGAUGAUUAUGGUAAUACUAAA UCUUAUCUAGGAGCAUAUACAUCUAAGAUUGGAGUACUAGUAGUC GUUUGUGGUUUCUAUUUUUUUUUAUAUUUAUCUAUGACAGUUUU UCUGUUUUUCGUUUUGAUAAUAAUAUAAUAAAAACUCAUGGACG UGAAAUCUGGCUUGGUUGUGGUGAUUUCAUUCUCAUUAUUGUUG UUUUCUUUCCGUCUUGCGGAUGAAGAUGUUGCGAUGCGGUUGUUG

		UUGGUGUUGCUAUACACCGAGAGAGAUGAUCUUUUUGUUCUUCUU UGUUUUUGUUCUGUUUUCUCUUGUUGGGAAUCGUCGACUUUGAA UUCUUCGAGUUAUCGGAAAGCUGAGGUACCCAAAUGUCUGUAGCU UUUUUCUUUUUACCCUCUUGUUUAUCAUCUGCGAUUCGUGGUAGG UAGGAGAGGGAAAUGAUAAUCCGAGAUUAAGGAAAGGAGAAGAU AAAAAAUAAAAAAAAAUAAUAAAACAGAAGCCGACCGGCCGCCGA CCCGUUCCCCAGGACCAGCCUACGAGGAACGGAUAACGCGGUGGC GACGGCAGCGGUGGUGGCGCUGGGGGUGGCGGUAGUGGUGCUGCU GAUGGUAGUCGGGACGGAGGAGAGACGAUGCAUACAUACACGCGU GCAUGCUGCAUGGGUGGAUGGUACGGCCGGGAGACGCGGAAGAGA AACUCACAUAAAAAGGUGAUAAAAAGAGCGGUUGAAAAAAGAAA ACGAGAUUCGACCAGACAGAAGAGAAGGACCGGGGCUUGGCGACC CUUCCACGACUGCCGUUGUCAUCUCGGCUCCUCCAUCUUCUCCCGG CCACGGGCGGCUAAGUCACCGCCGUUCUCCCCAUCCGUCCGAGCGC CGACCGACCAGCCGGCCGAUUCGCCCGCCGGGGCUUCUGGAGAAC GCCGGGGCAGCAGCGAUCUGGGGAUGUGCUAGCUCCGG
43	Antisense domain 4 deletion mutant: ΔD4AS	GGAGUCAAGCUUGCAUGCAAACUUCUCAUUUAUUGUGUCUACUA CUCUGUGUUGCUACAGGGAGUGAAGGGGGUGAAGGCAAACAAAA AAAAAAGGAACAAAAUAAUAGAUUAGCAGAAGGAAUAAUCCGUG CGACCGAGCUUGUGCUUCUUUUCUUAUAAGGAGGCAAAUAUACUA GGGAAAACUUAAGAAUAGGAAGAAACCGAGGUUUGGGAGAAAAG CUGAGAUAAAAUAGCGCAUUUUCCAUACAGAGGUUGUUGUUUUU GUGGAUCCUAAGAGGUUUCAAGUGCGAAUCUCAAAGUUCUCACGA GAAUAUUGUCUUCAAGAAUCGACAACUGUGGUCCAAGAUUUUUUU UUGGUCUUUUUAGGUUCUGCGAGGGACAUCACGAUGGAUCGUUGC GAUGAAGUCACGCGUACGCCUCUGGUGUGGCGCGGUGUCGUGACA GGAGAGUGUGUUUUCAGUGCAGAGCUGUCUUGAUUCCUAUAUCCG AGUAUCUGUUUUCUCGUAAGGACGGUAAUCUUCUUUGGUGUAAG UACAUCUAAAAGCUGCAAACUAUAUUUUAAGGGCUGUCUCUAGGU GUACUUUGAUGCUGGAGUUUUUCGCUGUGUUGAUGUGAAUAAAU CUACUACUACUAUUAUAUGCAGAAAGAGUGAUUAUGCCGAGACAA GAUUGCAUUGGCUGAACUGUUUCAAAAACGCCUACACUCUACUUA UCCGUAAACCUAAGGUAAUACUAUGUGUAAGUUGUUUUUUUUUC UUUUUGUAGUAAAAUGGUGAUACGUGCAAUUAAAACUGUAUUCC AUGUUUCCAUCCUUUCAUUUCAACUUUAAAGGCGGCUUUGAGAGC GAAGAAGUACCCGGGGAUCUUGGAUUCACCGUUUUCUCUCUUCUC UCUCUACAUACAGACCGGGUGGCAGGAGCGGUAAGGAAUCAUCGU CGUCUUUCAUUCUUCGAUGAUUAUGGUAAUACUAAAUCUUAUCUA GGAGCAUAUACAUCUAAGAUUGGAGUACUAGUAGUCGUUUGUGG UUUCUAUUUUUUUUUAUAUUUAUCUAUGACAGUUUUUCUGUUUU UCGUUUUGAUAAUAAUAUAAUAAAAACUCAUGGACGUGAAAUCU GGCUUGGUUGUGGUGAUUUCAUUCUCAUUAUUGUUGUUUUCUUU CCGUCUUGCGGAUGAAGAUGUUGCGAUGCGGUUGUUGUUGGUGU UGCUAUACACCGAGAGAGAUGAUCUUUUUGUUCUUCUGGUUCAUU UCCUAUGAUUGUUUGGCUGCUGACCGACGCGUCAGGAUGUGCAGG GCAUGCGGGGAAUCAGGACCGGACACGGGAUAAUUUCAUCUACCU AUACGGAGAUCGCGGUCCUCGCCAUGAGGAUCGCGACAGGCGCGU CGAGGGGGCAGGAACACCCUUGCGGAUUGACAUUCUUGGUGGUGU UUCGUUGUUGUCGGUAGUUGUUGUUGACGAUGAGGAUAAAUAAA AAUGACCUUGUUUUUGUUCUGUUUUCUCUUGUUGGGAAUCGUCGA

		CUUUGAAUUCUUCGAGUUAUCGGAAAGCUGAGGUACCCAAAUGUC UGUAGCUUUUUUCUUUUUACCCUCUUGUUUAUCAUCUGCGAUUCG UGGUAGGUAGGAGAGGGAAAUGAUAAUCCGAGAUUAAGGAAAGG AGAAGAUAAAAAAUAAAAAAAAAAUAAUAAAACAGAAGCCGACCG GCCGCCGACCCGUUCCCCAGGACCAGCCUACGAGGAACGGAUAAC GCGGUGGCGACGGCAGCGGUGGUGGCGCUGGGGGUGGCGGUAGUG GUGCUGCUGAUGGUAGUCGGGACGGAGGAGAGACGAUGCAUACAU ACACGCGUGCAUGCUGCAUGGGUGGAUGGUACGGCCGGGAGACGC GGAAGAGAAACUCACAUAAAAAGGUGAUAAAAAGAGCGGUUGAA AAAAGAAAACGAGAUUCGACCAGACAGAAGAGAAGGACCGGGGCU UGGCGACCCUUCCACGACUGCCGUUGUCAUCUCGGCUCCUCCAUC UUCUCCCGGCCACGGGCGGCUAAGUCACCGCCGUUCUCCCCAUCCG UCCGAGCGCCGACCGACCAGCCGGCCGAUUCGCCCGCCGGGGCUUC UGGAGAACGCCGGGGCAGCAGCGAUCUGGGGAUGUGCUAGCUCCG G

[00177] The following sequences were transfected as plasmid DNA using a CMV promoter and the SV40 polyA site. Hence the endogenously transcribed RNAs all start with UCAGAUCC which are the transcribed nucleotides of the CMV promoter then followed by a cleavage site, and they all end with **U**UUUUUUCACUG**C**$(A)_n$. The bold Cs indicate the two polyA cleavage sites which are then being followed by a polyA stretch $(A)_n$. so the correct end of the sequence might be either ..**U**UUUUUUCACUG**C**$(A)_n$ or …**U**$(A)_n$.

SEQ ID NO:	Name	Sequence
44	gGFP_β2.7_endo	UCAGAUCGCUAGCGCUACCGGUCGCCACCAUGGUGAGCAAGGGCGA GGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAGCUGGACGGC GACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAGGGCGAGGGC GAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUCUGCACCACCG GCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCACCCUGACCUA CGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAUGAAGCAGCAC GACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGUCCAGGAGCGCA CCAUCUUCUUCAAGGACGACGGCAACUACAAGACCCGCGCCGAGGU GAAGUUCGAGGGCGACACCCUGGUGAACCGCAUCGAGCUGAAGGG CAUCGACUUCAAGGAGGACGGCAACAUCCUGGGGCACAAGCUGGA GUACAACUACAACAGCCACAACGUCUAUAUCAUGGCCGACAAGCAG AAGAACGGCAUCAAGGUGAACUUCAAGAUCCGCCACAACAUCGAG GACGGCAGCGUGCAGCUCGCCGACCACUACCAGCAGAACACCCCCA UCGGCGACGGCCCCGUGCUGCUGCCCGACAACCACUACCUGAGCAC CCAGUCCGCCCUGAGCAAAGACCCCAACGAGAAGCGCGAUCACAUG GUCCUGCUGGAGUUCGUGACCGCCGCCGGGAUCACUCUCGGCAUGG ACGAGCUGUACAAGUCCGGAAGAGCUAGCUCCCCAGAUCGCUGCUG CCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGU CGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCG CCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGU CGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGA AUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUG

		UGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAG CAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUAC CAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCG UCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGG GUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUUU UAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUAC CUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAA GCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGAAU UCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAAACAAG GUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAA CGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCC UCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGU AUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAU GCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGG AAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUAUAGC AACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAAGACGGA AAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCAAGCCAG AUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAACGAAAA ACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAAUAGAAACCAC AAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUAGAU AAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGACGACGAU GAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAGAAG AGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCAUGCC GCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCGAGGA AUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAACAAUA CAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAUCAGU CGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGAAAAA AGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUCCUCU CCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCAUCAU CGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGACUCCCU GGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUCGCUCU CAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAUGGAAU ACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAGAAAAA AAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUAAGUAG AGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUUGUCUC GGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAUUUAUU CACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACCUAGAGA CAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUACACCA AAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGAUAUAGG AAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUCACGACAC CGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGAUCCAU CGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAAUCUUG GACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAGAACUU UGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACAACAACC UCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUCCCAAAC CUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUUUGCCUCC UUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUAUUCCUUC UGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGCCUUCACC CCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAAUAAAUGA GAAGUAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAGAAACU

		UGUUUAUUGCAGCUUAUAAUGGUUACAAUAAAGCAAUAGCAUCA CAAAUUUCACAAAUAAAGCAUUUUUUUCACUGC$(A)_n$
45	gGFP_s_β2 .7_endo	UCAGAUCGCUAGCGCUACCGGUCGCCACCAUGGUGAGCAAGGGCGA GGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAGCUGGACGGC GACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAGGGCGAGGGC GAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUCUGCACCACCG GCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCACCCUGACCUA CGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAUGAAGCAGCAC GACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGUCCAGGAGCGCA CCAUCUUCUUCAAGGACGACGGCAACUACAAGACCCGCGCCGAGGU GAAGUUCGAGGGCGACACCCUGGUGAACCGCAUCGAGCUGAAGGG CAUCGACUUCAAGGAGGACGGCAACAUCCUGGGGCACAAGCUGGA GUACAACUACAACAGCCACAACGUCUAUAUCAUGGCCGACAAGCAG AAGAACGGCAUCAAGGUGAACUUCAAGAUCCGCCACAACAUCGAG GACGGCAGCGUGCAGCUCGCCGACCACUACCAGCAGAACACCCCCA UCGGCGACGGCCCCGUGCUGCUGCCCGACAACCACUACCUGAGCAC CCAGUCCGCCCUGAGCAAAGACCCCAACGAGAAGCGCGAUCACAUG GUCCUGCUGGAGUUCGUGACCGCCGCCGGGAUCACUCUCGGCAUGG ACGAGCUGUACAAGUCCGGAUGACACCACCCCGGAGAACAGCUCCU CGCUAGCUCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCC CGGCGGGCGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGG GGAGAACGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGA GGAGCCGAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCG GUCCUUCUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCG CUCUUUUUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCG GCCGUACCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUC GUCUCUCCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCAC CCCCAGCGCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCU CGUAGGCUGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUG UUUUAUUAUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCU CGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUA AACAAGAGGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUC AGCUUUCCGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACA AGAGAAAACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUC GUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCA AUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCU CAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCC GUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUC GGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAA AGAUCAUCUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCG CAACAUCUUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGA AUGAAAUCACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUU AUUAUAUUAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUA AAUAUAAAAAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAA UCUUAGAUGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAU CAUCGAAGAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCAC CCGGUCUGUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAG AUCCCCGGGUCGGCGUCGGCAUGCCGCUGAUCGCAGUGGCCCCACC UCGGCAUGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAU CUUUCUGUAAAAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAA

		CCAACAAAAAGAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUA AACACAUGGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCAC CUUCCCGGCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAU GAUUCGAUCAAUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUC AAUCAGCGUUGCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCC AUUUUUAUCCUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUU GAAAUGAAAGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUA UCACCAUUUUACUACAAAAAGAAAAAAAAACAACUUACACAUAGU AUUACCUUAGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAA CAGUUCAGCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGC AUAUAAUAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAA CUCCAGCAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUU UGCAGCUUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUA CGAGAAAACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCAC UGAAAACACACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGU ACGCGUGACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAA CCUAAAAAGACCAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCU UGAAGACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAAC CUCUUAGGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGC UAUUUUAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCU UAAGUUUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCAC AAGCUCGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUG UUCCUUUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCA ACACAGAGUAGUAGACACAAUAAAUGAGAAGUAAGCUUGACUCCU AUAGUGUCACCUAAAUGUCUAGAAACUUGUUUAUUGCAGCUUAUA AUGGUUACAAAUAAAGCAAUAGCAUCACAAAUUUCACAAAUAAAG CAUUUUUUUCACUGC(A)$_n$
46	mtGFP_ s_β2.7_end o	UCAGAUCGCUAGCGCUACCGGUCGCCACCAUAGUGAGCAAGGGCGA GGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAGCUGGACGGC GACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAGGGCGAGGGC GAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUCUGCACCACCG GCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCACCCUGACCUA CGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAUGAAGCAGCAC GACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGUCCAGGAGCGCA CCAUCUUCUUCAAGGACGACGGCAACUACAAGACCCGCGCCGAGGU GAAGUUCGAGGGCGACACCCUGGUGAACCGCAUCGAGCUGAAGGG CAUCGACUUCAAGGAGGACGGCAACAUCCUGGGGCACAAGCUGGA GUACAACUACAACAGCCACAACGUCUAUAUCAUGGCCGACAAGCAG AAGAACGGCAUCAAGGUGAACUUCAAGAUCCGCCACAACAUCGAG GACGGCAGCGUGCAGCUCGCCGACCACUACCAGCAGAACACCCCCA UCGGCGACGGCCCCGUGCUGCUGCCCGACAACCACUACCUGAGCAC CCAGUCCGCCCUGAGCAAAGACCCCAACGAGAAGCGCGAUCACAUG GUCCUGCUGGAGUUCGUGACCGCCGCCGGGAUCACUCUCGGCAUGG ACGAGCUGUACAAGUCCGGAAGAGCACCACCCCGGAGAACAGCUCCU CGCUAGCUCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCC CGGCGGGCGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGG GGAGAACGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGA GGAGCCGAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCG GUCCUUCUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCG CUCUUUUUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCG

		GCCGUACCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUC GUCUCUCCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCAC CCCCAGCGCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCU CGUAGGCUGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUG UUUUAUUAUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCU CGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUA AACAAGAGGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUC AGCUUUCCGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACA AGAGAAAACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUC GUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCA AUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCU CAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCC GUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUC GGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAA AGAUCAUCUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCG CAACAUCUUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGA AUGAAAUCACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUU AUUAUAUUAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUA AAUAUAAAAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAA UCUUAGAUGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAU CAUCGAAGAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCAC CCGGUCUGUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAG AUCCCCGGGUCGGCGUCGGCAUGCCGCUGAUCGCAGUGGCCCCACC UCGGCAUGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAU CUUUCUGUAAAAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAA CCAACAAAAAGAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUA AACACAUGGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCAC CUUCCCGGCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAU GAUUCGAUCAAUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUC AAUCAGCGUUGCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCC AUUUUUAUCCUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUU GAAAUGAAAGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUA UCACCAUUUUACUACAAAAAGAAAAAAAAACAACUUACACAUAGU AUUACCUUAGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAA CAGUUCAGCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGC AUAUAAUAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAA CUCCAGCAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUU UGCAGCUUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUA CGAGAAAACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCAC UGAAAACACACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGU ACGCGUGACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAA CCUAAAAAGACCAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCU UGAAGACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAAC CUCUUAGGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGC UAUUUUAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCU UAAGUUUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCAC AAGCUCGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUG UUCCUUUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCA ACACAGAGUAGUAGACACAAUAAAUGAGAAGUAAGCUUGACUCCU AUAGUGUCACCUAAAUGUCUAGAAACUUGUUUAUUGCAGCUUAUA

		AUGGUUACAAAUAAAGCAAUAGCAUCACAAAUUUCACAAAUAAAG CAUUUUUUUCACUGC$(A)_n$
47	mtGFP_NLS_s_β2.7_endo	UCAGAUCGCUAGCGCUACCGGUCGCCACCAUAGUGAGCAAGGGCGA GGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAGCUGGACGGC GACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAGGGCGAGGGC GAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUCUGCACCACCG GCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCACCCUGACCUA CGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAUGAAGCAGCAC GACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGUCCAGGAGCGCA CCAUCUUCUUCAAGGACGACGGCAACUACAAGACCCGCGCCGAGGU GAAGUUCGAGGGCGACACCCUGGUGAACCGCAUCGAGCUGAAGGG CAUCGACUUCAAGGAGGACGGCAACAUCCUGGGGCACAAGCUGGA GUACAACUACAACAGCCACAACGUCUAUAUCAUGGCCGACAAGCAG AAGAACGGCAUCAAGGUGAACUUCAAGAUCCGCCACAACAUCGAG GACGGCAGCGUGCAGCUCGCCGACCACUACCAGCAGAACACCCCCA UCGGCGACGGCCCCGUGCUGCUGCCCGACAACCACUACCUGAGCAC CCAGUCCGCCCUGAGCAAAGACCCCAACGAGAAGCGCGAUCACAUG GUCCUGCUGGAGUUCGUGACCGCCGCCGGGAUCACUCUCGGCAUGG ACGAGCUGUACAAGGCCGGACUCAGAUCUCGAGCUGAUCCAAAAA AGAAGAGAAAGGUAGAUCCAAAAAAGAAGAGAAAGGUAGAUCCAA AAAAGAAGAGAAAGGUAAGGAUCCACCGGAUCUAGAUAACUGUCC GGAAGACACCACCCCGGAGAACAGCUCCUCGCUAGCUCCCCAGAUC GCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCC GGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGAC UUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAA CGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUC UGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCU UUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACC CAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCC CGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACC GCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGG GGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUU UAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCC UCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAA AGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACU CGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACA AAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUAC CGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUU CCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGC GAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAU UCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAAC AAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCG GUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCG CAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAA CCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCA AAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAU AGAAACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUG CUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAA GACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAG AGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCG

		UCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGC CGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAA GAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACC CGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUU UCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGA CACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAAC AACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGU AGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCA CUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUG GAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUA CAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUU ACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUG CAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGU AGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAA GUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGA UGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAU ACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUC UCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUGACUUCA UCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCA AAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUU CUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCA CAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAG CUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUA GUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCA CGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUU UGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUA GACACAAUAAAUGAGAAGUAAGCUUGACUCCUAUAGUGUCACCUA AAUGUCUAGAAACUUGUUUAUUGCAGCUUAUAAUGGUUACAAAUA AAGCAAUAGCAUCACAAAUUUCACAAAUAAAGCAUUUUUUUCACU GC(A)$_n$
48	mtGFP_s_endo	UCAGAUCGCUAGCGCUACCGGUCGCCACCAUAGUGAGCAAGGGCGA GGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAGCUGGACGGC GACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAGGGCGAGGGC GAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUCUGCACCACCG GCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCACCCUGACCUA CGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAUGAAGCAGCAC GACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGUCCAGGAGCGCA CCAUCUUCUUCAAGGACGACGGCAACUACAAGACCCGCGCCGAGGU GAAGUUCGAGGGCGACACCCUGGUGAACCGCAUCGAGCUGAAGGG CAUCGACUUCAAGGAGGACGGCAACAUCCUGGGGCACAAGCUGGA GUACAACUACAACAGCCACAACGUCUAUAUCAUGGCCGACAAGCAG AAGAACGGCAUCAAGGUGAACUUCAAGAUCCGCCACAACAUCGAG GACGGCAGCGUGCAGCUCGCCGACCACUACCAGCAGAACACCCCCA UCGGCGACGGCCCCGUGCUGCUGCCCGACAACCACUACCUGAGCAC CCAGUCCGCCCUGAGCAAAGACCCCAACGAGAAGCGCGAUCACAUG GUCCUGCUGGAGUUCGUGACCGCCGCCGGGAUCACUCUCGGCAUGG ACGAGCUGUACAAGUCCGGAAGACACCACCCCGGAGAACAGCUCCU CGGAUCCACCGGAUCUAGAUAACUGAUCAUAAUCAGCCAUACCACA UUUGUAGAGGUUUUACUUGCUUUAAAAAACCUCCCACACCUCCCCC UGAACCUGAAACAUAAAAUGAAUGCAAUUGUUGUUGUUAACUUGU

		UUAUUGCAGCUUAUAAUGGUUACAAAUAAAGCAAUAGCAUCACAA AUUUCACAAAUAAAGCAUUUUUUUCACUGC$(A)_n$
49	Full length β2.7 RNA_endo (sense)	UCAGAUCUAAUACGACUCACUAUAGGCGCUUCCGGAAGAGCUAGC UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUU CUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUU UUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUA CCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCU CCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGC GCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGC UGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUU AUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUA UCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA GGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUC CGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAA ACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACA ACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCA AGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCG AGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCG GUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGC AGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAU CUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUC UUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAU CACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAU UAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAA AAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAAUCUUAGA UGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAA GAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCU GUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCG GGUCGGCGUCGGCAUGCCGCUGAUC9GCAGUGGCCCCACCUCGGCA UGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCU GUAAAAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACA AAAAGAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACA UGGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCC GGCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCG AUCAAUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAG CGUUGCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUU UAUCCUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAU GAAAGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACC AUUUUACUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUAC CUUAGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUU CAGCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUA AUAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCA GCAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAG CUUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGA AAACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAA ACACACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCG UGACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAA

		AAAGACCAAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAG ACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUU AGGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUU UAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGU UUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCU CGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCU UUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACA GAGUAGUAGACACAAUAAAUGAGAAGUUUGCAUGCAGCUUGACUC CUAUAGUGUCACCUAAAUGUCUAGAAACUUGUUUAUUGCAGCUUA UAAUGGUUACAAAUAAAGCAAUAGCAUCACAAAUUUCACAAAUAA AGCAUUUUUUUCACUGC(A)$_n$
50	β2.7 RNA domain 2_endo (sense)	UCAGAUCUAAUACGACUCACUAUAGGCGCUUCCGGAAGAGCUAGC UUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUU CCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAA AAAGAAAAAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAGA AACUUGUUUAUUGCAGCUUAUAAUGGUUACAAAUAAAGCAAUAGC AUCACAAAUUUCACAAAUAAAGCAUUUUUUUCACUGC(A)$_n$
51	β2.7 RNA domain 3_endo (sense)	UCAGAUCUAAUACGACUCACUAUAGGCGCUUCCGGAAGAGCUAGC GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG GAAAUGAACCAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAG AAACUUGUUUAUUGCAGCUUAUAAUGGUUACAAAUAAAGCAAUAG CAUCACAAAUUUCACAAAUAAAGCAUUUUUUUCACUGC(A)$_n$
52	Multimer sequence D2x4_endo	UCAGAUCUAAUACGACUCACUAUAGGCGCUUCCGGAAGAGCUAGC UUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUU CCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAA AAAGAAAAAAGCGCGAAUUCCGAUCUUUUAUUUUUUAUCUUCUCC UUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAA UCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAGAUCGUAUCCG GUACCUGUGGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGG AUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAAC AAGAGGGUAAAAAGAAAAACCACACCUCCACCGGUGGGCCGUUUU AUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUC UCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAG AAAAACGGCCCAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUA GAAACUUGUUUAUUGCAGCUUAUAAUGGUUACAAAUAAAGCAAUA GCAUCACAAAUUUCACAAAUAAAGCAUUUUUUUCACUGC(A)$_n$
53	Multimer sequence D3x4_endo	UCAGAUCUAAUACGACUCACUAUAGGCGCUUCCGGAAGAGCUAGC CCGGCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGA CAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCU GCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAU CUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCC CGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUC AUAGGAAAUGAACCGCCGGGAAGCGCCGAAUUCAUAUCGAUCGGU CAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACG AAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUC GACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAU

		AGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCC CUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAA UGAACCGAUCGAAUAAAGGUACCUGUGGGGUCAUUUUUAUUUAUC CUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAGA AUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGC GAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAU UAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGA CGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCCCACAUU UUACCGGUAAUACCGGGGGGUCAUUUUUAUUUAUCCUCAUCGUCA ACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCC GCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUG GCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGU CCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUC AGCAGCCAAACAAUCAUAGGAAAUGAACCCCCCGGAAGCUUGACUC CUAUAGUGUCACCUAAAUGUCUAGAAACUUGUUUAUUGCAGCUUA UAAUGGUUACAAAUAAAGCAAUAGCAUCACAAAUUUCACAAAUAA AGCAUUUUUUUCACUGC(A)$_n$
54	Multimer sequence D3x4_D2x 4_endo	UCAGAUCUAAUACGACUCACUAUAGGCGCUUCCGGAAGAGCUAGC CCGGCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGA CAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCU GCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAU CUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCC CGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUC AUAGGAAAUGAACCGCCGGGAAGCGCCGAAUUCAUAUCGAUCGGU CAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACG AAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUC GACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAU AGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCC CUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAA UGAACCGAUCGAAUAAAGGUACCUGUGGGGUCAUUUUUAUUUAUC CUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAGA AUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGC GAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAU UAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGA CGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCCCACAUU UUACCGGUAAUACCGGGGGGUCAUUUUUAUUUAUCCUCAUCGUCA ACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCC GCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUG GCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGU CCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUC AGCAGCCAAACAAUCAUAGGAAAUGAACCCCCCGGAAGCUUUCCGG AAGAGCUAGCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGG AUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAAC AAGAGGGUAAAAAGAAAAAAGCGCGAAUUCCGAUCUUUUAUUUUU UAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUAC CUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAG AUCGUAUCCGGUACCUGUGGUUUUAUUUUUUAUCUUCUCCUUUCC UUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCA GAUGAUAAACAAGAGGGUAAAAAGAAAAACCACACCUCCACCGGU GGGCCGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUA

		UCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA GGGUAAAAAGAAAAACGGCCCAAGCUUGACUCCUAUAGUGUCACC UAAAUGUCUAGAAACUUGUUUAUUGCAGCUUAUAAUGGUUACAAA UAAAGCAAUAGCAUCACAAAUUUCACAAAUAAAGCAUUUUUUUCA CUGC$(A)_n$
55	β2.7_core	UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUU CUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUU UUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUA CCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCU CCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGC GCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGC UGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUU AUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUA UCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA GGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUC CGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAA ACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACA ACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCA AGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCG AGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCG GUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGC AGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAU CUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUC UUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAU CACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAU UAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAA AAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAAUCUUAGA UGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAA GAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCU GUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCG GGUCGGCGUCGGCAUGCCGCUGAUC9GCAGUGGCCCCACCUCGGCA UGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCU GUAAAAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACA AAAAGAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACA UGGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCC GGCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCG AUCAAUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAG CGUUGCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUU UAUCCUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAU GAAAGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACC AUUUUACUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUAC CUUAGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUU CAGCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUA AUAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCA GCAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAG CUUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGA AAACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAA

		ACACACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCG UGACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAA AAAGACCAAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAG ACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUU AGGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUU UAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGU UUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCU CGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCU UUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACA GAGUAGUAGACACAAUAAAUGAGAAGUUUGCAUGC
56	D1_core	CAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGUCGGCGCUCG GACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCGUGGCCGGGA GAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUGGAAGGGUCG CCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUCUCGUUUUCUU UUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGAGUUUCUCUUC CGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAUGCACGCGUGU AUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCAUCAGCAGCACC ACUACCGCCACCCCCAGCGCCACCACCGCUGCCGUCGCCACCGCGUU AUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGGGUCGGCGGCCGGU CGGCUUCUG
57	D2_core	UUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUU CCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAA AAAGAAAAA
58	D3_core	GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG GAAAUGAAC
59	D4_core	CGGCGUCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCC GGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAA AAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAA GAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGA AGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCG GCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCA AUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUU GCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCC UCGC
60	ΔD1_core	UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCUUUUAUUAUUUUUUUU UAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCC UCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAA AGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACU CGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACA AAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUAC CGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUU CCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGC GAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAU UCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAAC AAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCG GUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCG

		CAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAA CCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCA AAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAU AGAAACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUG CUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAA GACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAG AGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCG UCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGC CGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAA GAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACC CGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUU UCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGA CACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAAC AACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGU AGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCA CUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUG GAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUA CAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUU ACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUG CAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGU AGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAA GUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGA UGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAU ACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUC UCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUGACUUCA UCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCA AAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUU CUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCA CAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAG CUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUA GUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCA CGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUU UGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUA GACACAAUAAAUGAGAAGUUUGCAUGC
61	ΔD2_core	UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUU CUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUU UUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUA CCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCU CCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGC GCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGC UGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUU AUUUUUAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUC GAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAA AAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACC GACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUC CUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCG AUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUU

		CCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACA AUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGG UGUAUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGC AAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAAC CAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAA AACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUA GAAACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGC UCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAG ACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGA GAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGU CGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCC GGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAG AAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCC GAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUU CUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGAC ACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACA ACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUA GUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCAC UUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGG AAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUAC AAAAAGAAAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUA CGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGC AAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUA GUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAG UACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAU GUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUA CUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUC CUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUC GCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAA AAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCU CGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACA AAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCU UUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGU AUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACG GAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUG UUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGA CACAAUAAAUGAGAAGUUUGCAUGC
62	ΔD3_core	UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUU CUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUU UUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUA CCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCU CCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGC GCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGC UGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUU AUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUA UCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA GGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUC

		CGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAA ACAGAACAAAAACAAAGAAGAACAAAAAGAUCAUCUCUCUCGGUG UAUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAA GACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCA AGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAA CGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUAGA AACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUCC UAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGACG ACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAG AGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGG CAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGG CGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAA ACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCCGAG AUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUUCUU GAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGACACG CUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACA UCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUC GACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUC UUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAA CAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAA AAGAAAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGG AUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAU CUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUA GAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUAC ACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUA CUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUC GGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCU GUCACGACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGC AACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAA AAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCG UGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAA AACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUU UCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAU AUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGA UUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUU UGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACA CAAUAAAUGAGAAGUUUGCAUGC
63	ΔD4_core	UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUU CUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUU UUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUA CCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCU CCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGC GCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGC UGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUU AUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUA UCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA GGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUC

		CGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAA ACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACA ACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCA AGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCG AGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCG GUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGC AGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAU CUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUC UUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAU CACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAU UAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAA AAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAAUCUUAGA UGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAA GAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCU GUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCG GGUACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAG GAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUU ACUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAG GUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCC AAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAG UAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAU CAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUU UAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAAC AGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACAC ACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUGAC UUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAG ACCAAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAA UAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGA UCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUC UCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUC CCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGU CGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUU UUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGU AGUAGACACAAUAAAUGAGAAGUUUGCAUGC
64	β2.7 RNA_AS_ core)	GCAUGCAAACUUCUCAUUUAUUGUGUCUACUACUCUGUGUUGCUA CAGGGAGUGAAGGGGGUGAAGGCAAACAAAAAAAAAAGGAACAAA AUAAUAGAUUAGCAGAAGGAAUAAUCCGUGCGACCGAGCUUGUGC UUCUUUUCUUAUAAGGAGGCAAAUAUACUAGGGAAAACUUAAGAA UAGGAAGAAACCGAGGUUUGGGAGAAAAGCUGAGAUAAAAUAGCG CAUUUUCCAUACAGAGGUUGUUGUUUUUGUGGAUCCUAAGAGGUU UCAAGUGCGAAUCUCAAAGUUCUCACGAGAAUAUUGUCUUCAAGA AUCGACAACUGUGGUCCAAGAUUUUUUUUUGGUCUUUUUAGGUUC UGCGAGGGACAUCACGAUGGAUCGUUGCGAUGAAGUCACGCGUAC GCCUCUGGUGUGGCGCGGUGUCGUGACAGGAGAGUGUGUUUUCAG UGCAGAGCUGUCUUGAUUCCUAUAUCCGAGUAUCUGUUUUCUCGU AAGGACGGUAAUCUUCUUUGGUGUAAGUACAUCUAAAAGCUGCAA ACUAUAUUUUAAGGGCUGUCUCUAGGUGUACUUUGAUGCUGGAGU UUUUCGCUGUGUUGAUGUGAAUAAAUCUACUACUACUAUUAUAUG CAGAAAGAGUGAUUAUGCCGAGACAAGAUUGCAUUGGCUGAACUG UUUCAAAAACGCCUACACUCUACUUAUCCGUAAACCUAAGGUAAU

		ACUAUGUGUAAGUUGUUUUUUUUUCUUUUUGUAGUAAAAUGGUGA UACGUGCAAUUAAAACUGUAUUCCAUGUUUCCAUCCUUUCAUUUC AACUUUAAAGGCGGCUUUGAGAGCGAAGAAGUGCGAGGAUAAAAA UGGAUGACUCCUUCGUGUCCAGGGAGUCGACUACUGCAACGCUGA UUGAUUAAAAGAUGGUCUCCGAUGAUGAUGUUGUUAUUGAUCGAA UCAUGGUGCAGAACGGCGACGGAGAGGAGCGUGUCCGCCGCCGGG AAGGUGGUCUCUUUCUCUUUUCUUUUUUCAAGAAAUCUUCCAUGU GUUUAUCGUAGUGAUCGAAAUCGACUGAUCUCGGGUUCUUUUUGU UGGUUUCUUUUCGGUUAAUCAUGUAUUGUUUUCUUUUUUUACAGA AAGAUACUUUUUUCAUGAGCAAUUCCUCGCCCGGCGCCGGCAUGCC GAGGUGGGGCCACUGCGAUCAGCGGCAUGCCGACGCCGACCCGGGG AUCUUGGAUUCACCGUUUUCUCUCUUCUCUCUCUACAUACAGACCG GGUGGCAGGAGCGGUAAGGAAUCAUCGUCGUCUUUCAUUCUUCGA UGAUUAUGGUAAUACUAAAUCUUAUCUAGGAGCAUAUACAUCUAA GAUUGGAGUACUAGUAGUCGUUUGUGGUUUCUAUUUUUUUUUAUA UUUAUCUAUGACAGUUUUUCUGUUUUUCGUUUUGAUAAUAAUAUA AUAAAAACUCAUGGACGUGAAAUCUGGCUUGGUUGUGGUGAUUUC AUUCUCAUUAUUGUUGUUUUCUUUCCGUCUUGCGGAUGAAGAUGU UGCGAUGCGGUUGUUGUUGGUGUUGCUAUACACCGAGAGAGAUGA UCUUUUUGUUCUUCUGGUUCAUUUCCUAUGAUUGUUUGGCUGCUG ACCGACGCGUCAGGAUGUGCAGGGCAUGCGGGGAAUCAGGACCGG ACACGGGAUAAUUUCAUCUACCUAUACGGAGAUCGCGGUCCUCGCC AUGAGGAUCGCGACAGGCGCGUCGAGGGGGCAGGAACACCCUUGC GGAUUGACAUUCUUGGUGGUGUUUCGUUGUUGUCGGUAGUUGUUG UUGACGAUGAGGAUAAAUAAAAAUGACCUUGUUUUUGUUCUGUUU UCUCUUGUUGGGAAUCGUCGACUUUGAAUUCUUCGAGUUAUCGGA AAGCUGAGGUACCCAAAUGUCUGUAGCUUUUUUCUUUUUACCCUC UUGUUUAUCAUCUGCGAUUCGUGGUAGGUAGGAGAGGGAAAUGAU AAUCCGAGAUUAAGGAAAGGAGAAGAUAAAAAAUAAAAAAAAAUA AUAAAACAGAAGCCGACCGGCCGCCGACCCGUUCCCCAGGACCAGC CUACGAGGAACGGAUAACGCGGUGGCGACGGCAGCGGUGGUGGCG CUGGGGGUGGCGGUAGUGGUGCUGCUGAUGGUAGUCGGGACGGAG GAGAGACGAUGCAUACAUACACGCGUGCAUGCUGCAUGGGUGGAU GGUACGGCCGGGAGACGCGGAAGAGAAACUCACAUAAAAAGGUGA UAAAAAGAGCGGUUGAAAAAAGAAAACGAGAUUCGACCAGACAGA AGAGAAGGACCGGGGCUUGGCGACCCUUCCACGACUGCCGUUGUCA UCUCGGCUCCUCCAUCUUCUCCCGGCCACGGGCGGCUAAGUCACCG CCGUUCUCCCCAUCCGUCCGAGCGCCGACCGACCAGCCGGCCGAUU CGCCCGCCGGGGCUUCUGGAGAACGCCGGGGCAGCAGCGAUCUGGG GA
65	D1AS_core	CAGAAGCCGACCGGCCGCCGACCCGUUCCCCAGGACCAGCCUACGA GGAACGGAUAACGCGGUGGCGACGGCAGCGGUGGUGGCGCUGGGG GUGGCGGUAGUGGUGCUGCUGAUGGUAGUCGGGACGGAGGAGAGA CGAUGCAUACAUACACGCGUGCAUGCUGCAUGGGUGGAUGGUACG GCCGGGAGACGCGGAAGAGAAACUCACAUAAAAAGGUGAUAAAAA GAGCGGUUGAAAAAAGAAAACGAGAUUCGACCAGACAGAAGAGAA GGACCGGGGCUUGGCGACCCUUCCACGACUGCCGUUGUCAUCUCGG CUCCUCCAUCUUCUCCCGGCCACGGGCGGCUAAGUCACCGCCGUUC UCCCCAUCCGUCCGAGCGCCGACCGACCAGCCGGCCGAUUCGCCCG CCGGGGCUUCUG

66	D2AS_core	UUUUUCUUUUUACCCUCUUGUUUAUCAUCUGCGAUUCGUGGUAGG UAGGAGAGGGAAAUGAUAAUCCGAGAUUAAGGAAAGGAGAAGAUA AAAAAUAAAA
67	D3AS_core	GUUCAUUUCCUAUGAUUGUUUGGCUGCUGACCGACGCGUCAGGAU GUGCAGGGCAUGCGGGGAAUCAGGACCGGACACGGGAUAAUUUCA UCUACCUAUACGGAGAUCGCGGUCCUCGCCAUGAGGAUCGCGACAG GCGCGUCGAGGGGGCAGGAACACCCUUGCGGAUUGACAUUCUUGG UGGUGUUUCGUUGUUGUCGGUAGUUGUUGUUGACGAUGAGGAUAA AUAAAAAUGACC
68	D4AS_core	GCGAGGAUAAAAAUGGAUGACUCCUUCGUGUCCAGGGAGUCGACU ACUGCAACGCUGAUUGAUUAAAAGAUGGUCUCCGAUGAUGAUGUU GUUAUUGAUCGAAUCAUGGUGCAGAACGGCGACGGAGAGGAGCGU GUCCGCCGCCGGGAAGGUGGUCUCUUUCUCUUUUCUUUUUUCAAG AAAUCUUCCAUGUGUUUAUCGUAGUGAUCGAAAUCGACUGAUCUC GGGUUCUUUUUGUUGGUUUCUUUUCGGUUAAUCAUGUAUUGUUUU CUUUUUUUACAGAAAGAUACUUUUUUCAUGAGCAAUUCCUCGCCC GGCGCCGGCAUGCCGAGGUGGGGCCACUGCGAUCAGCGGCAUGCCG ACGCCG
69	ΔD1AS_core	GCAUGCAAACUUCUCAUUUAUUGUGUCUACUACUCUGUGUUGCUA CAGGGAGUGAAGGGGGUGAAGGCAAACAAAAAAAAAAGGAACAAA AUAAUAGAUUAGCAGAAGGAAUAAUCCGUGCGACCGAGCUUGUGC UUCUUUUCUUAUAAGGAGGCAAAUAUACUAGGGAAAACUUAAGAA UAGGAAGAAACCGAGGUUUGGGAGAAAAGCUGAGAUAAAAUAGCG CAUUUUCCAUACAGAGGUUGUUGUUUUUGUGGAUCCUAAGAGGUU UCAAGUGCGAAUCUCAAAGUUCUCACGAGAAUAUUGUCUUCAAGA AUCGACAACUGUGGUCCAAGAUUUUUUUUUGGUCUUUUUAGGUUC UGCGAGGGACAUCACGAUGGAUCGUUGCGAUGAAGUCACGCGUAC GCCUCUGGUGUGGCGCGGUGUCGUGACAGGAGAGUGUGUUUUCAG UGCAGAGCUGUCUUGAUUCCUAUAUCCGAGUAUCUGUUUUCUCGU AAGGACGGUAAUCUUCUUUGGUGUAAGUACAUCUAAAAGCUGCAA ACUAUAUUUUAAGGGCUGUCUCUAGGUGUACUUUGAUGCUGGAGU UUUUCGCUGUGUUGAUGUGAAUAAAUCUACUACUACUAUUAUAUG CAGAAAGAGUGAUUAUGCCGAGACAAGAUUGCAUUGGCUGAACUG UUUCAAAAACGCCUACACUCUACUUAUCCGUAAACCUAAGGUAAU ACUAUGUGUAAGUUGUUUUUUUUUCUUUUUGUAGUAAAAUGGUGA UACGUGCAAUUAAAACUGUAUUCCAUGUUUCCAUCCUUUCAUUUC AACUUUAAAGGCGGCUUUGAGAGCGAAGAAGUGCGAGGAUAAAAA UGGAUGACUCCUUCGUGUCCAGGGAGUCGACUACUGCAACGCUGA UUGAUUAAAAGAUGGUCUCCGAUGAUGAUGUUGUUAUUGAUCGAA UCAUGGUGCAGAACGGCGACGGAGAGGAGCGUGUCCGCCGCCGGG AAGGUGGUCUCUUUCUCUUUUCUUUUUUCAAGAAAUCUUCCAUGU GUUUAUCGUAGUGAUCGAAAUCGACUGAUCUCGGGUUCUUUUUGU UGGUUUCUUUUCGGUUAAUCAUGUAUUGUUUUCUUUUUUUACAGA AAGAUACUUUUUUCAUGAGCAAUUCCUCGCCCGGCGCCGGCAUGCC GAGGUGGGGCCACUGCGAUCAGCGGCAUGCCGACGCCGACCCGGGG AUCUUGGAUUCACCGUUUUCUCUCUUCUCUCUCUACAUACAGACCG GGUGGCAGGAGCGGUAAGGAAUCAUCGUCGUCUUUCAUUCUUCGA UGAUUAUGGUAAUACUAAAUCUUAUCUAGGAGCAUAUACAUCUAA GAUUGGAGUACUAGUAGUCGUUUGUGGUUUCUAUUUUUUUUUAUA UUUAUCUAUGACAGUUUUUCUGUUUUUCGUUUUGAUAAUAAUAUA

		AUAAAAACUCAUGGACGUGAAAUCUGGCUUGGUUGUGGUGAUUUC AUUCUCAUUAUUGUUGUUUUCUUUCCGUCUUGCGGAUGAAGAUGU UGCGAUGCGGUUGUUGUUGGUGUUGCUAUACACCGAGAGAGAUGA UCUUUUUGUUCUUCUGGUUCAUUUCCUAUGAUUGUUUGGCUGCUG ACCGACGCGUCAGGAUGUGCAGGGCAUGCGGGGAAUCAGGACCGG ACACGGGAUAAUUUCAUCUACCUAUACGGAGAUCGCGGUCCUCGCC AUGAGGAUCGCGACAGGCGCGUCGAGGGGGCAGGAACACCCUUGC GGAUUGACAUUCUUGGUGGUGUUUCGUUGUUGUCGGUAGUUGUUG UUGACGAUGAGGAUAAAUAAAAAUGACCUUGUUUUUGUUCUGUUU UCUCUUGUUGGGAAUCGUCGACUUUGAAUUCUUCGAGUUAUCGGA AAGCUGAGGUACCCAAAUGUCUGUAGCUUUUUUCUUUUUACCCUC UUGUUUAUCAUCUGCGAUUCGUGGUAGGUAGGAGAGGGAAAUGAU AAUCCGAGAUUAAGGAAAGGAGAAGAUAAAAAAUAAAAAAAAAUA AUAAAAGAGAACGCCGGGGCAGCAGCGAUCUGGGGA
70	ΔD2AS_co re	GCAUGCAAACUUCUCAUUUAUUGUGUCUACUACUCUGUGUUGCUA CAGGGAGUGAAGGGGGUGAAGGCAAACAAAAAAAAAAGGAACAAA AUAAUAGAUUAGCAGAAGGAAUAAUCCGUGCGACCGAGCUUGUGC UUCUUUUCUUAUAAGGAGGCAAAUAUACUAGGGAAAACUUAAGAA UAGGAAGAAACCGAGGUUUGGGAGAAAAGCUGAGAUAAAAUAGCG CAUUUUCCAUACAGAGGUUGUUGUUUUUGUGGAUCCUAAGAGGUU UCAAGUGCGAAUCUCAAAGUUCUCACGAGAAUAUUGUCUUCAAGA AUCGACAACUGUGGUCCAAGAUUUUUUUUUGGUCUUUUUAGGUUC UGCGAGGGACAUCACGAUGGAUCGUUGCGAUGAAGUCACGCGUAC GCCUCUGGUGUGGCGCGGUGUCGUGACAGGAGAGUGUGUUUUCAG UGCAGAGCUGUCUUGAUUCCUAUAUCCGAGUAUCUGUUUUCUCGU AAGGACGGUAAUCUUCUUUGGUGUAAGUACAUCUAAAAGCUGCAA ACUAUAUUUUAAGGGCUGUCUCUAGGUGUACUUUGAUGCUGGAGU UUUUCGCUGUGUUGAUGUGAAUAAAUCUACUACUACUAUUAUAUG CAGAAAGAGUGAUUAUGCCGAGACAAGAUUGCAUUGGCUGAACUG UUUCAAAAACGCCUACACUCUACUUAUCCGUAAACCUAAGGUAAU ACUAUGUGUAAGUUGUUUUUUUUUCUUUUUGUAGUAAAAUGGUGA UACGUGCAAUUAAAACUGUAUUCCAUGUUUCCAUCCUUUCAUUUC AACUUUAAAGGCGGCUUUGAGAGCGAAGAAGUGCGAGGAUAAAAA UGGAUGACUCCUUCGUGUCCAGGGAGUCGACUACUGCAACGCUGA UUGAUUAAAAGAUGGUCUCCGAUGAUGAUGUUGUUAUUGAUCGAA UCAUGGUGCAGAACGGCGACGGAGAGGAGCGUGUCCGCCGCCGGG AAGGUGGUCUCUUUCUCUUUUCUUUUUUCAAGAAAUCUUCCAUGU GUUUAUCGUAGUGAUCGAAAUCGACUGAUCUCGGGUUCUUUUUGU UGGUUUCUUUUCGGUUAAUCAUGUAUUGUUUUCUUUUUUUACAGA AAGAUACUUUUUUCAUGAGCAAUUCCUCGCCCGGCGCCGGCAUGCC GAGGUGGGGCCACUGCGAUCAGCGGCAUGCCGACGCCGACCCGGGG AUCUUGGAUUCACCGUUUUCUCUCUUCUCUCUCUACAUACAGACCG GGUGGCAGGAGCGGUAAGGAAUCAUCGUCGUCUUUCAUUCUUCGA UGAUUAUGGUAAUACUAAAUCUUAUCUAGGAGCAUAUACAUCUAA GAUUGGAGUACUAGUAGUCGUUUGUGGUUUCUAUUUUUUUUUAUA UUUAUCUAUGACAGUUUUUCUGUUUUUCGUUUUGAUAAUAAUAUA AUAAAAACUCAUGGACGUGAAAUCUGGCUUGGUUGUGGUGAUUUC AUUCUCAUUAUUGUUGUUUUCUUUCCGUCUUGCGGAUGAAGAUGU UGCGAUGCGGUUGUUGUUGGUGUUGCUAUACACCGAGAGAGAUGA UCUUUUUGUUCUUCUGGUUCAUUUCCUAUGAUUGUUUGGCUGCUG

		ACCGACGCGUCAGGAUGUGCAGGGCAUGCGGGGAAUCAGGACCGG ACACGGGAUAAUUUCAUCUACCUAUACGGAGAUCGCGGUCCUCGCC AUGAGGAUCGCGACAGGCGCGUCGAGGGGGCAGGAACACCCUUGC GGAUUGACAUUCUUGGUGGUGUUUCGUUGUUGUCGGUAGUUGUUG UUGACGAUGAGGAUAAAUAAAAAUGACCUUGUUUUUGUUCUGUUU UCUCUUGUUGGGAAUCGUCGACUUUGAAUUCUUCGAGUUAUCGGA AAGCUGAGGUACCCAAAUGUCUGUAGCUAAAAAUAAUAAAACAGA AGCCGACCGGCCGCCGACCCGUUCCCCAGGACCAGCCUACGAGGAA CGGAUAACGCGGUGGCGACGGCAGCGGUGGUGGCGCUGGGGGUGG CGGUAGUGGUGCUGCUGAUGGUAGUCGGGACGGAGGAGAGACGAU GCAUACAUACACGCGUGCAUGCUGCAUGGGUGGAUGGUACGGCCG GGAGACGCGGAAGAGAAACUCACAUAAAAAGGUGAUAAAAAGAGC GGUUGAAAAAAGAAAACGAGAUUCGACCAGACAGAAGAGAAGGAC CGGGGCUUGGCGACCCUUCCACGACUGCCGUUGUCAUCUCGGCUCC UCCAUCUUCUCCCGGCCACGGGCGGCUAAGUCACCGCCGUUCUCCC CAUCCGUCCGAGCGCCGACCGACCAGCCGGCCGAUUCGCCCGCCGG GGCUUCUGGAGAACGCCGGGGCAGCAGCGAUCUGGGGA
71	ΔD3AS_core	GCAUGCAAACUUCUCAUUUAUUGUGUCUACUACUCUGUGUUGCUA CAGGGAGUGAAGGGGGUGAAGGCAAACAAAAAAAAAAGGAACAAA AUAAUAGAUUAGCAGAAGGAAUAAUCCGUGCGACCGAGCUUGUGC UUCUUUUCUUAUAAGGAGGCAAAUAUACUAGGGAAAACUUAAGAA UAGGAAGAAACCGAGGUUUGGGAGAAAAGCUGAGAUAAAAUAGCG CAUUUUCCAUACAGAGGUUGUUGUUUUUGUGGAUCCUAAGAGGUU UCAAGUGCGAAUCUCAAAGUUCUCACGAGAAUAUUGUCUUCAAGA AUCGACAACUGUGGUCCAAGAUUUUUUUUUGGUCUUUUUAGGUUC UGCGAGGGACAUCACGAUGGAUCGUUGCGAUGAAGUCACGCGUAC GCCUCUGGUGUGGCGCGGUGUCGUGACAGGAGAGUGUGUUUUCAG UGCAGAGCUGUCUUGAUUCCUAUAUCCGAGUAUCUGUUUUCUCGU AAGGACGGUAAUCUUCUUUGGUGUAAGUACAUCUAAAAGCUGCAA ACUAUAUUUUAAGGGCUGUCUCUAGGUGUACUUUGAUGCUGGAGU UUUUCGCUGUGUUGAUGUGAAUAAAUCUACUACUACUAUUAUAUG CAGAAAGAGUGAUUAUGCCGAGACAAGAUUGCAUUGGCUGAACUG UUUCAAAAACGCCUACACUCUACUUAUCCGUAAACCUAAGGUAAU ACUAUGUGUAAGUUGUUUUUUUUUCUUUUUGUAGUAAAAUGGUGA UACGUGCAAUUAAAACUGUAUUCCAUGUUUCCAUCCUUUCAUUUC AACUUUAAAGGCGGCUUUGAGAGCGAAGAAGUGCGAGGAUAAAAA UGGAUGACUCCUUCGUGUCCAGGGAGUCGACUACUGCAACGCUGA UUGAUUAAAAGAUGGUCUCCGAUGAUGAUGUUGUUAUUGAUCGAA UCAUGGUGCAGAACGGCGACGGAGAGGAGCGUGUCCGCCGCCGGG AAGGUGGUCUCUUUCUCUUUUCUUUUUUCAAGAAAUCUUCCAUGU GUUUAUCGUAGUGAUCGAAAUCGACUGAUCUCGGGUUCUUUUUGU UGGUUUCUUUUCGGUUAAUCAUGUAUUGUUUUCUUUUUUUACAGA AAGAUACUUUUUUCAUGAGCAAUUCCUCGCCCGGCGCCGGCAUGCC GAGGUGGGGCCACUGCGAUCAGCGGCAUGCCGACGCCGACCCGGGG AUCUUGGAUUCACCGUUUUCUCUCUUCUCUCUCUACAUACAGACCG GGUGGCAGGAGCGGUAAGGAAUCAUCGUCGUCUUUCAUUCUUCGA UGAUUAUGGUAAUACUAAAUCUUAUCUAGGAGCAUAUACAUCUAA GAUUGGAGUACUAGUAGUCGUUUGUGGUUUCUAUUUUUUUUUAUA UUUAUCUAUGACAGUUUUUCUGUUUUUCGUUUUGAUAAUAAUAUA AUAAAAACUCAUGGACGUGAAAUCUGGCUUGGUUGUGGUGAUUUC

		AUUCUCAUUAUUGUUGUUUUCUUUCCGUCUUGCGGAUGAAGAUGU UGCGAUGCGGUUGUUGUUGGUGUUGCUAUACACCGAGAGAGAUGA UCUUUUUGUUCUUCUUUGUUUUUGUUCUGUUUUCUCUUGUUGGGA AUCGUCGACUUUGAAUUCUUCGAGUUAUCGGAAAGCUGAGGUACC CAAAUGUCUGUAGCUUUUUUCUUUUUACCCUCUUGUUUAUCAUCU GCGAUUCGUGGUAGGUAGGAGAGGGAAAUGAUAAUCCGAGAUUAA GGAAAGGAGAAGAUAAAAAAUAAAAAAAAAAUAAUAAAACAGAAGC CGACCGGCCGCCGACCCGUUCCCCAGGACCAGCCUACGAGGAACGG AUAACGCGGUGGCGACGGCAGCGGUGGUGGCGCUGGGGGUGGCGG UAGUGGUGCUGCUGAUGGUAGUCGGGACGGAGGAGAGACGAUGCA UACAUACACGCGUGCAUGCUGCAUGGGUGGAUGGUACGGCCGGGA GACGCGGAAGAGAAACUCACAUAAAAAGGUGAUAAAAAGAGCGGU UGAAAAAAGAAAACGAGAUUCGACCAGACAGAAGAGAAGGACCGG GGCUUGGCGACCCUUCCACGACUGCCGUUGUCAUCUCGGCUCCUCC AUCUUCUCCCGGCCACGGGCGGCUAAGUCACCGCCGUUCUCCCCAU CCGUCCGAGCGCCGACCGACCAGCCGGCCGAUUCGCCCGCCGGGGC UUCUGGAGAACGCCGGGGCAGCAGCGAUCUGGGGA
72	ΔD4AS_core	GCAUGCAAACUUCUCAUUUAUUGUGUCUACUACUCUGUGUUGCUA CAGGGAGUGAAGGGGGUGAAGGCAAACAAAAAAAAAAGGAACAAA AUAAUAGAUUAGCAGAAGGAAUAAUCCGUGCGACCGAGCUUGUGC UUCUUUUCUUAUAAGGAGGCAAAUAUACUAGGGAAAACUUAAGAA UAGGAAGAAACCGAGGUUUGGGAGAAAAGCUGAGAUAAAAUAGCG CAUUUUCCAUACAGAGGUUGUUGUUUUUGUGGAUCCUAAGAGGUU UCAAGUGCGAAUCUCAAAGUUCUCACGAGAAUAUUGUCUUCAAGA AUCGACAACUGUGGUCCAAGAUUUUUUUUUGGUCUUUUUAGGUUC UGCGAGGGACAUCACGAUGGAUCGUUGCGAUGAAGUCACGCGUAC GCCUCUGGUGUGGCGCGGUGUCGUGACAGGAGAGUGUGUUUUCAG UGCAGAGCUGUCUUGAUUCCUAUAUCCGAGUAUCUGUUUUCUCGU AAGGACGGUAAUCUUCUUUGGUGUAAGUACAUCUAAAAGCUGCAA ACUAUAUUUUAAGGGCUGUCUCUAGGUGUACUUUGAUGCUGGAGU UUUUCGCUGUGUUGAUGUGAAUAAAUCUACUACUACUAUUAUAUG CAGAAAGAGUGAUUAUGCCGAGACAAGAUUGCAUUGGCUGAACUG UUUCAAAAACGCCUACACUCUACUUAUCCGUAAACCUAAGGUAAU ACUAUGUGUAAGUUGUUUUUUUUUCUUUUUGUAGUAAAAUGGUGA UACGUGCAAUUAAAACUGUAUUCCAUGUUUCCAUCCUUUCAUUUC AACUUUAAAGGCGGCUUUGAGAGCGAAGAAGUACCCGGGGAUCUU GGAUUCACCGUUUUCUCUCUUCUCUCUCUACAUACAGACCGGGUGG CAGGAGCGGUAAGGAAUCAUCGUCGUCUUUCAUUCUUCGAUGAUU AUGGUAAUACUAAAUCUUAUCUAGGAGCAUAUACAUCUAAGAUUG GAGUACUAGUAGUCGUUUGUGGUUUCUAUUUUUUUUUAUAUUUAU CUAUGACAGUUUUUCUGUUUUUCGUUUUGAUAAUAAUAUAAUAAA AACUCAUGGACGUGAAAUCUGGCUUGGUUGUGGUGAUUUCAUUCU CAUUAUUGUUGUUUUCUUUCCGUCUUGCGGAUGAAGAUGUUGCGA UGCGGUUGUUGUUGGUGUUGCUAUACACCGAGAGAGAUGAUCUUU UUGUUCUUCUGGUUCAUUUCCUAUGAUUGUUUGGCUGCUGACCGA CGCGUCAGGAUGUGCAGGGCAUGCGGGGAAUCAGGACCGGACACG GGAUAAUUUCAUCUACCUAUACGGAGAUCGCGGUCCUCGCCAUGA GGAUCGCGACAGGCGCGUCGAGGGGGCAGGAACACCCUUGCGGAU UGACAUUCUUGGUGGUGUUUCGUUGUUGUCGGUAGUUGUUGUUGA CGAUGAGGAUAAAUAAAAAUGACCUUGUUUUUGUUCUGUUUUCUC

		UUGUUGGGAAUCGUCGACUUUGAAUUCUUCGAGUUAUCGGAAAGC UGAGGUACCCAAAUGUCUGUAGCUUUUUUCUUUUUACCCUCUUGU UUAUCAUCUGCGAUUCGUGGUAGGUAGGAGAGGGAAAUGAUAAUC CGAGAUUAAGGAAAGGAGAAGAUAAAAAAUAAAAAAAAAUAAUAA AACAGAAGCCGACCGGCCGCCGACCCGUUCCCCAGGACCAGCCUAC GAGGAACGGAUAACGCGGUGGCGACGGCAGCGGUGGUGGCGCUGG GGGUGGCGGUAGUGGUGCUGCUGAUGGUAGUCGGGACGGAGGAGA GACGAUGCAUACAUACACGCGUGCAUGCUGCAUGGGUGGAUGGUA CGGCCGGGAGACGCGGAAGAGAAACUCACAUAAAAAGGUGAUAAA AAGAGCGGUUGAAAAAAGAAAACGAGAUUCGACCAGACAGAAGAG AAGGACCGGGGCUUGGCGACCCUUCCACGACUGCCGUUGUCAUCUC GGCUCCUCCAUCUUCUCCCGGCCACGGGCGGCUAAGUCACCGCCGU UCUCCCCAUCCGUCCGAGCGCCGACCGACCAGCCGGCCGAUUCGCC CGCCGGGGCUUCUGGAGAACGCCGGGGCAGCAGCGAUCUGGGGA
73	Multimer sequence D2x4_core	UUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUU CCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAA AAAGAAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGA UUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACA AGAGGGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUU AAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGA UGAUAAACAAGAGGGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCU CCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACG AAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAA
74	Multimer sequence D3x4_core	GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG GAAAUGAACCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAAC UACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGU GUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGAC CGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCU GAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCA AACAAUCAUAGGAAAUGAAGGUCAUUUUUAUUUAUCCUCAUCGUC AACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUC CGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAU GGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUG UCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGU CAGCAGCCAAACAAUCAUAGGAAAUGAACCGGUCAUUUUUAUUUA UCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAA GAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUC GCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAA AUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCU GACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACC
75	Multimer sequence D3x4_D2x4_core	GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG GAAAUGAACCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAAC

		UACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGU GUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGAC CGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCU GAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCA AACAAUCAUAGGAAAUGAAGGUCAUUUUUAUUUAUCCUCAUCGUC AACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUC CGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAU GGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUG UCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGU CAGCAGCCAAACAAUCAUAGGAAAUGAACCGGUCAUUUUUAUUUA UCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAA GAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUC GCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAA AUUAUCCCGUGUCCGGUCCUGAUUCCCCCGCAUGCCCUGCACAUCCU GACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCUUUU AUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUC UCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAG AAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAU CAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAG GGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUC UCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAU AAACAAGAGGGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCUCCUU UCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUC GCAGAUGAUAAACAAGAGGGUAAAAAGAAAAACGGCCC
76	Multimer sequence D2x4_D3X 4_core	UUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUU CCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAA AAAGAAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGA UUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCUUUUAUUUUUUA UCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCU ACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAUUU UAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCC UCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAA AGAAAAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUAC CGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUU CCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGC GAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAU UCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAAC AAUCAUAGGAAAUGAACCGGUCAUUUUUAUUUAUCCUCAUCGUCA ACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCC GCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUG GCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGU CCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUC AGCAGCCAAACAAUCAUAGGAAAUGAACCGGUCAUUUUUAUUUAU CCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAG AAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCG CGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAA UUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUG ACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGGUCA UUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAA ACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGA

		CGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAG GUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCU GCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUG AACC
77	Multimer sequence (D3_D2)x4 _core	GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG GAAAUGAACCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGG AUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAAC AAGAGGGUAAAAAGAAAAAGGUCAUUUUUAUUUAUCCUCAUCGUC AACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUC CGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAU GGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUG UCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGU CAGCAGCCAAACAAUCAUAGGAAAUGAACCUUUUAUUUUUUAUCU UCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACC ACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAGGUCAU UUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAA CACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGAC GCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGG UAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUG CACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGA ACCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCA UUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGG UAAAAAGAAAAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACA ACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGG GUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGG ACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCC UGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCC AAACAAUCAUAGGAAAUGAACCUUUUAUUUUUUAUCUUCUCCUUU CCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCG CAGAUGAUAAACAAGAGGGUAAAAAGAAAAA
78	gGFP_β2.7 _core	AUGGUGAGCAAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUC CUGGUCGAGCUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUG UCCGGCGAGGGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGA AGUUCAUCUGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCU CGUGACCACCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCC GACCACAUGAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAG GCUACGUCCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUA CAAGACCCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAAC CGCAUCGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCC UGGGGCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUA UCAUGGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGA UCCGCCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUA CCAGCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGAC AACCACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACG AGAAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGG GAUCACUCUCGGCAUGGACGAGCUGUACAAGUGAUCCCCAGAUCGC

		UGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGG CUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUU AGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACG GCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUG GUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUU UUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCA UGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCG ACUACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGC UGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGG AACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUA UUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCU CCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGA AAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGA AGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAA ACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGAC AACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUG CCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUC UCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCC GCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCA UAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUA UAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAAGA CGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCAAG CCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAACG AAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAAUAGAAA CCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUA GAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGACGAC GAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAG AAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCA UGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCG AGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAAC AAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAU CAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGA AAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUC CUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCA UCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGAC UCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUC GCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAU GGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAG AAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUA AGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUU GUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAU UUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACCU AGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUA CACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGAU AUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUCAC GACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGA UCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAA UCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAG AACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACA ACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUC

		CCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUU UGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUA UUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGC CUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAA UAAAUGAGAAGU
79	gGFP_s_β2 .7_core	AUGGUGAGCAAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUC CUGGUCGAGCUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUG UCCGGCGAGGGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGA AGUUCAUCUGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCU CGUGACCACCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCC GACCACAUGAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAG GCUACGUCCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUA CAAGACCCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAAC CGCAUCGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCC UGGGGCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUA UCAUGGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGA UCCGCCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUA CCAGCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGAC AACCACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACG AGAAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGG GAUCACUCUCGGCAUGGACGAGCUGUACAAGUGAUCCCCAGAUCGC UGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGG CUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUU AGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACG GCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUG GUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUU UUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCA UGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCG ACUACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGC UGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGG AACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUA UUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCU CCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGA AAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGA AGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAA ACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGAC AACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUG CCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUC UCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCC GCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCA UAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUA UAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAAGA CGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCAAG CCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAACG AAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAAUAGAAA CCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUA GAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGACGAC GAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAG AAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCA UGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCG

		AGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAAC AAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAU CAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGA AAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUC CUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCA UCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGAC UCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUC GCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAU GGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAG AAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUA AGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUU GUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAU UUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACCU AGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUA CACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGAU AUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUCAC GACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGA UCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAA UCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAG AACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACA ACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUC CCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUU UGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUA UUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGC CUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAA UAAAUGAGAAGU
80	mtGFP_s_β2.7_core	AUAGUGAGCAAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUC CUGGUCGAGCUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUG UCCGGCGAGGGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGA AGUUCAUCUGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCU CGUGACCACCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCC GACCACAUGAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAG GCUACGUCCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUA CAAGACCCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAAC CGCAUCGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCC UGGGGCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUA UCAUGGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGA UCCGCCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUA CCAGCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGAC AACCACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACG AGAAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGG GAUCACUCUCGGCAUGGACGAGCUGUACAAGAGAUCCCCAGAUCGC UGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGG CUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUU AGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACG GCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUG GUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUU UUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCA UGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCG ACUACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGC

		UGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGG AACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUA UUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCU CCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGA AAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGA AGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAA ACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGAC AACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUG CCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUC UCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCC GCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCA UAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUA UAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAAGA CGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCAAG CCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAACG AAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAAUAGAAA CCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUA GAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGACGAC GAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAG AAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCA UGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCG AGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAAC AAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAU CAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGA AAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUC CUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCA UCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGAC UCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUC GCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAU GGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAG AAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUA AGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUU GUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAU UUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACCU AGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUA CACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGAU AUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUCAC GACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGA UCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAA UCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAG AACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACA ACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUC CCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUU UGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUA UUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGC CUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAA UAAAUGAGAAGU
81	mtGFP_s_core	AUAGUGAGCAAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUC CUGGUCGAGCUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUG UCCGGCGAGGGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGA

		AGUUCAUCUGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCU CGUGACCACCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCC GACCACAUGAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAG GCUACGUCCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUA CAAGACCCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAAC CGCAUCGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCC UGGGGCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUA UCAUGGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGA UCCGCCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUA CCAGCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGAC AACCACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACG AGAAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGG GAUCACUCUCGGCAUGGACGAGCUGUACAAGAGA
82	asATP6_s6 _ β2.7_core	AGUAGAAUUAGAAUUGUGAAGAUGAUAAGUGUAGAGGGAAGGUUA AUGGUUGAUAUUGCUAGGGUGGCGCUUCCAAUUAGGUGCGUGAGU AGGUGGCCUGCAGUAAUGUUAUCCCCAGAUCGCUGCUGCCCCGGCG UUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGUCGGC GCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCGUGGCC GGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUGGAAGG GUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUCUCGUUU UCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGAGUUUCU CUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAUGCACGC GUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCAUCAGCAG CACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCGUCGCCACCG CGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGGGUCGGCGGC CGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUUUUAUCUUCUC CUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGA AUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAAGCUACAGAC AUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGAAUUCAAAGUCG ACGAUUCCCAACAAGAGAAAACAGAACAAAAACAAGGUCAUUUUU AUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACC ACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGC CUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGA UGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACA UCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCA GAAGAACAAAAAGAUCAUCUCUCUCGGUGUAUAGCAACACCAACA ACAACCGCAUCGCAACAUCUUCAUCCGCAAGACGGAAAGAAAACAA CAAUAAUGAGAAUGAAAUCACCACAACCAAGCCAGAUUUCACGUCC AUGAGUUUUUAUUAUAUUAUUAUCAAAACGAAAAACAGAAAAACU GUCAUAGAUAAAUAUAAAAAAAAAAUAGAAACCACAAACGACUACU AGUACUCCAAUCUUAGAUGUAUAUGCUCCUAGAUAAGAUUUAGUA UUACCAUAAUCAUCGAAGAAUGAAAGACGACGAUGAUUCCUUACC GCUCCUGCCACCCGGUCUGUAUGUAGAGAGAGAAGAGAGAAAACG GUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCAUGCCGCUGAUCGCA GUGGCCCCACCUCGGCAUGCCGGCGCCGGGCGAGGAAUUGCUCAUG AAAAAAGUAUCUUUCUGUAAAAAAAGAAAACAAUACAUGAUUAAC CGAAAAGAAACCAACAAAAAGAACCCGAGAUCAGUCGAUUUCGAU CACUACGAUAAACACAUGGAAGAUUUCUUGAAAAAAGAAAAGAGA AAGAGACCACCUUCCCGGCGGCGGACACGCUCCUCUCCGUCGCCGU UCUGCACCAUGAUUCGAUCAAUAACAACAUCAUCAUCGGAGACCAU

		CUUUUAAUCAAUCAGCGUUGCAGUAGUCGACUCCCUGGACACGAA GGAGUCAUCCAUUUUUAUCCUCGCACUUCUUCGCUCUCAAAGCCGC CUUUAAAGUUGAAAUGAAAGGAUGGAAACAUGGAAUACAGUUUUA AUUGCACGUAUCACCAUUUUACUACAAAAAGAAAAAAAAACAACU UACACAUAGUAUUACCUUAGGUUUACGGAUAAGUAGAGUGUAGGC GUUUUUGAAACAGUUCAGCCAAUGCAAUCUUGUCUCGGCAUAAUC ACUCUUUCUGCAUAUAAUAGUAGUAGUAGAUUUAUUCACAUCAAC ACAGCGAAAAACUCCAGCAUCAAAGUACACCUAGAGACAGCCCUUA AAAUAUAGUUUGCAGCUUUUAGAUGUACUUACACCAAAGAAGAUU ACCGUCCUUACGAGAAAACAGAUACUCGGAUAUAGGAAUCAAGAC AGCUCUGCACUGAAAACACACUCUCCUGUCACGACACCGCGCCACA CCAGAGGCGUACGCGUGACUUCAUCGCAACGAUCCAUCGUGAUGUC CCUCGCAGAACCUAAAAAGACCAAAAAAAAAUCUUGGACCACAGU UGUCGAUUCUUGAAGACAAUAUUCUCGUGAGAACUUUGAGAUUCG CACUUGAAACCUCUUAGGAUCCACAAAAACAACAACCUCUGUAUGG AAAAUGCGCUAUUUUAUCUCAGCUUUUCUCCCAAACCUCGGUUUCU UCCUAUUCUUAAGUUUUCCCUAGUAUAUUUGCCUCCUUAUAAGAA AAGAAGCACAAGCUCGGUCGCACGGAUUAUUCCUUCUGCUAAUCU AUUAUUUUGUUCCUUUUUUUUUUGUUUGCCUUCACCCCCUUCACUC CCUGUAGCAACACAGAGUAGUAGACACAAUAAAUGAGAAGU
83	β2.7_s8_as ATP8_core	UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUU CUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUU UUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUA CCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCU CCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGC GCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGC UGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUU AUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUA UCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA GGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUC CGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAA ACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACA ACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCA AGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCG AGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCG GUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGC AGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAU CUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUC UUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAU CACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAU UAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAA AAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAAUCUUAGA UGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAA GAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCU GUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCG GGUCGGCGUCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAU GCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUG

		UAAAAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAA AAAGAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAU GGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCG GCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGA UCAAUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGC GUUGCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUU AUCCUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUG AAAGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCA UUUUACUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACC UUAGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUC AGCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUA AUAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCA GCAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAG CUUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGA AAACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAA ACACACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCG UGACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAA AAAGACCAAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAG ACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUU AGGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUU UAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGU UUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCU CGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCU UUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACA GAGUAGUAGACACAAUAAAUGAGAAGU**UUUCGUUCAUUUUGGUUC** **UCAGGGUUUGUUAUAAUUUUUUAUUUUUAUGGGCUUUGGUGAGGG** **AGGUAGGUGGUAGUUUGUGUUUAAUAUUUUUAGUUGGGUGAUGA**
84	ATP6_D3$_4$ _D2$_4$ (core)	AGUAGAAUUAGAAUUGUGAAGAUGAUAAGUGUAGAGGGAAGGUUA AUGGUUGAUAUUGCUAGGGUGGCGCUUCCAAUUAGGUGCGUGAGU AGGUGGCCUGCAGUAAUGUUGGUCAUUUUUAUUUAUCCUCAUCGU CAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAU CCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCA UGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGU GUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGG UCAGCAGCCAAACAAUCAUAGGAAAUGAACCGGUCAUUUUUAUUU AUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCA AGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGU CGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGA AAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCC UGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGGU CAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACG AAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUC GACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAU AGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCC CUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAA UGAACCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCG ACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCC UGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGA UCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUC CCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAA

		UCAUAGGAAAUGAACCUUUUAUUUUUUAUCUUCUCCUUUCCUUAA UCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUG AUAAACAAGAGGGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCUCC UUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAA UCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAUUUUAUUUUUU AUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACC UACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAUU UUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCC CUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAA AAGAAAAA
85	*in vitro* transcribed ATP6_(D3)$_4$_(D2)$_4$ RNA with indicated 5' end, 3' end, domains D3 and D2, and spacers	GGCGCUUCCGGAAGAAAGCGCCAGUAGAAUUAGAAUUGUGAAGAU GAUAAGUGUAGAGGGAAGGUUAAUGGUUGAUAUUGCUAGGGGGGC GCUUCCAAUUAGGUGCAUGAGUAGGUGGCCUGCAGUAAUGUUAAA GCAAGGGCCUUAUUCAUGGGCUAGCCCGGCGGUCAUUUUUAUUUA UCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAA GAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUC GCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAA AUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCU GACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGCCGG GAAGCGCCGAAUUCAUAUCGAUCGGUCAUUUUUAUUUAUCCUCAU CGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUC AAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCC UCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCC CGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGU CGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGAUCGAAUAAA GGUACCUGUGGGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAA CUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGG UGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGA CCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCU GAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCA AACAAUCAUAGGAAAUGAACCCCACAUUUUACCGGUAAUACCGGG GGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAAC AACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCC CCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCC GUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGC AUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUA GGAAAUGAACCCCCCGGAAGCUUUCCGGAAGAGCUAGCUUUUAUU UUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCC UACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAA AAAGCGCGAAUUCCGAUCUUUUAUUUUUUAUCUUCUCCUUUCCUU AAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGA UGAUAAACAAGAGGGUAAAAAGAAAAAGAUCGUAUCCGGUACCUG UGGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCA UUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGG UAAAAAGAAAAACCACACCUCCACCGGUGGGCCGUUUUAUUUUUU AUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACC UACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAACG GCCCAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAGAUACUA AGGGAGUCUUGC

86	Multimer $(D3)_4$_$(D2)_4$ RNA including domains D3 and D2 and spacers	GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG GAAAUGAACCGCCGGGAAGCGCCGAAUUCAUAUCGAUCGGUCAUU UUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAAC ACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACG CGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGU AGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGC ACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGA ACCGAUCGAAUAAAGGUACCUGUGGGGUCAUUUUUAUUUAUCCUC AUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUG UCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAU CCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAU CCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGC GUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCCCACAUUUU ACCGGUAAUACCGGGGGGUCAUUUUUAUUUAUCCUCAUCGUCAAC AACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGC AAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGC GAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCC GGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAG CAGCCAAACAAUCAUAGGAAAUGAACCCCCCGGAAGCUUUCCGGAA GAGCUAGCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAU UAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAA GAGGGUAAAAAGAAAAAAGCGCGAAUUCCGAUCUUUUAUUUUUUA UCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCU ACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAGAU CGUAUCCGGUACCUGUGGUUUUAUUUUUUAUCUUCUCCUUUCCUU AAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGA UGAUAAACAAGAGGGUAAAAAGAAAAACCACACCUCCACCGGUGG GCCGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUC AUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGG GUAAAAAGAAAAA
87	Multimer $(D3)_4$_$(D2)_4$ RNA core only including domains D3 and D2 but without any spacers	GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG GAAAUGAACCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAAC UACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGU GUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGAC CGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCU GAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCA AACAAUCAUAGGAAAUGAACCGGUCAUUUUUAUUUAUCCUCAUCG UCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAA UCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUC AUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCG UGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCG GUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGGUCAUUUUUAUU

		UAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACC AAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUG UCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUG AAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUC CUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCUU UUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCC CUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAA AAGAAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAU UAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAA GAGGGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUUA AUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAU GAUAAACAAGAGGGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCUC CUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGA AUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAA

Colour codes for sequences 1 to 84

Domain 1; Domain 2; Domain 3; Domain 4

UCAGAUC: Last 7 bases of CMV promoter; GGCGCU: last 6 bases of T7 promoter

GGAGUC : Last 6 bases of SP6 promoter

AUG: Genomic start codon; UGA: Genomic stop codon

UCCGGA (Sequence only: UCCGGA): BspEI restriction site; GCUAGC: NheI restriction site

ACCACCCCGGAGAACAGCUCCUC: spacer stabilizing GFP structure

AUA: mitochondria specific start codon; AGA: mitochondria specific stop codon

GAAUUC: EcoRI restriction site; ACCGGU: AgeI restriction site

AAGCUU: HindIII restriction site; UCUAGA: XbaI restriction site

UCCGGA: BspEI restriction site; AAUAAA :PolyA cleavage site

CCGGC: S1a; GCCGG: S1b

CGAUC: S2a; GAUCG: S2b

UGUGG: S3a;CCACA: S3b

CCGGGG: S4a; CCCCGG: S4b

AAGCAAGGGUUAUUCCGAAUUGG : S6a; CCAAUUCGGAAUAACCC: S6b

GGUUGGAUUGGGG: S8a; CCCCAAACCAACCUCUACCGGAAGCGCCUUUU: S8b

Antisense AP8; Antisense ATP6

Colour codes for SEQ ID NOs: 85 to 87

ATP6 antisense RNA

4 Domains D3 (separated by spacers)

4 Domains D2 (separated by spacers)

Promoter-derived sequence

GGCGCUUCCGGAAGAAAGCGCC

ATP6-(D3x4_D2x4) spacer: AAAGCAAGGGCCUUAUUCAUGGGCUAGCCCGGC

D3 spacer 1: GCCGGGAAGCGCCGAAUUCAUAUCGAUC

D3 spacer 2: GAUCGAAUAAAGGUACCUGUGG

D3 spacer 3: CCACAUUUUACCGGUAAUACCGGGG
(CCACAUUUUACCGGUAAUACCGGGG)

D3x4-D2x4 spacer: CCCCGGAAGCUUUCCGGAAGAGCUAGC
(CCCCGGAAGCUUUCCGGAAGAGCUAGC)

D2 spacer 1: AGCGCGAAUUCCGAUC (AGCGCGAAUUCCGAUC)

D2 spacer 2: GAUCGUAUCCGGUACCUGUGG (GAUCGUAUCCGGUACCUGUGG)

D2 spacer 3: CCACACCUCCACCGGUGGGCCG (CCACACCUCCACCGGUGGGCCG)

RNA 3' end including polyadenylation signal:
CGGCCCAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAGAUACUAAGGGAGUCUU
GC

CLAIMS

1. A nucleic acid delivery construct and a payload, wherein the nucleic acid delivery construct comprises at least one sense or antisense RNA subdomain of the human cytomegalovirus β2.7 RNA, wherein each subdomain is capable of localization within the mitochondria.

2. The nucleic acid delivery construct of claim 1, wherein the RNA sequences from human cytomegalovirus β2.7 RNA has a sequence identity of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of one or more of the RNA sequences selected from the group consisting of β2.7 RNA (SEQ ID NO: 1 or SEQ ID NO: 2), domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7) of β2.7 RNA, domain 2 (D2; SEQ ID NO: 4 or SEQ ID NO: 8) of β2.7 RNA, domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) β2.7 RNA, domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of β2.7 RNA and combinations thereof.

3. The nucleic acid delivery construct of claim 1 or claim 2, wherein the RNA sequences from human cytomegalovirus β2.7 RNA are selected from the group consisting of β2.7 RNA (SEQ ID NO: 1 or SEQ ID NO: 2), domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7) of β2.7 RNA, domain 2 (D2; SEQ ID NO: 4 or SEQ ID NO: 8) of β2.7 RNA, domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) of β2.7 RNA, domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of β2.7 RNA and combinations thereof.

4. The nucleic acid delivery construct of claim 3, wherein the RNA sequences from human cytomegalovirus β2.7 RNA comprise sequences selected from the group consisting of the full length sequence of β2.7 RNA (SEQ ID NO: 1 (sense)), the full length sequence of β2.7 RNA (SEQ ID NO: 2 (antisense)), domain 1 of β2.7 RNA (SEQ ID NO: 3 (sense)), domain 1 of β2.7 RNA (SEQ ID NO: 7 (antisense)), domain 2 of β2.7 RNA (SEQ ID NO: 4 (sense)), domain 2 of β2.7 RNA (SEQ ID NO: 8 (antisense)), domain 3 of β2.7 RNA (SEQ ID NO: 5 (sense)), domain 3 of β2.7 RNA (SEQ ID NO: 9 (antisense)), domain 4 of β2.7 RNA (SEQ ID NO: 6 (sense)), and domain 4 of β2.7 RNA (SEQ ID NO: 10 (antisense)).

5. The nucleic acid delivery construct of claim 3, wherein the RNA sequence from human cytomegalovirus β2.7 RNA comprises domain 2, domain 3 and domain 4 of β2.7 RNA (SEQ ID NO: 11 (sense) or SEQ ID NO: 40(antisense)); or domain 1, domain 3 and domain 4 of β2.7 RNA (SEQ ID NO: 12 (sense) or SEQ ID NO: 41 (antisense)); or domain 1, domain 2 and


domain 4 of β2.7 RNA (SEQ ID NO: 13 (sense) or SEQ ID NO: 42 (antisense)); or domain 1, domain 2 and domain 3 of β2.7 RNA (SEQ ID NO: 14 (sense) or SEQ ID NO: 43 (antisense)).

6. The nucleic acid delivery construct of any one of claims 1 to 5, wherein the nucleic acid delivery construct comprises at least one spacer sequence.

7. The nucleic acid delivery construct of claim 6, wherein if the nucleic acid delivery construct comprises at least two spacer sequences, at least one spacer sequence is at the 5' end and at least one another spacer sequence is at the 3' end of the RNA sequence from human cytomegalovirus β2.7 RNA.

8. The nucleic acid delivery construct of claim 6 or claim 7, wherein the at least one spacer sequence is selected from the group consisting of S1a (SEQ ID NO:27), S1b (SEQ ID NO:28), S2a (SEQ ID NO:29), S2b (SEQ ID NO:30), S3a (SEQ ID NO:31), S3b (SEQ ID NO:32), S4a (SEQ ID NO:33), S4b (SEQ ID NO:34), S6a (SEQ ID NO:35), S6b (SEQ ID NO:36), S8a (SEQ ID NO:37), S8b (SEQ ID NO:38) and Spacer F3A (SEQ ID NO: 39); and/or optionally, wherein the spacer sequence comprises a stop codon.

9. The nucleic acid delivery construct of claim 3, wherein each RNA sequence is selected from the group consisting of domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7), domain 2 (D2 SEQ ID NO: 4 or SEQ ID NO: 8), domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) and domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of β2.7 RNA, according to formula I:




(I)

wherein each X is independently selected from the group consisting of D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof, including duplicates, triplicates, quadruplicates, quintuplicates, sextuplicates, septuplicates, octuplicates, or longer repeats of single domains; and wherein each X is optionally preceded or followed or flanked by at least one or more spacer sequences as defined in any one of claims 6 to 8.

10. The nucleic acid delivery construct of claim 3, wherein the RNA sequence from human cytomegalovirus β2.7 RNA is a tetramer of a RNA sequences, wherein each RNA sequence is

selected from the group consisting of domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7), domain 2 (D2 SEQ ID NO: 4 or SEQ ID NO: 8), domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) and domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of β2.7 RNA, according to formula II:




(II)

wherein each X is independently selected from the group consisting of D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof, including duplicates, triplicates, quadruplicates, quintuplicates, sextuplicates, septuplicates, octuplicates, or longer repeats of single domains; and wherein the spacer sequences S1a, S1b, S2a, S2b, S3a, S3b S4a and S4b are as defined in claim 8.

11. The nucleic acid delivery construct of claim 10, wherein each X is D2 (SEQ ID NO: 4 or SEQ ID NO: 8); or wherein each X is D3 (SEQ ID NO: 5 or SEQ ID NO: 9); or wherein the nucleic acid delivery construct comprises a nucleic acid sequence according to SEQ ID NO: 15 or SEQ ID NO: 52 or wherein the nucleic acid delivery construct comprises a nucleic acid sequence according to SEQ ID NO: 16 or SEQ ID NO: 53.

12. The nucleic acid delivery construct of claim 3, wherein the RNA sequence from human cytomegalovirus β2.7 RNA is an octamer of a RNA sequences selected from the group consisting of domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7), domain 2 (D2; SEQ ID NO: 4 or SEQ ID NO: 8), domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) and domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of β2.7 RNA, according to formula III:




(III)

wherein X and Y are different from each other, wherein each X and each Y are independently selected from the group consisting of D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof, including duplicates, triplicates, quadruplicates, quintuplicates, sextuplicates, septuplicates, octuplicates, or longer repeats of single domains;

and wherein the spacer sequences S1a, S1b, S2a, S2b, S3a, S3b S4a and S4b are as defined in claim 8.

13. The nucleic acid delivery construct of claim 12, wherein X is D3 (SEQ ID NO: 5 or SEQ ID NO: 9) and Y is D2 (SEQ ID NO: 4 or SEQ ID NO: 8); or wherein X is D2 (SEQ ID NO: 4 or SEQ ID NO: 8) and Y is D3 (SEQ ID NO: 5 or SEQ ID NO: 9); or wherein the nucleic acid delivery construct comprises a nucleic acid sequence according to SEQ ID NO: 17 or SEQ ID NO: 54; or wherein the nucleic acid delivery construct comprises a nucleic acid sequence according to SEQ ID NO: 18.

14. The nucleic acid delivery construct of claim 3, wherein the RNA sequence from human cytomegalovirus β2.7 RNA is an octamer of a RNA sequences selected from the group consisting of domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7), domain 2 (D2; SEQ ID NO: 4 or SEQ ID NO: 8), domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) and domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of β2.7 RNA, according to formula IV:



(IV)

wherein X and Y are different from each other, wherein each X and each Y are independently selected from the group consisting of D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof, including duplicates, triplicates, quadruplicates, quintuplicates, sextuplicates, septuplicates, octuplicates, or longer repeats of single domains; and wherein the spacer sequences S1a, S1b, S2a, S2b, S3a, S3b S4a and S4b are as defined in claim 8.

15. The nucleic acid delivery construct of claim 14, wherein X is D3 (SEQ ID NO: 5 or SEQ ID NO: 9) and Y is D2 (SEQ ID NO: 4 or SEQ ID NO: 8); or wherein the nucleic acid delivery construct comprises a nucleic acid sequence according to SEQ ID NO: 19.

16. The nucleic acid delivery construct of any one of claims 1 to 15, wherein the nucleic acid delivery construct comprises a sequence according to any one of SEQ ID NO: 20 to SEQ ID

NO:84.

17. A vector, a recombinant cell, or a recombinant organism comprising the nucleic acid delivery construct of any one of claims 1 to 16.

18. The recombinant cell or the recombinant organism of claim 17, wherein the nucleic acid delivery construct is expressed constitutively or not constitutively.

19. A nucleic acid sequence comprising at least one or more sense or antisense RNA sequences of the human cytomegalovirus β2.7 RNA selected from group consisting of domain 1 (Dl; SEQ ID NO: 3 or 7), domain 2 (D2; SEQ ID NO: 4 or 8), domain 3 (D3; SEQ ID NO: 5 or 9) and domain 4 (D4; SEQ ID NO: 6 or 10).

20. Use of the nucleic acid delivery construct and payload according of any one of claims 1 to 16 in the manufacture of a medicament for treating a mitochondrial disorder.

21. The use of claim 20, wherein the nucleic acid delivery construct and payload enhances mitochondrial gene function, or suppresses defective mitochondrial gene function, or both (provided that in this case the mitochondrial genes are different from each other), wherein the mitochondrial gene functions are different from each other.

22. The use of claim 21, wherein the payload comprises an antisense RNA.

23. The use of claim 21 or claim 22, wherein the mitochondrial disorder is selected from the group consisting of maternally inherited diabetes mellitus, Leber's hereditary optic neuropathy (LHON), neuropathy, ataxia, retinitis pigmentosa, myoclonic epilepsy with ragged red fibres (MERRF), mitochondrial myopathy encephalopathy lactic acidosis and stroke like symptoms (MELAS), Parkinson's disease, chronic obstructive pulmonary disorder (COPD), Kearns-Sayre Syndrome (KSS), Pearson Syndrome and progressive opthalmoplegia (PEO).

24. The use of claim 21 or claim 22, wherein the mitochondrial disorder is to be treated by targeting at least one affected (mitochondrial) gene selected from the group consisting of MT-TL1 (tRNA leucine), MT-ND1, MT-ND4, MT-ND6, MT-ATP6, MT-TK (tRNA lysine), MT-ND1, MT-ND5, MT-TH (histidine), MT-TL1 (leucine), MT-TV (valine), and combinations thereof.